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Rare variants of TREM2 have been associated with increased risk of developing several
neurodegenerative diseases. In particular, the heterozygous p.R47H variant (rs75932628)
has been associated with approximately three times increased risk to develop Alzheimer’s
disease (AD). Other homozygous TREM2 variants have been associated with developing
Nasu-Hakola disease and frontotemporal-like dementia. This PhD project aimed to develop
an in vitro TREM2 model endogeneously expressing the disease-associated variants with
intact downstream signalling pathways. This cell model would be suitable in screening
assays including for use to identify disease-modifying therapeutic compounds.
CRISPR/Cas9 genome editing was used to knock in the disease-associated variants into
BV2 immortalised mouse microglia cell line. Various steps in the CRISPR/Cas9 workflow
were optimised for use with BV2 cells. Despite four iterative improvements in experimental
design, knock-in of the variants were unsuccessful. This has been attributed to very low
efficiency of homogeneous editing in individual cells with chromosomal instability and
hyperploidy that frequently occur in immortalised cell lines. Nevertheless, four clonal lines
with homogeneous editing resulting in indels in Trem2 were generated and predicted to
result in loss of functional TREM2 expression.
Post-mortem hippocampal brain tissue from AD cases with and without a disease-associated
TREM2 variant were immunostained for functional microglial activation markers: CD68,
HLA-DP, -DQ, -DR and Iba-1 to investigate the effects of these variants on microglia.
AD cases with disease-associated TREM2 variants, particularly p.R47H, have decreased
CD68 expression and fewer HLA-DP, -DQ, -DR-expressing cells compared to those without
variants in hippocampal CA4 despite no differences in the density of Iba-1-expressing cells.
DNA indels generated in the Trem2 -edited cell lines were stable and the correct clonal lines
were selected and expanded from cryopreservation in 96-well culture plates. Protein-coding
Trem2 transcripts were disrupted in these cells and functional TREM2 protein was not
expressed as predicted from changes in Trem2 DNA sequence. Functional characterisation
of these cell lines using a TREM2-activating antibody revealed potential co-regulation
of shared immunoreceptor tyrosine-based activation motif (ITAM)-mediated signalling
pathways downstream of TREM2 and FcγR. Furthermore, TREM2 deficiency did not affect
protein levels of CD68 and Iba-1 after stimulation with the TREM2-activating antibody,
unlike in AD cases with a disease-associated TREM2 variant. Low or tonic ligand-binding
2
avidity from monoclonal antibody stimulation or amino acid variants of these receptors
that decrease ligand-binding may result in inhibitory ITAM signals that can suppress
innate immune responses. This suggests a disease-causing mechanism conveyed by TREM2
variants that impair ligand binding, such as the p.R47H, p.R62H and p.D87N variants.
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1.1 History of Alzheimer’s disease
Alzheimer’s disease (AD) is first described by psychiatrist and neuropathologist Alois
Alzheimer in 1906 on his patient Auguste Deter. Before her death, Auguste Deter had
untreatable paranoia and rapid progression of several neurological disorders including sleep
disorders, disturbances of memory, aggressiveness, crying and confusion1. After her death
in 1906, Alzheimer found these symptoms were associated with extensive cerebral atrophy
and two distinctive pathologies, senile plaques and neurofibrillary tangles (NFT)2.
About 80 years later, the main components of senile plaques and NFT that Alzheimer
described were found to be amyloid beta (Aβ)3 and hyperphosphorylated microtubule-
associated protein tau4, respectively. In 1991, genetic studies identified the first causative
gene for familial AD, APP which encodes for the amyloid precursor protein5, and shortly
followed by PSEN1 6 and PSEN2 7. Since then, the number of studies on AD rapidly
increased, with the first major AD risk gene, APOE encoding apolipoprotein E (ApoE),
was described in 1993 where the ε4 variant allele was associated with an increased risk
of developing AD8. In 1996, the acetylecholinesterase inhibitor Donepezil was approved
as the first symptomatic treatment for AD9. In 2004, the discovery of the Pittsburgh
Compound B (PiB) allowed clinicians to monitor the progression of amyloid deposition in
living patients by positron emission tomography (PET) scan10. In 2010, studies found the
development of AD pathology can precede the onset of clinical symptoms by decades11,
which resulted in a new revision of criteria and guidelines to diagnose AD12. Despite the
progression in our understanding of AD, there still are no disease-modifying treatments for
AD up until today.
This is a worrying prospect because the risk of developing AD increases with age and
the average lifespan of the global population is steadily increasing. It has been estimated
that the risk of developing sporadic AD is 2% at 65 years old and this further increases
up to 40% over the age of 8013. The incidence of AD over the age of 65 is 40–58%14,15
and its prevalence will continue to increase. In 1976, AD was declared the most common
cause of dementia, accounting for 60–80% of all cases with an estimated prevalence of
about 1 million people in the USA in 197016. At present, 850,000 people in the UK and
more than 40 million people globally are diagnosed with dementia. This is predicted to
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double every 20 years to about 2 million in the UK and 115 million people globally by
the year 205017,18 as developing countries are set to contribute proportionally more than
Western Europe and the USA due to improved healthcare and lower mortality rates19.
This puts a tremendous economic burden on international healthcare as dementia care
worldwide has been estimated to cost USD604 billion in 201020 and is predicted to increase
by approximately 85% within the next 20 years because of the increasing prevalence.
1.2 Amyloid cascade hypothesis
The amyloid cascade hypothesis is a landmark proposal that kickstarted the amyloidocentric
research of AD and became the basis for therapeutic interventions21. It is proposed by
Selkoe (1991)22 and coined by Hardy and Higgins (1992)23 after the discovery that mutations
in APP result in AD5. The hypothesis proposed Aβ as the causative agent of AD pathology,
preceding and causing abnormal tau hyperphosphorylation, neuronal death, vascular
damage and dementia (Figure 1.1). The hypothesis is later refined24 after the discovery of
additional AD-causing mutations in PSEN1 6 and PSEN2 7 genes encoding for presenilin 1
and 2, respectively, which are part of the γ-secretase complex involved in APP processing.
APP mutations cluster at or very close to α-, β- or γ-secretase cleavage sites in the APP
protein, which affect its processing24.
APP can be cleaved by one of two pathways to generate extracellular fragments that are
non-amyloidogenic (mediated by α-secretase, ADAM10 in neurons26) or amyloidogenic
(mediated by β-secretase, BACE1 in neurons27). The remaining membrane-bound peptides
after α- or β-secretase cleavage are then cleaved by γ-secretase to produce the P3 or Aβ
peptide, respectively, and APP intracellular cytoplasmic domain (AICD)28,29 (Figure 1.2).
γ-secretase cleaves at multiple sites within the transmembrane region of APP, resulting in
Aβ peptides varying in length between 38—43 amino acids30. Regardless, cleavage products
from α- and γ-secretase processing of APP are non-amyloidogenic and are potentially
neurotrophic and neuroprotective31,32. On the other hand, β- and γ-secretase cleavage
yields the amyloidogenic Aβ peptide.
Mutations in the familial AD genes promote amyloidogenic processing of APP through β-
and γ-secretase cleavage to produce Aβ33–36. Moreover, mutations within the Aβ sequence
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Figure 1.1. The amyloid cascade hypothesis proposed that Aβ is the primary
cause of Alzheimer’s disease and leads to several pathogenic events and the
onset of dementia.
Aβ oligomers can directly affect phosphorylation of tau as well.
Figure adapted from Selkoe and Hardy (2016)25.
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Figure 1.2. Non-amyloidogenic or amyloidogenic processing of APP is medi-
ated by α-secretase or β-secretase, respectively, followed by γ-secretase cleav-
age.
Various peptides are produced from the sequential cleavage of the secretases, including the
amyloidogenic Aβ peptide.
Figure adapted from O’Brien and Wong (2011)29.
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of APP increase the propensity for self-aggregation of Aβ into amyloid fibrils37. The
presenilin genes encode for the active site on γ-secretase38,39. Mutations in PSEN1 and
PSEN2 tend to promote the cleavage of APP to produce the 42-amino acid rather than
the 40-amino acid Aβ peptide, increasing the Aβ1–42:Aβ1–40 ratio30.
Since the proposal of the amyloid cascade hypothesis, various pieces of evidence have been
found to support it. Individuals with Down’s syndrome, a disease associated with the
trisomy of chromosome 21 where the APP gene is located, have been found to also develop
AD pathology. This has been attributed to increased APP gene copy number40 and not the
other genes located within chromosome 2141. This suggested that lifelong overexpression of
APP even without familial AD mutations can cause AD25. Additionally, mutations in the
MAPT gene encoding the microtubule-associated protein tau cause severe tau aggregation
in the brain but are not associated with amyloid deposition. Therefore, it has been posited
that the NFT observed in AD is likely to occur after changes in Aβ metabolism42. In
animal studies, mutant human APP and tau transgenic mice have increased tau pathology
but there is no additional amyloid pathology compared to tau transgenic-only mice43. This
has been thought to indicate that altered APP processing occurs before tau dysfunction24.
1.3 Progression of Alzheimer’s disease
1.3.1 Clinical
A definitive diagnosis of AD can only be made in post-mortem with pathological confirma-
tion of the presence of amyloid plaques and NFT pathology. While the patient is alive, only
a “probable” diagnosis of AD can be made from the manifestation of multiple cognitive
deficits and memory decline. These symptoms are often assessed by detailed history
reported by patients or their carers to determine their impact on social or occupational
functioning44. The National Institute on Neurological and Communicative Disorders and
Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS/ADRDA)
proposed the first criteria for the diagnosis of AD in 198445. Subsequent revisions of the
diagnostic criteria have incorporated new findings in clinical, imaging and fluids assessments
to improve sensitivity and specificity for diagnosing as early as possibly11,12,46,47. It was in
the 2011 iteration of the NINCDS/ADRDA criteria that suggested the clinical diagnosis of
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AD is only “probable” while the patient is still alive and a “definite” AD diagnosis can only
be made after post-mortem neuropathological assessments. This criteria also was the first
time that the assessment of AD pathology in vivo using PiB-PET was considered. These
guidelines generally have good sensitivity and specificity of more than 80% to distinguish
AD patients from non-demented individuals but were inconsistent in distinguishing be-
tween dementia subtypes48. A more recent criteria proposed by the International Working
Group for New Research Criteria for the Diagnosis of Alzheimer’s Disease included in vivo
biomarker evidence of pathophysiology indicative of AD47. Some of the biomarkers include
the detection of Aβ49 and tau50 pathology and neuroinflammation (TSPO)51 PET imaging,
brain volume by magnetic resonance imaging (MRI)52–54, and cerebrospinal fluid (CSF)
Aβ1–42, total tau and phosphorylated tau (p-tau)55–57.
There is a long preclinical, asymptomatic phase of AD pathology preceding the early
presentation of cognitive impairment58. In early AD, patients tend to be clinically normal
with only slight impediment of daily living. Signs of cognitive decline are variable but
often manifest slowly in the early symptomatic phase. Common complaints at this stage
include significant decline in short term memory, aphasia and spatial disorientation59.
Patients are often affected by problems with executive function and decreased verbal
fluency. Less common symptoms include subtle mood changes in about 20–30% of patients
and personality changes in 25–50% of patients60. As the disease progresses, patients often
show signs of agitation, psychosis and anxiety61. In moderate to severe AD, patients
start to develop functional impairment and dependency on others marked by extreme
difficulty in retaining new information, prosopagnosia (difficulty in recognising familiar
people) and significant deterioration of executive function. Behavioural symptoms such as
hallucinations, delusions, aggression and anxiety are not always apparent but are more
common in the advanced stages of AD. In severe AD, dysphagia (impairment of basic
motor functions) can manifest alongside an almost complete loss of cognitive function and
patients are usually completely dependent on comprehensive care.
1.3.2 Pathology
AD is characterised by the pathological hallmarks of extracellular deposits of amyloid
plaques and intracellular aggregates of NFT. Amyloid plaques consist of aggregated Aβ
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peptides, particularly Aβ1–423, while NFTs consist of aggregated hyperphosphorylated tau
protein62,63. NFT pathology have been found to correlate better than Aβ deposition to
neurodegeneration, synaptic loss and cognitive symptoms64. The MAPT gene encodes for
six tau isoforms which are generated by alternative splicing of exon 1065,66. This leads to a
protein with three or four microtubule-binding domain repeats (3R or 4R) in the C-terminal
region. This structure is involved in microtubule polymerisation and stabilisation67 and
normally regulates cytoskeletal organisation. In disease, hyperphosphorylation of tau
impairs its binding to microtubules. This leads to destabilisation of axons and disruption
of axonal transport. Eventually, this causes axonal degeneration and neuronal death68. In
AD, all isoforms of tau can become hyperphosphorylated and form insoluble aggregates
known as paired helical filaments69 which are the main component of NFTs70. Tau from
AD brains are four times more phosphorylated than in non-AD brains71. Despite the
characteristic amyloid plaques and NFT, synaptic loss is still the best pathological correlate
to cognitive impairment in AD72–74.
AD pathogenesis is known to begin many years before clinical symptoms manifest75.
Although the amyloid cascade hypothesis has suggested that amyloid pathology precedes
tau pathology, these pathologies develop spatially and temporally independent of each
other within the AD brain. Amyloid and hyperphosphorylated tau have characteristic
patterns of deposition as disease progresses. The Braak tau staging was developed to
characterise the spatial and temporal progression of tau pathology [NFT and neuropil
threads (NPT)] burden in the brain on a 6-point scale76,77. In AD, tau pathology begins in
the transentorhinal region and spread into the entorhinal cortex and hippocampus, as well as
into the limbic regions including the amygdala, thalamus, putamen and nucleus accumbens.
Tau pathology eventually reaches the neocortical regions including the temporal, occipital
and frontal cortices. Separately, the Thal amyloid staging78 assesses the spatial and
temporal progression of amyloid pathology which tends to begin in the neocortical region
including the frontal, parietal, temporal and occipital cortices. It then spreads to the
entorhinal region and hippocampus before progressing into the subcortical regions including
the caudate nucleus, putamen, claustrum, basal forebrain nuclei, substatia innominata,
thalamus, hypothalamus, lateral habenular nucleus and white matter tracts. Towards end
stage AD, amyloid pathology develops deeper into the midbrain, brainstem and finally the
cerebellum.
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Alongside the abnormal protein aggregation, degeneration of cholinergic neurons in the
nucleus basalis of Meynert, which is the primary nucleus of cholinergic neurons that project
to the neocortex79, is also characteristic in early AD80. As AD progresses, increasing
neurodegeneration can be found in the cerebral cortex, mainly the lateral temporal and
medial parietal cortex followed by atrophy of the lateral parietal and frontal lobes81. By
the time clinical symptoms develop, the temporal, parietal and frontal cortices would have
undergone extensive atrophy but with relative preservation of the occipital and primary
sensory-motor cortex80,82.
1.4 Risk factors of Alzheimer’s disease
1.4.1 Genetic
Mutations in the APP5, PSEN1 6 and PSEN2 7 genes have been identified to cause familial
AD, which accounts for ∼4% of people with AD83,84. Additional rare variants in APP,
PSEN1, PSEN2 and ADAM10 also modulate sporadic AD risk85–90. Other than the
familial AD genes, risk genes for sporadic AD were also discovered. APOE is the first AD
risk gene to be described8. Its association with AD has been consistently replicated in many
independent studies and remains the top-ranking gene with variants conferring risk for AD.
Three haplotypes (ε2, ε3 and ε4) based on two variants in the coding region of the APOE
gene have different association with AD8. The ε3 allele is the most common variant with
about 77% of the total population carrying it. The ε4 allele is found to convey an increased
risk of developing AD with homozygous ε4 alleles associated with a 12-fold increased AD
risk and heterozygous ε3/ε4 alleles associated with a 3-fold increased AD risk8,91–93. The
ε4 allele variant is also associated with the decreased age of onset8,94 and the increased rate
of cognitive decline95,96. It has been reported that 15% of the total population carries the
ε4 allele97 and in the AD population, about 60% of people can be expected to carry the
allele98. Meanwhile, the ε2 allele can be found in 8% of the total population97 and appears
to be protective. It conveys a decreased risk of developing AD and is associated with a
later age of onset8,91,99–101. ApoE has a central role in cholesterol metabolism102 and is
important in mediating several functions in the central nervous system (CNS) including
cholesterol transport, neuroplasticity and inflammation103. ApoE also binds Aβ to mediate
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the clearance of soluble and aggregated Aβ103,104. Moreover, ApoE indirectly regulates Aβ
metabolism through the interaction with receptors such as LRP1105 and more recently has
been shown to bind to TREM2106–108. The APOE ε4 allele produces a protein variant
that is less efficient at mediating the clearance of Aβ104.
Recently, next-generation whole-genome and whole-exome sequencing have identified rare
variants in genes like TREM2, ABI3, PLD3 and PLCG2 that convey a substantial increase
in the risk of developing AD109–112. Furthermore, genome-wide association studies (GWAS)
have identified many other AD risk genes including ABCA7, BIN1, CASS4, CD33, CELF1,
CLU, CR1, CD2AP, DSG2, EPHA1, FERMT2, HLA-DRB5–DRB1, INPP5D, MEF2C,
MS4A6A–MS4A4E, NME8, PICALM, PTK2B, SLC24A4, SORL1 and ZCWPW1 113–117
(Figure 1.3). In addition to APP metabolism, these genes highlight the involvement of
cholesterol metabolism, inflammation, endocytosis, cytoskeleton/axon development and
epigenetics in the pathogenesis of AD (Figure 1.3). Variants in these genes have varying
population frequency and convey different risk values to develop sporadic AD (Figure 1.3).
1.4.2 Epigenetic
The study of epigenetics and its role in AD is relatively recent. Epigenetic regulation
is associated with changes in gene regulation through modifications to DNA packaging
proteins or small chemical groups that are attached to DNA without changes to the
actual DNA sequence118,119. Epigenetics has been found to be a major component of
aging120,121. Similar changes in epigenetics have also been observed in AD brains122–124.
Another study found that epigenetic regulation is involved in the loss of phenotypic
plasticity associated with aging125. As aging is the biggest risk factor for AD, it is not
surprising that aging-associated epigenetic modulation is involved in the pathogenesis of
AD126,127. There are two main forms of epigenetic modifications: methylation of DNA
mediated by DNA methyltransferases128 and the binding of epigenetic factors, such as
acetylation, methylation and phosphorylation, to histones that package DNA129,130. The
latter is mediated by enzymes including histone acetyltransferases and deacetylases, histone
methyltransferases and demethylases, and kinase and phosphatases, which attach and
remove the small chemical groups from histones131.
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Figure 1.3. Recent whole-genome sequencing and genome-wide association
studies have identified novel AD-associated risk genes.
These genes convey varying risks and have different population frequencies. They highlight
various functional pathways involved in the pathogenesis of AD.
Figure adapted from Scheltens et al. (2016)19.
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Several studies observed genome-wide changes in DNA methylation in AD compared to non-
AD patients132–134. Epigenome-wide association studies also found hypermethylation in
genes such as SORBS3 and ANK1, associated with cytoskeletal function, in AD vulnerable
brain regions131,135,136. There have been mixed findings on histone modifications in AD
post-mortem studies with some finding increased137 and decreased138 modifications. The
role of epigenetics in the pathogenesis of AD is an interesting avenue for therapeutics
as epigenetic changes in AD patients can potentially be pharmacologically targeted and
may provide benefits. For example, folic acid and vitamin B12 have been shown to
modulate DNA methylation through a mechanism mediated by 1-carbon metabolism139.
Additionally, histone deacetylase modifiers like 2-valproate can modulate the removal of
histone acetylation140.
1.4.3 Lifestyle
Many studies have found that physical activity and exercise141–143, midlife obesity144,
alcohol consumption145, nutrition146, education147 and smoking148,149 affect the risk of
developing AD.
Physical exercise, even at low intensities, is beneficial and delays the onset of AD142,143. It
has been shown to induce hippocampal neurogenesis150 and improve learning in rodents151.
Interestingly, the protective effect of exercise is more pronounced in individuals with the
APOE ε4 risk allele152. Increased BMI at midlife is also a risk factor for not only AD but also
many dementias144,153. Obesity is associated with cognitive decline and directly associated
with AD154,155. Besides that, alcohol consumption is a well-known risk for dementia. Middle-
aged heavy drinkers have a 3-fold higher risk to develop AD156 while light and moderate
drinkers have significantly lower risk relative to heavy drinkers157,158. Regardless, any
level of alcohol consumption is associated with increased brain atrophy159. Additionally, a
large-scale study has found that increased cognitive reserve from mental activity, occupation
and especially education level conveyed a significant protective effect and delay the onset of
dementia160. The protective effect of cognitive reserve can be beneficial even in older adults
who performed mental exercises and cognitive stimulation160,161. Furthermore, several
studies on smoking have suggested that current smokers have 1.5-fold increased risk of
developing AD149.
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Many of the lifestyle risk factors for AD are also associated with poor cardiovascular
health. Stroke162,163, atherosclerosis164,165, type-2 diabetes166–170, hypertension165,171,172
and hypercholesterolaemia173–175 increase the risk of developing AD. Findings from a large
population study suggested that if cardiovascular risks could be managed or prevented,
the incidence of dementia would decrease by about 30%172. Compromised cardiovascular
health is likely related to dysregulated cholesterol and energy metabolism, both of which
are implicated in AD176,177. Moreover, hypertension is linked to increased brain atrophy
and NFT deposition178. However, clinical trials that managed hypertension reported that
there are minimal benefits in lowering the risk of developing dementia179. Evidence for
dietary factors contributing to AD risk is mixed. While the Mediterranean diet appears to
have a positive effect on cognition180,181, dietary supplements and vitamins have failed to
show any effects on the risk of developing AD182–184.
1.5 Neuroinflammation in Alzheimer’s disease
A link between inflammation and AD has been suggested as early as in the original
amyloid hypothesis22. Recent genetic evidence indicates inflammation may even have a
causal role in the pathogenesis of AD, contributing as much as plaques and tangles185.
Furthermore, its role in AD is highlighted by the discovery of immune-related AD risk genes
like TREM2 109,110 and CD33 186,187. In the CNS, neuroinflammation is predominantly
mediated by microglia and astrocytes.
1.5.1 Microglia
Microglia are the resident phagocytes of the CNS. They originate from yolk sac-derived
erythromyeloid progenitors188–190 and are distributed throughout the brain. In adulthood,
they are considered very long-lived cells and can proliferate when required191. They have
highly motile processes that survey the microenvironment for pathogens or cellular debris
and simultaneously provide factors to support tissue maintenance and homeostasis192.
Recent evidence suggests microglia may also contribute to the remodelling and protection
of synapses193. These functions are mediated by trophic factors such as brain-derived neu-
rotrophic factor (BDNF), which is a key factor involved in memory formation194. Microglia
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also recognise dying neurons or protein aggregates which cause them to extend processes
and migrate to the lesion site as part of the innate immune response195. Pathological
stimuli are detected by damage- or pathogen-associated molecular pattern (DAMP/PAMP)
recognition receptors195 which cause them to switch from surveillance to a reactive phe-
notype, whereby they become more amoeboid in shape196 and express specific activation
markers depending on the stimulus197,198.
In AD, microglia can bind and recognise soluble and fibrillar Aβ through receptors including
SCARA1, CD36, CD14, α6β1 integrin, CD47, Toll-like receptors TLR2, TLR4, TLR6 and
TLR9199–202 resulting in activation of microglia to produce proinflammatory cytokines
and chemokines201–205. CD36, TLR4 and TLR6 deficiency in vitro result in decreased
Aβ-induced cytokine production201,205,206. Absence of these receptors also prevent early
intracellular Aβ accumulation and the activation of inflammasomes206. On ligand binding,
microglia phagocytose Aβ fibrils which enter the endolysosomal pathway195. Meanwhile,
soluble oligomeric Aβ can be degraded by various extracellular proteases such as neprilysin
and insulin-degrading enzyme (IDE)207. In sporadic AD, inefficient Aβ clearance is recog-
nised to be a major contributor of pathogenesis208. This is associated with increased
cytokine production and downregulation of Aβ-binding receptors which leads to insufficient
microglial phagocytosis of Aβ209. Interestingly while microglia can still phagocytose fibrillar
Aβ, they are ineffective at doing so and microglia-deficiency in AD mice do not appear to
affect amyloid load in the brain210–212.
Microglial activation can result in a spectrum of phenotypes reflecting their high degree of
plasticity and their ability to respond to a wide range of stimuli. In peripheral macrophages,
inflammatory activation can lead to the classic proinflammatory phenotype, coined M1,
associated with the expression of genes involved in cytotoxic function213 or the non-
inflammatory M2 phenotype associated with the expression of ARG1, FIZZ1, YM1 and
IGF1 genes implicated in tissue repair and resolution of inflammation214,215. The M1
activation state is characterised by an increased expression of proinflammatory cytokines
such as TNF-α, IL-1, IL-6, IL-12, IL-18 and reduced phagocytosis216. Alternatively, the M2
activation state is characterised by the expression of anti-inflammatory cytokines like IL-4,
IL-10, IL-13, TGF-β and increased phagocytosis without nitric oxide (NO) release217–219.
The M1 and M2 states represent the extreme ends of an activation spectrum which does not
36
fully capture the many phenotypes that microglia can exhibit depending on the stimulus.
As such, the M2 classification has been expanded into subgroups M2a (response to Th2
activation), M2b (Th2-activating) and M2c (immunoregulation) to account for additional
activation phenotypes220.
Microglial activation in AD has been described as both beneficial and detrimental to the
pathogenesis of AD. Microglia can have varying functions and roles depending on the
stimuli, disease stage or brain region affected. Typically after exposure to pathology or
cellular debris, microglia respond immediately to remove the offending stimuli. In AD, this
inflammatory response is sterile where it involves similar receptors but do not have living
pathogens associated. This short term or acute response usually resolves pathology with
immediate benefit to the microenvironment. However the continuous formation of Aβ in
AD causes positive feedback loops between Aβ production and inflammatory responses,
characterised by production of inflammatory mediators IL-1, IL-6, IL-12, IL-23, GM-CSF
and TNF221–224 and damaging oxidative radicals195,225,226, which prevent its resolution.
Thus, chronic exposure to Aβ, cytokines, chemokines and other inflammatory mediators
lead to dysfunctional microglia which can be found next to amyloid plaques227,228. Sup-
porting this, IL-10-deficient AD mice exhibit lower amyloid burden and increased microglia-
mediated phagocytosis of Aβ229. Conversely when IL-10 is overexpressed, amyloid burden
is increased and phagocytosis of Aβ is impaired230. CD33, another microglial-enriched
receptor also inhibit phagocytosis of Aβ187. The protective gene variant of CD33 reduces
its protein expression due to reduced expression of an RNA isoform with the extracellu-
lar immunoglobulin domain186,187. CD33-deficient AD mice produce less amyloid than
mice with normal CD33 expression187. Besides that, decreased expression of microglial
autophagy-associated protein Beclin-1 in AD interferes with efficient phagocytosis and lead
to dysfunctional receptor recycling of CD36 and TREM2231. Beclin-1 is involved in the
retromer-mediated sorting of proteins including receptors like TREM2, APP, BACE1 and
CD36 in the endolysosomal pathway for degradation231.
The resolution of inflammation in microglia is just as critical as their activation. Prolonged
activation can lead to by-stander damage due to the release of neurotoxic mediators like
IL-1β, TNF-α and NO195. The resolution has been associated with the conversion from
the proinflammatory M1-like state to the alternative M2-like state associated with tissue
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repair, phagocytosis of debris and release of anti-inflammatory factors195. This conversion
was suggested to be linked with the modulation of proinflammatory signalling pathways
such as the NLRP3 inflammasome195.
The role of microglia in neurodegenerative diseases is highlighted by studies on CSF1R
signalling. Mutations in the CSF1R gene result in white matter disease including hered-
itary diffuse leukoencephalopathy with axonal spheroids (HDLS)232–234 and pigmentary
orthochromatic leukodystrophy (POLD)235. These diseases are associated with white mat-
ter degeneration with axonal spheroids and pigmented glia236. CSF1R signalling plays
a crucial role in microglial activation and proliferation. Microglia in neurodegenerative
diseases including prion disease and AD have increased proliferation that is associated with
upregulation of CSF1R-mediated mitogenic signalling pathways237,238. Pharmacological
inhibition of CSF1R signalling in the APP/PS1 mouse model of AD prevented microglial
proliferation and resulted in the skewing towards an anti-inflammatory microglial phe-
notype238. This translated into improved cognition and prevented synaptic loss in the
mice238, which demonstrates a beneficial effect of dampening the chronic and neurotoxic
microglial activation in neurodegenerative diseases.
In addition to microglia, there is some evidence that infiltrating peripheral macrophages
may be involved in inflammatory responses during AD pathogenesis. Some studies have
observed plaque-associated myeloid cells that express high levels of CD45 and low P2RY12
that is characteristic of peripheral macrophages239. However, the expression levels of CD45
and P2RY12 in microglia can vary depending on stimuli and activation state240, which
could explain the observation of plaque-associated CD45hi-P2RY12lo cells. Parabiosis
experiments using CD45.2-expressing AD mice and CD45.1 B6 congenic mice do not show
any significant infiltration of peripheral macrophages into the brain nor their association
with amyloid plaques241. However, peripheral macrophage recruitment into the brain has
been observed in microglia-deficient AD mice but were ineffective at responding towards
amyloid plaques210,212. Together, these evidences suggest that microglia are likely to be
the dominant plaque-associated immune cell population in AD.
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1.5.2 Astrocytes
Besides microglia, astrocytes can also undergo activation or astrogliosis in response to
pathology. Astrogliosis usually involves complex, multistage and pathology-specific re-
actions to provide neuroprotection and recovery of injured CNS tissue242,243. In normal
physiological conditions, astrocytes are important for the maintenance of synaptic transmis-
sion. Dysfunctional astrocytes can lead to cognitive deficits244–248. In disease, astrocytes
can often be found clustered next to microglia at lesion sites such as amyloid plaques
in AD244,249. Some studies have suggested that glial activation including microglia and
astrocytes may even precede Aβ deposition in AD250.
Activated or reactive astrocytes are characterised by increased expression of GFAP and
signs of dysfunction245. In vivo studies using AD animal models have detected an early
response to disease associated with the loss of astrocytes244. The loss of astrocytes appears
to follow a spatial and temporal progression that first start in the entorhinal cortex and
later progressing to even affecting astrocytes far from amyloid plaques195. Like microglia,
astrocytes can also release cytokines, NO and other cytotoxic mediators in response to Aβ.
This is supported by in vivo studies that inhibited a key astrocytic signalling pathway, the
calcineurin/NFAT signalling, which decrease astrocytic activation and result in improved
cognition and low Aβ load251. Besides that, astrocytes in vivo can endocytose and degrade
Aβ252 through an APOE-mediated mechanism253. Furthermore, lipidation of APOE by
astrocytes increases microglial clearance of Aβ254,255, highlighting a concerted role of
microglia and astrocytes in AD. Plaque-associated astrocytes upregulate the expression
of extracellular Aβ-degrading enzymes including neprilysin, IDE, endothelin-converting
enzyme 2 and angiotensin I-converting enzyme256, suggesting that the loss of astrocytes
in AD may contribute to decreased proteolytic clearance of oligomeric Aβ. Additionally,
astrocytes have been implicated in paravenous drainage of soluble Aβ from the brain, a
process that is dependent on the astrocytic water channel aquaporin 4257. A recent study
has described that astrocytes are also capable of activation into a neurotoxic A1 state
or neuroprotective A2 state akin to macrophage activation states258. The study found
that A1 astrocytes are induced by activated microglia and these astrocytes have decreased
phagocytic capabilities, are synaptotoxic and highly neurotoxic. Moreover, in microglia-
deficient Csf1r -/- mice, A1 astrocytes could not be induced258. Also, in vitro experiments
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revealed that IL-1α, TNF-α and C1q could induce these neurotoxic A1 astrocytes258.
1.5.3 Cytokines
In neurodegenerative diseases like AD, microglia and astrocytes are major sources of
cytokines which contribute to inflammatory responses including pro- and anti-inflammation,
cytotoxicity and chemotaxis. In aging mouse models of AD, increased amyloid deposition is
associated with increased proinflammatory cytokines such as TNF-α, IL-1α, IL-6 and GM-
CSF222. In vitro treatment of microglia with fibrillar Aβ1–42 result in increased production
of similar proinflammatory cytokines including IL-1β, IL-6, TNF-α, MIP-1α and M-CSF259.
Besides that, caspase 1 activity, which is crucial to convert inactive IL-1β into its active
form, is higher in MCI and AD brains260. This leads to the detection of increased IL-1β
production by plaque-associated microglia and in CSF260. IL-1β signalling may be involved
in AD pathogenesis by increasing Aβ deposition by affecting APP expression and its
processing261.
Proinflammatory cytokines produced in AD can be cytotoxic and neurotoxic. In patients,
increased TNF-α and decreased TGF-β levels in CSF have been associated with an increased
risk of converting from MCI to AD262. Supporting this, rheumatoid arthritis patients
on anti-TNF-α therapy have a decreased risk of developing AD later in life263. The
proinflammatory cytokines IL-1β and TNF-α impair neuronal function early by suppressing
long-term potentiation (LTP) of synaptic transmission195. In in vitro studies, treatment of
neuron-microglia co-cultures with Aβ and interferon-γ (IFN-γ) or CD40L resulted in the
release of TNF-α and reactive oxygen species (ROS)264–266. Similarly, stimulation of the
TLR4 receptor elevated TNF-α and MIP-1α levels in AD mouse models267.
Interestingly, some of the same proinflammatory responses have been shown to be beneficial,
at least in AD mouse models. Decreased amyloid plaque burden have been observed
from transgenic TNF-α AD mice, which has been associated with increased microglial
activation268. Besides that, increased expression of IFN-γ, IL-6 or TNF-α enhance clearance
of amyloid exhibited by decreased soluble Aβ and amyloid plaque burden, which are
associated with increased microglia and astrocyte activation269–271. Additionally, transgenic




Chemokines function to recruit microglia to sites of neuroinflammation in response to
AD pathology in the CNS274. In the AD brain, increased expression of CCL2, CCR3
and CCR5 in microglia275,276 and CCL4 in plaque-associated astrocytes275 have been
observed. CCR2 and CCR5 modulate AD progression through its role in inducing chemo-
taxis in microglia277–280. Besides that, experimental in vitro treatment of Aβ cause
production of CXCL8, CCL2 and CCL3 in microglia and astrocytes281,282. Additionally,
CX3CL1/CX3CR1 (fractalkine and its receptor) signalling between neurons and microglia
mediate neuronal survival283 and protect against cognitive deficits284 in AD mouse models.
Interestingly, CX3CR1 deficiency reduces amyloid plaque burden and is associated with
enhanced microglial Aβ phagocytosis285. This could be due to elevated expression of IL-6
and TNF-α observed in CX3CR1- or CX3CL1-deficient animals286 resulting in activation
of microglia to mediate clearance of Aβ.
1.5.5 Nitric oxide and reactive oxygen species
Proinflammatory cytokines can stimulate the expression of inducible nitric oxide synthase
(iNOS) in microglia and astrocytes to produce the cytotoxic NO195. iNOS is upregulated in
the AD brain287. In contrast, iNOS deficiency in AD mice appears to be neuroprotective,
reducing premature mortality, amyloid burden, protein tyrosine nitration, and activation
of astrocytes and microglia288. However, there are differences in the production of NO
in human macrophages compared to rodent macrophages289–293, which can affect the
interpretation of NO-related findings in rodent AD models. The synthesis of NO in mice
from L-arginine requires arginase and the synthesis of the co-factor tetrahydrobiopterin.
These systems are not functional in human macrophages and thus, they do not produce
NO294,295. Even so, NO production in humans do occur but in other cell types such as
hepatocytes and smooth muscle cells296,297.
Another source of cytotoxic molecules in inflammation is from NADPH oxidase which
produces ROS. NADPH oxidase expression is enriched in microglia and is upregulated in
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AD and after Aβ treatment in vitro. This leads to the production of hydrogen peroxide
(H2O2) which itself can activate microglia225,226. H2O2 can also react with NO to form
peroxynitrite, a strong oxidising and nitrating agent that can damage DNA and proteins298.
Oxidative stress can induce the nitration of Aβ peptides at the tyrosine 10 residue and this
increases its propensity to aggregate299,300. Nitrated Aβ is found in the core of amyloid
plaques and has been shown to induce plaque formation in AD mice300. Moreover, nitrated
Aβ can suppress hippocampal LTP more effectively than unmodified Aβ300.
1.5.6 Caspases
Caspases are cysteine-aspartic proteases commonly associated with apoptosis and inflam-
mation. While ubiquitously expressed in most cells, in microglia, caspase-1 is not only
involved in apoptosis but also the autocatalysis and the subsequent conversion of inac-
tive IL-1β and IL-17 into their active forms301,302. Caspase-1 involvement in microglial
apoptosis is established by the prevention of chromogranin A-induced apoptosis with
IL-1β-converting enzyme-like caspase inhibitor YVAD-CHO or caspase-1 inhibitor z-Tryp-
Glu(OMe)-His-Asp(OMe)-fluoromethyl ketone303,304. The role of caspase-1 in mediating
microglial apoptosis is unaffected by changes in active IL-1β production as the blocking of
IL-1β activity with antibodies did not prevent apoptosis304. Caspase-1 activity is regulated
by signal-dependent autoactivation within inflammasomes301,302. One form of inflamma-
some, NLRP3, is found to be activated by Aβ fibrils by lysosomal damage in microglia305.
AD mice deficient in NLRP3 or caspase-1 are protected from cognitive deficits associated
with AD260. The lack of NLRP3 or caspase-1 appear to shift microglial activation from the
proinflammatory M1-like state to the alternative anti-inflammatory M2-like phenotype260.
Other caspases involved in neuroinflammation include caspase-8 and caspase-3/7, which
are found activated in microglia responding to various proinflammatory factors in vitro
and in microglia within AD brains195,306. Activated caspase-3 has been shown to modulate
NFκB activation through PKCδ that results in the production of proinflammatory and cy-
totoxic factors such as IL-1β, TNF-α and NO307–309. Inhibition of these caspases suppresses
microglial activation and neurotoxicity, and thus has neuroprotective effects307–309.
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1.5.7 Complement system
The complement system is a major component of the innate immune system involved in
the response against pathogens. Activation of the complement cascade by specific immune
responses lead to the opsonisation and lysis of invading microorganisms through the action
of the membrane attack complex310. Although components of the complement system are
primarily synthesised by hepatocytes, microglia and astrocytes in the CNS can express most
of the proteins involved in the complement system in response to injury311,312. Multiple
elements of the classical complement cascade (C1q, C3d, C4d, C5b–C9) have been detected
in AD brain tissue313 and complement receptors such as CR3 have been found around
amyloid plaques314. In addition, in vitro studies found that Aβ can activate the complement
system314, suggesting that Aβ may act as a mimic for pathogenic microorganisms.
Complement and microglia appear to mediate synaptic pruning during brain develop-
ment315,316 and synaptic loss in early AD317. Super-resolution microscopy revealed increased
C1q and C3 colocalisation with PSD95, a post-synaptic marker, in the hippocampus of
J20 mouse model of AD overexpressing human APP carrying two familial AD mutations
compared to WT mice317. This suggests that there are more synapses targeted with compo-
nents of the complement system for removal by microglia. When C1qa and C3 are knocked
out from J20 or APP/PS1 mice, the characteristic synaptic loss was ameliorated317, further
suggesting that the complement pathway is involved in the microglia-mediated elimination
of synapses in AD. Indeed, all CR3-expressing cells also express P2RY12, indicating that
they are resident microglia317. Furthermore, CR3 KO mice rescued synaptic loss compared
to WT mice when treated with synaptotoxic soluble Aβ oligomers317.
Recently, gene variants of CLU encoding clusterin/apolipoprotein J (ApoJ) and CR1
encoding complement receptor 1 have been associated with AD113,114. Both clusterin and
complement receptor 1 are inhibitors of the complement system. Clusterin can bind directly
to and inactivate C7, C8β and the b domain of C9318. On the other hand, complement
receptor 1 acts as a competitive inhibitor to several complement convertases and promotes
the clearance of opsonised immune complexes319.
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1.5.8 Systemic inflammation
Systemic inflammation appears to play a role in the pathogenesis of neurodegenerative
diseases including AD. For example, upper respiratory tract infections are associated with
approximately 33% of relapses in multiple sclerosis patients320,321. Besides that, delirium
caused by infection is associated with developing cognitive impairment and increased risk
of dementia322. AD patients with delirium is also associated with an increased rate of
cognitive decline323,324. Similarly, acute systemic inflammation in AD patients associated
with elevated serum TNF-α result in an increased rate of cognitive decline325. This is in
contrast with AD patients with lower serum levels of TNF-α that remained cognitively
stable during the study325. In animal models of AD, such as human APP transgenic mice,
systemic LPS injection results in increased production of IL-1, amyloid deposition and
cognitive impairment compared to control mice326.
Systemic inflammation could impact neurodegenerative diseases through microglial priming,
in which microglia exhibit an exaggerated inflammatory response after exposure to an
initial stimuli327. Neuronal and glial injury in early chronic neurodegeneration has been
suggested to induce microglial activation and priming327. When this is combined with
systemic inflammation, the cytokines produced could result in excessive activation and
inflammatory response of microglia associated with increased production of IL-1, TNF and
IL-6328–330.
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1.6 Triggering receptor expressed on myeloid cells 2
Rare homozygous mutations in the triggering receptor expressed on myeloid cells 2 (TREM2)
receptor have been found in people with polycystic lipomembraneous osteodysplasia with
sclerosing leucoencephalopathy otherwise known as Nasu-Hakola disease (NHD). NHD is
characterised by dementia, changes in the brain white matter and bone cysts associated with
bone fractures331. The onset of clinical symptoms in NHD can begin as early as the second
decade of life332. Some of these homozygous mutations can also cause a frontotemporal
dementia (FTD)-like syndrome but without bone involvement333. Recently, it is found that
additional rare heterozygous variants in the TREM2 gene increase the risk of developing
AD by 2.65–4.35 fold109,110,334–337 (Table 1.1). The most common and established AD
risk variant of TREM2 in Caucasian populations is the rs75932628, which results in the
p.R47H amino acid substitution. It has a minor allele frequency (MAF) of 0.0012–0.0063 in
healthy populations110 and 0.009–0.02 amongst AD cases109. Other TREM2 variants have
since been associated with AD and other neurodegenerative diseases including Parkinson’s








disease(s) Population(s) MAF (%) OR (95% CI) References
p.Q33X c.97C>T rs104894002 AD Caucasian 0.15 7.21 (1.28–40.78)* 338
FTD/FTLD Italian 0.9 N/A 339
PD Han Chinese 0 N/A 340
NHD ‡ – – 341–343
p.Y38C c.113A>G rs797044603 AD Caucasian 0.27 ns 109
FTD/FTLD ‡ – – 333,344
NHD ‡ – – 342
PD Han Chinese 0 N/A 340
p.W44X c.132G>A rs104894001 NHD ‡ – – 331
p.R47H c.140G>A rs75932628 AD Caucasian 0.12–2 3.40 (2.65–4.35)* 109,110,334–338
African American 0.11 ns 345
East Asian 0.02 ns* 340,346–354
ALS Caucasian 0.45 2.40 (1.29–4.15) 355
Han Chinese 0 N/A 350
FTD/FTLD Caucasian 2.1 5.06 (1.9–13.51) 356
MSA Han Chinese 0.12 ns 347
PD Caucasian 0.3–1.32 2.67 (1.13–6.33) 335,356
Spanish 0.45 N/A 335
Han Chinese 0–0.2 ns 340,347–349
PSP Caucasian 0.6 ns 356
Stroke Caucasian 0.7 ns 356
p.R62H c.185G>A rs143332484 AD Caucasian 1.53 1.65 (1.24–2.21)* 338,357
African American 0.17 ns 345
PD Han Chinese 0 N/A 340
p.T66M c.197C>T rs201258663 AD Caucasian 0.09 ns 109
FTD/FTLD ‡ – – 333,344,358
PD Han Chinese 0 N/A 340







disease(s) Population(s) MAF (%) OR (95% CI) References
p.W78X c.233G>A rs104893998 NHD ‡ – – 331
p.D86V c.257A>T novel FTD/FTLD ‡ – – 344
p.D87N c.259G>A rs142232675 AD Caucasian 0.55 N/A 109,359
African American 0.06 ns 345
PD Han Chinese 0 N/A 340
p.T96K† c.287C>A rs2234253 AD Caucasian 0.37 ns 109
FTD/FTLD Caucasian 0.5 N/A 360
PD Han Chinese 0 N/A 348
p.A105V c.314C>T rs145080901 AD African American 0.2 ns 345
p.V126G c.377T>G rs121908402 NHD ‡ – – 342
p.D134G c.401A>G rs28939079 NHD ‡ – – 331
p.E151K c.451G>A rs79011726 AD African American 0.35 ns 345
p.H157Y c.469C>T rs2234255 AD Han Chinese 0.4 11.01 (1.38–88.05) 361
Caucasian 0.36 ns 109
p.K186N c.558G>A rs28937876 NHD ‡ – – 331
p.W191X c.572G>A rs2234258 AD African American 3.96 ns 345
p.W198X c.594G>A novel FTD/FTLD ‡ – – 334
p.L211P† c.632T>C rs2234256 AD African American 12.67 1.27 (1.05–1.54) 345
Caucasian 0 N/A 109
FTD/FTLD Caucasian 0.5 N/A 360
Table 1.1. Disease-associated TREM2 variants.
Population-specific minor allele frequencies (MAFs) shown if available. Odds ratio (OR) shown for variants significantly associated with disease.
*: meta-analysis, †: in linkage disequilibrium, ‡: family/individual studies, ns: no statistical significance.
AD: Alzheimer’s disease, ALS: amyotrophic lateral sclerosis, FTD: frontotemporal dementia, FTLD: frontotemporal-like dementia, NHD: Nasu-Hakola
disease, PD: Parkinson’s disease, PSP: progressive supranuclear palsy.
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1.6.1 TREM2 gene expression
The TREM2 gene is located on chromosome 6q21.1 clustered with other TREM family genes,
including TREM1, TREM4, TREM5, TREML1 and TREML2 362. Three alternatively
spliced transcripts are expressed from the human TREM2 gene357. The longest transcript
produces isoform 1, a transmembrane protein with 230 amino acids residues which is
the most highly expressed isoform in human brain363. The other splice variants produce
219- and 222-amino acid isoforms that lack the transmembrane domain and the resulting
proteins are predicted to be secreted. The 219-amino acid isoform has a lower expression
in the hippocampus of AD brains compared to isoform 1364 whereas the expression pattern
of the 222-amino acid isoform is still unknown362.
The expression of TREM2 is regulated by various factors including transcription factors,
epigenetics and post-transcriptional processing. Binding sites for transcriptional factors
such as PU.1, the master regulator of myeloid cell fate365, and retinoid X receptor (RXR)366
are found in the promotor sequences of TREM2 or upstream of the TREM gene cluster.
Increased binding of RXR at this locus is observed only in AD mice but not WT mice
when treated with a RXR agonist367, suggesting that expression of TREM genes may
be modulated in a disease-specific context. Furthermore, it has been suggested that
the transcription factor NFκB may negatively regulate TREM2 expression through a
microRNA34a-mediated mechanism368–373.
Besides that, evidence of epigenetic modulation of TREM2 expression have been found. A
marker of active demethylation, 5-hydroxymethylcytosine (5hmc), on the transcriptional
start site of TREM2 positively correlate with TREM2 mRNA levels in the hippocampus of
human brains363. Other forms of epigenetic changes in AD include increased methylation
upstream of the TREM2 transcription start site that positively correlate with TREM2
protein expression134. Conversely, decreased methylation of CpG sites in Intron 1 of
TREM2 in leucocytes of AD patients correlate with lower TREM2 mRNA374. Moreover,
histone-associated epigenetic markers of active gene transcription H3Kme2 and H3Kme3 are
increased at the TREM2 locus in differentiating dendritic cells and macrophages375 as well
as in db/db mice (model for diabetic dyslipidaemia)376. Both cases have elevated TREM2
mRNA levels, indicating that histone modifications can modulate TREM2 expression.
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Activation of TLR signalling significantly decrease the half-life of TREM2 mRNA in
human-derived peripheral blood mononuclear cells (PBMC)377, suggesting that there may
be post-transcriptional downregulation of TREM2 by pro-inflammatory TLR signalling
occurring in AD.
1.6.2 TREM2 protein
The TREM2 protein is a single-pass transmembrane receptor with an extracellular V-type
immunoglobulin (Ig) domain378 containing N-linked glycosylation sites379–382. TREM2 has
a short cytoplasmic tail with no known function383 and therefore must associate with the
intracellular signalling adaptor protein DNAX-activation protein 12 (DAP12), encoded
by TYROBP, to mediate downstream signalling380,384–386. Binding between TREM2 and
DAP12 occurs at the lysine residue 186 on TREM2 and aspartic acid residue 50 on DAP12
on their respective transmembrane domains387–389 (Figure 1.4).
On TREM2 activation, tyrosine residues within the immunoreceptor tyrosine-based acti-
vation motif (ITAM) on DAP12 become phosphorylated by PKC at residues 79–81 and
by Src-family kinases at residues 85–88390. Src-family kinases consist of eight proteins
with a similar domain arrangement that can be grouped into two subfamilies: Src-related
(Src, Fgr, Fyn, Yes) and Lyn-related (Lyn, Blk, Hck, Lck)391. The expression of Src-family
kinases can vary between cell types392 and it is not fully established which of these mediate
the phosphorylation of DAP12 ITAMs after TREM2 activation. The phosphorylated
tyrosine residues on DAP12 ITAMs then become binding sites for Syk (Figure 1.4). Syk
further activates downstream signalling cascades including phosphatidylinositol 3-kinase
(PI3K)–Akt, mitogen-activated protein kinases (MAPKs), Rac, Vav and intracellular Ca2+
mobilisation through IP3-gated Ca2+ stores380,384,393–400. Activation of TREM2 and sub-
sequent signalling cascades result in immune-related responses such as phagocytosis, cell
migration, proliferation, survival and production of cytokines and chemokines401.
TREM2 is predominantly expressed in myeloid cells including mononuclear phagocytes
such as dendritic cells375,380,402–405, granulocytes406, bone marrow- and monocyte-derived
macrophages375,403,405,407,408, and tissue macrophages such as microglia384,402,409–417, os-
teoclasts385,418,419, Kupffer cells420, alveolar macrophages421,422 and splenocytes384. There
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Figure 1.4. TREM2 associates with DAP12 to mediate downstream signalling.
Binding between these proteins occurs at lysine (K) residue 186 on TREM2 and aspartic
acid (D) 50 on DAP12. The extracellular basic region on TREM2 is associated with anionic
ligand binding which results in phosphorylation of tyrosine residues in the ITAM of DAP12
and recruitment of intermediate signalling proteins. TREM2 variants associated with NHD
(red) and AD (green) affect protein function.
Figure adapted from Ulrich et al. (2017)362.
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are some contradicting evidence for TREM2 expression in monocytes with some studies
reporting a lack of TREM2 expression in circulating monocytes241,375,402,405,423 and others
that did detect TREM2 expression in whole blood374,424–426. Meanwhile, microglial expres-
sion of TREM2 is well established, although several in vivo studies have observed that only
a subset of microglia appear to express TREM2394,427–430. In the brain, TREM2 is highly
expressed but not limited to cells in the white matter402,431, hippocampus402,416,431 and
spinal cord331,416. This expression pattern is likely to reflect the high density of microglia
in these regions402.
TREM2 is normally located intracellularly432 on membranes associated with the trans-Golgi
network416,433,434 and in exocytic vesicles434. The translocation of TREM2 to the cell
surface membrane appears to be mediated by an increase in intracellular Ca2+ levels434
that occurs on immune activation. Membrane-bound TREM2 also appears to be recycled in
clathrin-coated vesicles mediated by Beclin-1231 and Vps35231,435. When TREM2 recycling
is inhibited, the receptor associates with lysosomes and is proteolytically degraded435.
1.6.3 TREM2 ligands
It is not entirely clear what the in vivo ligands of TREM2 are, nor which are the most
relevant to AD. Several in vitro experiments and binding assays have identified lipid
components of the cell membrane, lipoproteins, nucleotides and other anionic molecules as
candidate ligands378,423,429,436–439. ApoE, which is the major apolipoprotein in the CNS
and is strongly associated with AD risk, was found to bind to TREM2106–108,440. The
lipidated form of ApoE binds to TREM2 at a much higher affinity than its non-lipidated
form108. However, TREM2 appears to bind all ApoE isoforms equally, so this interaction
does not appear to connect these two risk genes to AD vulnerability108,440. ApoE can also
bind to apoptotic cells106 and Aβ103,104,441, suggesting that TREM2 may indirectly bind
to these and mediate phagocytosis through ApoE383. Additional apolipoproteins such as
ApoA1, ApoB and ApoJ/clusterin, particularly when lipidated, can also bind to TREM2108.
High-density lipoprotein (HDL) and low-density lipoprotein (LDL) also activate TREM2
signalling, potentially through their lipid moieties108,423. In addition, TREM2 can bind
heparin sulfate proteoglycans and other negatively charged carbohydrates378 as well as
high molecular weight nucleic acids429 and heat-shock protein 60 (Hsp60)442.
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Some studies have suggested that TREM2 can modulate myeloid cell activity in response to
bacterial components443. TREM2 binds to some bacteria including S. aureus, E. coli and
F. tularensis444,445 but not S. cerevisiae439,446, Salmonella or Typinmurin447. Furthermore,
toxins from pertusis448 and cholera449 have been observed to bind to TREM2.
There have been reports of several unidentified TREM2 ligands found on the surface of
macrophages450, astrocytoma439, dendritic cells451, neuroblastoma378,412, monocytes378
and apoptotic cells429. TREM2 deficiency leads to the impairment of microglial responses
against apoptotic cells108,412,429 and it has been suggested that TREM2 binding to apoptotic
cells can occur through externalised phosphatidylserine412 or myelin debris from neuronal
death437.
1.6.4 Effects of disease-associated variants on TREM2 protein
NHD-associated TREM2 variants like the p.Q33X, p.Y38C and p.T66M result in the
functional loss of TREM2. The p.Q33X results in premature truncation of the protein
whereas p.Y38C and p.T66M impair trafficking of TREM2 to the cell surface378,379,432,452,453.
The latter variants cause the protein to accumulate in the endoplasmic reticulum379,452
and lead to an increase in proteosomal degradation of TREM2393. Structural studies
reveal that these residues are located within the Ig fold and these amino acid changes
disrupt disulfide bonds and protein folding of TREM2, which result in decreased protein
stability333,378. The p.T66M variant may also affect gene expression as decreased TREM2
mRNA is found in carriers of the variant454. Despite this, the p.T66M variant appears to
enhance TREM2-DAP12 binding when expressed432. The NHD-associated variants suggest
that other disease-associated TREM2 variants are likely to increase disease risk through
loss of normal TREM2 function.
The most frequent AD-associated p.R47H variant does not appear to impact protein folding,
trafficking, stability or the levels of mRNA or protein364,378,423,438,452,455. However, there
have been mixed findings on the effect of p.R47H on the maturation of TREM2. An
in vitro study found decreased glycosylation of TREM2 with p.R47H452 whereas human
studies have reported no difference in glycosylation levels364 but instead saw changes in
glycosylation patterns379,382. Another study reported that the TREM2 p.R47H variant
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appears to increase lysosomal degradation, which is mediated by decreased association
with Vps35435.
Variants located on the extracellular domain is found to impact ligand binding rather than
alter protein structure. The p.R47H, p.R62H and p.D87N variants have been reported
to decrease ApoE binding to TREM2106,108,378. In addition, p.R47H and p.R62H also
decrease proteoglycan binding to TREM2378. Conversely, p.T96K appears to have an
opposite effect by increasing TREM2 binding affinity to proteoglycans378. Electrostatic
mapping and structural analyses reveal that the p.R47 and p.R62 residues are located
within a large basic region associated with binding of anionic ligands378 (Figure 1.4). On
the other hand, the p.T96 residue is located adjacent to this basic region and the p.T96K
variant is predicted to extend the basic ligand binding region and enhance affinity for
anionic ligands378 (Figure 1.4).
In contrast, variants within the stalk region of TREM2 including p.R136W, p.E151K and
p.H157Y or the intracellular domain such as p.L211P are not expected to affect ligand
binding383. Recently, it has been suggested that the p.H157Y variant may enhance TREM2
cleavage by ADAM10 and ADAM17 to produce soluble TREM2 (sTREM2)456.
1.6.5 TREM2 and Alzheimer’s disease
1.6.5.1 TREM2 effects in AD
A weighted gene co-expression network analysis in several AD mouse models has highlighted
Trem2 as a central gene in an immune-enriched gene module which also contains other
AD risk genes such as Cd33, Inpp5d and Ms4a6d457. A Bayesian network analysis of gene
expression in late onset AD patients found that TYROBP (DAP12) is highly upregulated
and appears to be a key regulatory gene within a complement-enriched gene module185,457.
Additionally, TREM2 protein expression is increased in AD brains363,364,409,458–462 and
AD mice239,417,433,457,463–465, which correlated with amyloid burden417,466,467 especially in
plaque-associated microglia461,462,468–470. AD tau mouse models also exhibit increased
TREM2 expression457,471. The increase in TREM2 expression levels after NFT pathology
is well established in these mice457 and consistent with increased TREM2 levels in the
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later stages of human AD461. Together, these findings highlight the role of innate immune
responses mediated by TREM2 in microglia during AD progression.
1.6.5.2 TREM2 and plaque-associated microglia
Studies using AD mouse models have consistently shown that TREM2 mediates microglial
clustering around amyloid plaques. AD mice haploinsufficient or deficient for TREM2
have fewer plaque-associated microglia239,241,438,468,470,472, especially in younger mice at
the very early stages of pathology241,468. Two of these studies have also observed decreased
total microglial population241,468. Similarly, there are fewer plaque-associated microglia in
DAP12-deficient AD mice470. In humans, AD patients with the TREM2 p.R47H variant
also have fewer plaque-associated microglia compared to AD patients without TREM2
variants470,473. These similar observations between TREM2-deficient mice and AD patients
with the p.R47H variant support the view that the variant conveys a loss-of-function of
TREM2.
1.6.5.3 Role of TREM2 in microglia
High-resolution microscopy of plaque-associated microglia in AD mouse models revealed
microglial processes in contact with amyloid fibrils are highly enriched with TREM2, DAP12
and phosphorylated tyrosine residues that indicate increased activation of the TREM2–
DAP12 signalling pathway470. In haploinsufficient or TREM2-deficient and DAP12-deficient
AD mice, amyloid plaques appear less compact241,470. Amyloid plaque filaments are longer
in TREM2-deficient mice which suggest that TREM2 function is crucial for microglia-
mediated capping of amyloid filament growth and plaque compaction470. AD patients
with TREM2 p.R47H variant also exhibit a relative increase in the number of filamentous,
uncompacted plaques similar to amyloid plaque morphology in TREM2-deficient mice470.
These findings suggest that microglial processes surrounding amyloid plaques may function
to limit exposure of neurotoxic protofibrillar Aβ to adjacent neurons474. Supporting this,
regions of amyloid plaques with the highest Aβ1–42 incorporation also have increased
microglial presence and tend to have increased numbers of dystrophic axons474. Consistent
with this, TREM2- and DAP12-deficient AD mice and AD patients with TREM2 p.R47H
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variant exhibit a greater level of plaque-associated dystrophic axons241,470. Thus, loss of
TREM2 function may result in neuronal damage from increased exposure to neurotoxic Aβ
due to failure of microglia to form a protective barrier around amyloid plaques.
A study has suggested that peripherally-derived macrophages contribute to the TREM2-
expressing cell population in the CNS239. TREM2 is found expressed on CD45hi–Ly6C+–
P2RY12– cells, which are associated with peripheral monocytes, in the brain239. It has
been recently reported that TREM2 expression in post-mortem human brains is exclusive
to intravascular and invading monocytes475. In that study, Iba-1-expressing microglia
and perivascular macrophages were found to be TREM2-negative475, suggesting that
disease-causing mechanisms due to TREM2 variants may not originate in CNS microglia.
1.6.5.4 TREM2 and amyloid pathology burden
Despite consistent observations on the effects of dysfunctional TREM2 on plaque-associated
microglia, the role of TREM2 on amyloid plaque burden is still unclear. While TREM2
haploinsufficiency in APP/PS1 mice did not affect cortical amyloid burden compared to
normal TREM2472, complete deficiency of TREM2 in APP/PS1 mice appear to have age-
dependent effects on amyloid deposition. In these TREM2-deficient APP/PS1 mice, at 2 m
old they have decreased cortical amyloid burden, at 4 m old mice they have similar cortical
amyloid burden and at 8m old they have increased cortical amyloid burden compared
to control APP/PS1 mice239,468. In the 5XFAD mouse model, cortical and hippocampal
insoluble Aβ1–42 and Aβ1–40 load is not affected by TREM2 deficiency at 4 m241 whereas
at 8.5 m, insoluble Aβ1–42 and Aβ1–40 load is increased in the hippocampus but not in
the cortex of TREM2-deficient 5XFAD mice438. The differences observed may be due to
differences in the AD mouse models used that affected the rate of amyloid accumulation.
AD cases with the TREM2 p.R47H variant have more rapid disease progression than
normal473, but their degree of amyloid plaque deposition compared to other people with
AD is less clear. Some studies do not see a difference476 while others find increased
amyloid plaque deposition455 in AD cases with the TREM2 p.R47H compared to AD cases
without TREM2 variants. Mechanisms in which TREM2 modulate amyloid burden is
still not completely understood but evidence so far indicate that dysfunctional TREM2
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impairs phagocytosis and clearance of amyloid by microglia. Alternatively, findings from a
genome-wide siRNA screen indicate that TREM2 signalling could alter APP processing
and therefore the production of Aβ477.
1.6.5.5 TREM2 and neuritic dystrophy
TREM2-deficient AD mice241,470 and AD cases with the TREM2 p.R47H variant455 exhibit
increased neuritic dystrophy around amyloid plaques. In contrast, overexpressing TREM2
increases the levels of synaptophysin, a synaptic marker, in 7-m but not 18-m old AD
mice, hinting that increased TREM2 signalling may be protective against Aβ-mediated
synaptotoxicity417,478. It has been suggested that larger, diffuse amyloid plaques associated
with the later stages in TREM2 deficiency468 have higher levels of soluble Aβ470 which are
synaptotoxic and neurotoxic. Indeed, soluble Aβ oligomers can block LTP479 and induce tau
hyperphosphorylation, resulting in its aggregation480,481. Therefore, dysfunctional TREM2
may alter microglial cytoskeletal responses to negatively impact microglial clustering
and barrier formation around amyloid plaques, which are necessary to restrict neuritic
dystrophy383 as well as being required for effective phagocytosis. In addition, TREM2 may
also mediate phagocytosis and clearance of dystrophic neurites467.
1.6.5.6 TREM2 and tau pathology
Like amyloid pathology, the contribution of TREM2 to tau pathology originating in dys-
trophic neurites remain uncertain. Studies have observed both increased241 and decreased239
tau hyperphosphorylation adjacent to amyloid plaques in TREM2-deficient AD amyloid
mouse models. In a recent study using a TREM2-deficient tau mouse model of FTD482,
these mice exhibited decreased brain atrophy with preserved entorhinal and piriform cortex
volume and less synapse loss compared to mice expressing TREM2. Thus, an absence of
TREM2 which leads to fewer activated microglia and astrocytes may be protective in the
context of tauopathies482. However, the degree of tau pathology appears to be unaffected
by TREM2 deficiency in these mice482. In contrast, TREM2 overexpression driven by
the CD11b promoter results in decreased levels of p-tau in a P301S tau model, which
is associated with decreased levels of the tau kinases CDK5 and GSK3β483. Conversely,
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levels of p-tau is increased when TREM2 expression is knocked down in the same tau
model471. In AD brains, TREM2 protein levels correlate with the degree of tau pathology
in the temporal cortex458. Moreover, CSF levels of sTREM2 and tau also correlate in
early AD484. TREM2 p.R47H AD cases have elevated CSF levels of p-tau compared to the
common variant485,486. These evidence indicate that TREM2 levels may reflect ongoing
neuroinflammation that correlate with the degree of tau pathology in AD.
1.6.5.7 TREM2 and synaptic/neuronal loss
Considering the potential role of TREM2 in modulating amyloid and tau pathology as well
as neuritic dystrophy, it is not surprising that TREM2 is also associated with synaptic
and neuronal loss. TREM2-deficient AD mice exhibit decreased numbers of neurons in
cortical layer V438. In contrast, TREM2 overexpression rescues neuronal loss in amyloid417
and tau483 mouse models of AD. However, in human AD brains, elevated levels of TREM2
protein positively correlate with cleaved caspase 3 (apoptotic marker) and negatively
correlate with SNAP25 (presynaptic marker) in the temporal cortex, indicating increased
neurodegeneration458. Furthermore, TREM2 expression levels negatively correlate with
grey matter volume426. Interestingly, TREM2 p.R47H AD cases also exhibit decreased
grey matter volume in the temporal cortex and hippocampus486,487, which is associated
with cognitive deficits in old age110. While increased TREM2 expression appears to be
neuroprotective in mouse models, TREM2 levels in AD seem to reflect the activity of
microglia in the clearance of apoptotic neurons in vulnerable brain regions during AD.
1.6.6 TREM2 and phagocytosis
Numerous studies have shown that TREM2 is involved in phagocytosis. TREM2 deficiency
in vitro impairs phagocytosis of various substrates including apoptotic neurons106,384,412,429,
components of bone418,488, whole bacteria or bacterial components381,432,442,452 and lipids108,393.
In addition, primary microglia with TREM2 deficiency also exhibit dysfunctional phago-
cytosis of bacteria, fluorescent beads and Aβ1–42 fibrils417,452. TREM2-deficiency in N9
microglial cells and bone marrow-derived macrophages (BMDM) also impair uptake and
clearance of Aβ1–42 and amyloid plaques from brain slice cultures from AD mice489.
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Conversely, increased TREM2 signalling by ligand binding or overexpression enhances
phagocytosis384,394,417. TREM2 levels appear to correlate with phagocytosis of Aβ1–40 in
BV2 microglia with TREM2 knock down or overexpression428. Moreover, TREM2-deficient
primary microglia are ineffective at phagocytosing lipoproteins such as ApoJ/clusterin and
LDL108. By extension, phagocytosis of Aβ1–42 fibrils complexed to clusterin or LDL by
these microglia is also decreased108. Monocyte-derived macrophages from AD patients
with TREM2 p.R62H have lower uptake of Aβ-LDL complexes and Aβ fibrils than those
without the variant108. Interestingly, the loss of TREM2 function can be rescued by
anti-inflammatory TGF-β stimulation. TREM2-deficient primary microglia treated with
TGF-β have comparable levels of phagocytosis of apoptotic cells and Aβ to cells with intact
TREM2438,490.
Together, these findings suggest that TREM2-mediated phagocytosis may require lipopro-
tein interaction with the phagocytic substrate for efficient uptake and may be affected by
microglial activation state. However, there are conflicting evidence that TREM2 activation
alone is sufficient to trigger phagocytosis independent of substrate. TREM2 activation by
Hsp60 increase phagocytosis of bacteria442, indicating that specificity of phagocytosis could
be mediated by other receptors. Supporting this, MerTK, Fc-gamma receptor (FcγR) and
components of the complement cascade which are implicated in phagocytosis are associated
with TREM2 expression402,465. Studies that stimulated TREM2-deficient N9 microglia or
BMDM with antibodies against fibrillar Aβ1–42 observe increased FcγR-mediated phago-
cytosis but this did not return to TREM2 WT levels489. Besides that, C1q expression
increase with phagocytosis in TREM2-deficient alveolar macrophages491. Thus, TREM2 is
not the only receptor involved in phagocytosis and is likely to function in concert with
other receptors to to mediate clearance of pathology.
TREM2-mediated phagocytosis appears to be modulated by proinflammatory signals. On
LPS treatment, the correlation between TREM2 expression and phagocytosis of Aβ by
BV2 microglia is lost428. Similarly, in an in vivo model of sepsis, LPS treatment result in
the failure for injected myeloid cells overexpressing TREM2 to enhance phagocytosis of
bacteria compared to untreated mice492. Curiously, phagocytosis through TREM2 can be
dependent on the cell type. BMDM from TREM2-deficient mice have decreased phagocy-
tosis but TREM2-deficient alveolar macrophages appear to have increased phagocytosis of
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bacteria491.
Disease-associated variants largely impair TREM2 function including phagocytosis. In
microglia, the p.R47H435 and p.R62H108 variants has been reported to impair phagocyto-
sis. Evidence suggests that there may be variant-specific effects on the phagocytosis of
different substrates. TREM2 p.Y38C, p.R47H and p.T66M variants impair phagocytosis
of polystyrene beads whereas p.Y38C and p.T66M but not p.R47H impair phagocytosis of
E. coli particles452.
There are some studies that suggest TREM2 may be involved in lysosomal degradation of
phagocytosed substrates. Gene network analyses have shown that lysosomal-associated
genes are co-regulated with TREM2 in the brain and in monocyte-derived macrophages402.
In addition, the uptake of myelin debris by TREM2-deficient microglia is not impaired
but the debris remain in the cells longer than TREM2-expressing microglia in a study
using models of demyelination493. Furthermore, bacterial uptake is unaffected by TREM2
deficiency in macrophages but they are unable to kill and degrade the bacteria399. Even so,
degradation of Aβ1–42 appears not to be altered by TREM2-deficient primary microglia417,
suggesting that impaired phagocytosis by the loss of TREM2 function may be dependent
on the ligand and phagocytic substrate.
1.6.7 TREM2 and modulation of inflammatory responses
TREM2 expression is found to be co-regulated with the expression of pro- and anti-
inflammatory-associated genes in the brain402. Proinflammatory stimulation in vitro using
TNF-α369,380, IL-1β369,380,485, ROS369,494, IFN-γ495, TLR agonists including
LPS380,381,405,427,494–497, CpGs498 and other ligands377,408,409,427, mitochondrial lysates499
and bacteria491 decrease TREM2 expression. Conversely, anti-inflammatory mediators
such as vasoactive intestinal peptide500 and IL-4495 increase TREM2 expression.
On the other hand, in vitro knockdown of TREM2 expression increase levels of proinflam-
matory mediators including iNOS, TNF-α, IL-1β and IL-6435 after cells are stimulated
with neuronal debris384, Aβ1–42417 and TLR activation381,394,495,497,501. Interestingly, ROS
production in response to bacteria is lower with TREM2 knockdown399,447. Likewise, in
vitro LPS treatment of TREM2-deficient primary microglia lead to exaggerated release of
59
proinflammatory cytokines like IL-1β and TNF-α compared to TREM2-expressing primary
microglia496.
In in vivo models, increased TREM2 expression is generally associated with inflam-
matory responses. Inflammatory stimuli such as cigarette smoke, bacterial and vi-
ral infection, and acute injury in the lungs increase TREM2 expression in alveolar
macrophages421,491,500,502–506. Besides that, high fat diet is associated with increased
numbers of Iba-1- and CD68-expressing cells in the brain507 as well as increased immune-
related gene expression (CCL5, CD97, IL10RB) in adipose tissue which coincides with
increased TREM2508. Increased TREM2 expression is also observed in numerous other
proinflammatory conditions including sepsis492, rheumatoid arthritis509, corneal infection395,
macular degeneration369, glioma510, cancers of the mouth511, oesophagus512 and liver513,
after prosthetic joint implants514, osteoporosis515, mucosal injury of the colon516, colitis517,
gastrointestinal mucositis518 and muscular sarcoidosis519. Furthermore, in neurological
diseases other than AD, TREM2 levels are increased in traumatic brain injury (TBI)520,521,
stroke429,522, spinal nerve transection523, amyotrophic lateral sclerosis355, Parkinson’s dis-
ease524, prion disease415,525, demyelination394,410,437,526,527 and also after Aβ vaccination528.
Moreover, TREM2 expression is also positively correlated with aging in mice433,529 and
humans402. This is likely because aging is associated with chronic systemic inflammation530.
Loss of TREM2 function in in vivo models appears to result in different immune responses
depending on disease. TREM2 knockdown in a tau model of AD and an aging mouse
model increase levels of proinflammatory cytokines460,529. A TREM2-deficient model of
colonic mucosal injury also increase the production of IFN-γ, TNF-α and iNOS516. On
the other hand, decreased expression of proinflammatory cytokines is observed in other
TREM2-deficient models of AD amyloid239,438,468, TBI520, stroke522, lung infection491,502
and demyelination437. Conflicting observations are also seen in studies overexpressing
TREM2. TREM2 overexpressed in in vitro and in vivo models of AD decrease expression
of proinflammatory cytokines417,483. Despite this, activation of TREM2 in vitro in a
macrophage cell line increase NO levels380 and in vivo after spinal nerve injury increase
levels of TNF-α and IL-1β523. Likewise, TREM2 overexpression in mice result in increased
expression of IL-6, TNF-α and MCP-1 in adipose tissue393. These suggest that TREM2 may
differentially affect the regulation of inflammatory responses depending on the underlying
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pathology, potentially mediated by the different ligands that bind TREM2 in these diseases.
There are limited studies that looked at the effects of TREM2 variants on inflammatory
responses. The p.R47H variant increase proinflammatory Il6 and Tnf mRNA expression in
response to LPS compared to WT TREM2 in BV2 microglia435. Similarly, RANTES and
IFN-γ are increased in AD cases with the p.R47H variant compared to normal TREM2455.
Other studies have suggested that TREM2 may modulate astrocyte function. TREM2-
deficient mouse models of AD239,468 and demyelination493 exhibit decreased astrocyte
activation as measured by GFAP levels. However, GFAP is unaltered in a TREM2-deficient
TBI mouse model520, suggesting that TREM2 may have disease-specific effects on astrocyte
activation. Additionally, expression of TREM2 may be associated with the activation of the
adaptive immune system. Myeloid cells with elevated levels of TREM2 are more effective at
inducing T cell proliferation428. Gene network analyses also found that TREM2 co-enriched
with genes associated with T cell- and B cell-mediated adaptive immunity402. However,
TREM2 activation did not lead to increased expression of antigen presentation-associated
proteins394,531, suggesting that TREM2 may require other signals to activate adaptive
immune responses.
In summary, TREM2 function appears to mediate and modulate numerous inflammatory
responses. In various in vivo models of diseases associated with proinflammatory responses,
the level of TREM2 is increased, likely reflecting microglial activity. However, TREM2
deficiency in mouse models result different inflammatory responses depending on disease
context. The TREM2 p.R47H variant seem to result in increased proinflammatory responses,
similar to the effects of in vitro TREM2 deficiency. TREM2 appear to affect the activity
of other cell types including astrocytes and T cells but further investigation is required to
confirm the role of TREM2 in modulating their activation in context of disease.
1.6.8 TREM2 and chemotaxis/migration
The loss of TREM2 function also impairs chemotaxis. TREM2 knockdown decrease chemo-
tactic response in BV2 microglia in a scratch assay428. TREM2 deficiency in glioma also
impair chemotaxis towards serum and downregulated genes involved in tissue invasion such
as CXCL10, CXCR3, MMP2 and MMP9510. Likewise, TREM2-deficient primary microglia
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are found to downregulate chemotaxis-related genes relative to TREM2-expressing primary
microglia532. Furthermore, chemotaxis of TREM2-deficient microglia towards AD mouse
brain slice cultures when co-cultured together is impaired532. TREM2 deficiency also
decrease migration of N9 microglia towards CCL2 and C5a in transwell assays532. In
contrast, TREM2 activation by antibody stimulation increase CCR7-mediated chemo-
taxis380,384,385. Additionally, network analyses revealed TREM2 co-enriched with genes
involved in purinergic signalling which is implicated in mediating microglial chemotaxis402,
although TREM2 regulation of purinergic receptor-mediated chemotaxis has yet to be
investigated. DOCK2 and DOCK8, associated with tissue transmigration, are also co-
expressed with TREM2402. However, other studies found conflicting evidence for the role
of TREM2 in chemotaxis. Chemotaxis is not impaired in osteoclasts derived from NHD
patients with TREM2 variants418. PBMC derived from similar patients exhibit mixed
expression of genes involved in chemotaxis as well405. These suggest that TREM2-mediated
chemotaxis may be dependent on cell type.
TREM2-deficient mice with middle cerebral artery occlusion have decreased microglial
infiltration associated with decreased levels of CCL2522. Similarly, DAP12-deficient mice
have decreased recruitment of peripheral macrophages into the lungs in response to cigarette
smoke or intranasal CCL2 treatment421. These effects are ameliorated by the introduction
of a TREM2–DAP12 fusion construct421, suggesting that immune cell recruitment could
be mediated by TREM2 signalling.
1.6.9 TREM2 and cell survival/proliferation
Knockdown of TREM2 in primary microglia lower cell survival in culture496. In in vivo
models, TREM2-deficient AD mice have decreased total brain myeloid cells241,438, which
is linked to the loss of plaque-associated myeloid cells468,470. This change could be due
to increased apoptosis and/or decreased proliferation. The lack of TREM2 in various
cell types including osteoclasts397, BMDM426, hepatic cancer513 and glioma510 increase
the levels of caspase 3, Bax, Annexin V and TUNEL positive staining that are markers
of apoptosis. Likewise, plaque-associated microglia in TREM2-deficient AD mice have
increased expression of apoptotic markers438. However, PBMC-derived osteoclasts with
the NHD-associated TREM2 E14X variant that results in the loss of functional TREM2
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do not appear more vulnerable to apoptosis418. Correspondingly, primary microglia and
BV2 microglia with decreased TREM2 expression have lower cell survival associated
with decreased levels of Wnt/β-catenin signalling components533. Furthermore, decreased
TREM2 expression in microglia533, glioma510 and hepatic cancer cells513 results in cell
cycle arrest.
Cell proliferation may be modulated by TREM2 as well. TREM2 deficiency in osteoclast
precursor cells prevents CSF1R-mediated proliferation397, a key signalling pathway for
proliferation of myeloid cell types383. Myeloid cell proliferation is decreased in TREM2-
deficient in vivo models of AD241,468, demyelination437,493, colonic mucosal injury516, TBI520,
ischaemia429,522 and aging437. These suggest that loss of TREM2 function can lower cell
survival, resulting in increased apoptosis as well as reduce proliferation to decrease overall
cell density.
1.6.10 Soluble TREM2
sTREM2 is produced from cleavage of TREM2 by ADAM10 and ADAM17380,452,456,534.
Similar to APP, the remaining membrane-bound fragment after ADAM10/17 processing
can be cleaved by γ-secretase534 to produce carboxy-terminal fragments (CTFs). NHD-
associated TREM2 variants p.Y38C and p.T66M appear to dramatically decrease sTREM2
release in vitro452,535, potentially due to impaired protein trafficking to the cell mem-
brane378,379,432,452,453. On the other hand, the AD-associated TREM2 variant p.R47H
exhibit an intermediate phenotype relative to the p.Y38C and p.T66M variants with
slightly decreased sTREM2 release382,452, which the mechanism remain unclear. It has
been suggested that the p.R47H variant partially impairs protein trafficking compared to
the p.Y38C and p.T66M variants and result in intermediate protein degradation382. Inter-
estingly, the AD-associated TREM2 variant p.H157Y361 is located at the recently identified
ADAM10/17 cleavage site of TREM2456. ADAM10/17 has an increased preference for
tyrosine at the P1’ position of its cleavage site and therefore the p.H157Y variant may
enhance proteolytic cleavage of TREM2 to release sTREM2. This suggests a potential loss
of TREM2 function due to decreased availability of membrane-bound TREM2 to mediate
innate immune signalling.
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The physiological role of sTREM2 is yet to be elucidated. sTREM2 may act as a decoy
receptor to negatively regulate TREM2 signalling452,527. Supporting this, osteoclastogenesis,
which is dependent on TREM2 signalling is inhibited by a chimaeric TREM2-Fc protein used
to model sTREM2536. Besides that, sTREM2 appear to enhance cell survival. Treatment
of sTREM2 on microglia with or without TREM2 expression537 and TREM2-deficient
BMDM489 improve cell survival which is not associated with increased cell proliferation.
sTREM2 is found to activate Akt–GSK3β–β-catenin and NFκB signalling pathways to
mediate microglial cell survival537. sTREM2 also appears to modulate inflammatory
responses. In vitro treatment of sTREM2 on primary microglia results in increased
expression of proinflammatory cytokine genes such as Il1b, Il6, Il10 and Tnf but not anti-
inflammatory related genes like Arg1 and Ym1 537. Similar treatment on TREM2-deficient
primary microglia also results in the same observations537, indicating that sTREM2-
mediated activation is independent of full length TREM2 expression and there may be an
endogeneous receptor for sTREM2. AD-associated TREM2 p.R47H and p.R62H variants
also appear to impair sTREM2-mediated proinflammatory activation and survival537. It is
further suggested that intracellular cleavage by-products of TREM2 may have a functional
role in regulating inflammatory activation. TREM2 CTFs promote TREM2-mediated
anti-inflammatory signalling in response to LPS501. Alternatively, these fragments could
negatively regulate TREM2 signalling by sequestering DAP12 and decreasing DAP12
association with receptors534. This leads to a decrease in overall DAP12 phosphorylation
and lower activation of downstream signalling pathways534,538.
So far, established fluid biomarkers for AD include Aβ1–42 and tau levels in the CSF. The
earliest detectable change in AD is the decrease in CSF Aβ1–42 level539 associated with
its incorporation into amyloid plaques540. This can occur many years before symptoms
of dementia show539 (Figure 1.5). On the other hand, CSF tau and p-tau correlate with
the progression of tau pathology in the brain which is indicative to neuronal damage
and cognitive deficits541. Recently, studies have suggested that the proteolytic cleavage
of TREM2 to produce sTREM2 reflect ongoing inflammation in AD associated with the
transition of pre-clinical to symptomatic AD452,527 (Figure 1.5). CSF sTREM2 levels
are increased in AD patients and positively correlate with CSF tau and p-tau but not
Aβ1–42484,535,542,543 (Figure 1.5). This seems contrary to the functional consequences of
TREM2 deficiency on amyloid burden and implies that CSF sTREM2 level is associated
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with neuronal damage rather than amyloid plaque deposition362. In pre-clinical AD, CSF
sTREM2 level appears normal but is increased in patients with AD-associated MCI484
(Figure 1.5). CSF sTREM2 is also increased after deposition of Aβ and coincide with changes
in hippocampal volume, precuneus glucose metabolism and cognitive performance484.
Moreover, CSF sTREM2 level is elevated in familial AD cases with cognitive deficits
but not in cognitive normal cases484. Further implication of CSF sTREM2 level and
neuroinflammation is seen in MS patients treated with an antibody inhibiting T cell
migration into the CNS, which result in decreased CSF sTREM2 and inflammation as well
as improvements in clinical outcome544. CSF sTREM2 level appears to be elevated in AD
patients with the TREM2 variant p.R47H but not in p.R62H when compared to cognitively
normal controls535. However, this study was performed in a small cohort and cases with
TREM2 variants were a mixture of symptomatic AD and cognitively normal individuals535.
There are some studies that reported contradicting findings on CSF sTREM2 level in AD
which are unchanged452 or decreased545 compared to control cases. It could be that CSF
sTREM2 increases in early clinical AD and fall off in the later stages of AD484 (Figure 1.5).
Figure 1.5. CSF levels of Aβ1–42, p-tau and sTREM2 changes throughout the
progression of AD.
CSF Aβ1–42 decrease as amyloid deposition begin in the brain while p-tau and sTREM2, in
correlation, increase with neuronal damage, neuroinflammation and progression of cognitive
deficits.
Figure adapted from Ulrich et al. (2017)362.
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1.6.11 Conclusion
TREM2 appears to be involved in various microglial-mediated innate immune responses
that occur in AD. Some of these responses, particularly those that are related to im-
munoregulation towards anti-inflammatory effects and clearance of pathology and cellular
debris by phagocytosis appear to be beneficial by suppressing cytotoxic proinflammatory
responses. Studies investigating TREM2 dysfunction found that disease-associated TREM2
variants, which increases the risk of developing neurodegenerative diseases like AD result in
a similar phenotype to TREM2-deficient models. This suggests that most of these variants
convey a loss or decreased TREM2 function. However, protein structure and tracking
studies observed that the variants have different effects on TREM2, either affecting ligand
binding, protein folding, post-transcriptional modifications or protein cleavage. Apart
from the variants that cause loss of functional TREM2 expression on the cell membrane,
it is unclear how these variants impact signalling pathways downstream of TREM2 and
lead to dysfunctional inflammatory responses. Although there is an increasing number of
studies exploring the role of TREM2, studies that use experimental models endogeneously
expressing the TREM2 variants to study their effects on AD pathogenesis have been limited.
Furthermore, to my knowledge, there has not been any studies investigating the effects of
these variants on the signalling pathways downstream of TREM2.
Thus, this project will explore and generate an in vitro model carrying the disease-associated
TREM2 variants with endogeneous downstream signalling pathways suitable for use in
screening assays. The cell model will then be characterised for changes in key proteins
of the signalling pathways downstream of TREM2 to elucidate differences caused by the
disease-associated variants. This will pave the way for these cells to be used to screen
therapeutic compounds that can take advantage of the beneficial effects of TREM2 function.
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1.7 Aims and objectives
Overall aim
To generate an in vitro model carrying disease-associated TREM2 variants with endogeneous
downstream signalling components. The generated cells will be characterised for changes
in key signalling proteins downstream of TREM2 as well as functional phenotype due
to disease-associated TREM2 variants. These cells can then be used to screen disease-
modifying therapeutic compounds.
Specific aims
1. To identify a suitable cell model for use in large scale or high-throughput experiments
and introduce the AD-associated TREM2 variants into the cells.
(a) To choose a cell type relevant for TREM2 function and AD.
(b) To use the most effective method to perform genome editing.
2. To study the effects of disease-associated TREM2 variants on microglia in the
hippocampus of AD brains.
(a) To assess abundance and morphological activation of microglia expressing com-
monly used functional microglial markers between disease-associated TREM2
variant carriers and normal TREM2 carriers.
(b) To establish microglial markers from dysfunction conveyed by disease-associated
TREM2 variants in people, which can be used to characterise the generated in
vitro TREM2 model.
3. To characterise the generated in vitro TREM2 model.
(a) To confirm that CRISPR/Cas9-mediated editing of Trem2 in the generated cell
line resulted in the expected functional expression of TREM2 protein.
(b) To investigate changes in the activation of key signalling mediators downstream
of TREM2 and compare functional microglial markers identified from people







Reagent Catalog # Manufacturer
100 bp DNA Ladder 15628-019 Thermo Fisher Scientific
Acetic acid, glacial 20102 VWR Chemicals
Adenosine 5’-triphosphate (ATP) P0756 New England Biolabs
Aluminium potassium sulfate dodecahydrate 10647411 Acros Organics
Ammonium acetate (7.5M) A2706 Sigma-Aldrich
Avidin biotin complex horseradish peroxidase solution,
VECTASTAIN Elite ABC HRP Kit (Peroxidase, Standard)
PK-6100 Vector Laboratories
Bicinchoninic acid (BCA) protein assay 10678484 Thermo Fisher Scientific
BlueJuice Gel Loading Buffer (10×) 10816015 Thermo Fisher Scientific
Boric acid B7660 Sigma-Aldrich
Bovine serum albumin (BSA) sc-2323 Santa Cruz
Cell Line Nucleofector Kit L VCA-1005 Lonza
Cell Line Optimization Nucleofector Kit for Nucleofector 2b
Device
VCO-1001N Lonza
CellTracker Red CMTPX Dye C34552 Thermo Fisher Scientific
Chloroform (99+%, stabilised with amylene) AC167735000 Acros Organics
Dabco 33-LV 290734 Sigma-Aldrich
3,3’-diaminobenzidine tetrahydrochloride (DAB) D5905 Sigma-Aldrich
DPX new 100579 Merck
Dulbecco’s Modified Eagle Medium (DMEM), high glucose,
GlutaMAX, pyruvate
31966 Thermo Fisher Scientific
Dimethyl sulfoxide (DMSO) D5879 Sigma-Aldrich
DL-Dithiothreitol (DTT) D0632 Sigma-Aldrich
Dulbecco’s phosphate-buffered saline (DPBS) 14190 Thermo Fisher Scientific
EndoFree Plasmid Maxi Kit 12362 QIAGEN
Ethanol, absolute E7023 Sigma-Aldrich
Ethylenediaminetetraacetic acid (EDTA, 0.5 M) 03690 Sigma-Aldrich
Ethylenediaminetetraacetic acid disodium salt dihydrate E4884 Sigma-Aldrich
FastDigest BpiI (BbsI) FD1014 Thermo Fisher Scientific
Filter paper, grade 3 qualitative 1003-917 GE Healthcare
Foetal bovine serum (FBS), heat inactivated 10500064 Thermo Fisher Scientific
Formic acid (80%) 20315 VWR Chemicals
Formalin solution, neutral buffered (NBF, 10%) HT501128 Sigma-Aldrich
FuGENE 6 Tranfection Reagent E2693 Promega
GelRed nucleic acid stain (10,000×) BT41003 Biotium
Glycerol G5516 Sigma-Aldrich
Glycine sc-29096B Santa Cruz
Haematoxylin monohydrate 115938 Merck
Hoechst 33342, trihydrochloride, trihydrate solution in water H3570 Thermo Fisher Scientific
Hydrochloric acid (HCl, 5 M) 10695872 Fisher Chemical
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Reagent Catalog # Manufacturer
Hydrogen peroxide (H2O2, 30%) 23615 VWR Chemicals
Industrial methylated spirit (IMS, 99%) IMS005 Solmedia Ltd
Isopropanol 20839.297 VWR Chemicals
KASP V4.0 2× Master mix, High ROX KBS-1016-022 LGC Genomics
LB agar, powder (Lennox L Agar) 22700 Thermo Fisher Scientific
LB broth base 12780 Thermo Fisher Scientific
Lipofectamine 2000 transfection reagent 11668 Thermo Fisher Scientific
Lipofectamine 3000 transfection reagent L3000 Thermo Fisher Scientific
Methanol MET005 Solmedia Ltd
MicroAmp Clear Adhesive Film 4306311 Thermo Fisher Scientific
MicroAmp Optical Adhesive Film 4311971 Thermo Fisher Scientific
Mowiol 4-88 81381 Sigma-Aldrich
Nitrocellulose membrane, Amersham Protran NC 15259804 GE Healthcare
Nocodazole, Ready Made Solution SML1665 Sigma-Aldrich
Normal goat serum X0907 Dako
Normal swine serum X0901 Dako
Nuclease-free water (not DEPC-treated) AM9937 Ambion
NuPAGE Antioxidant NP0005 Thermo Fisher Scientific
NuPAGE LDS Sample Buffer (4×) NP0007 Thermo Fisher Scientific
NuPAGE MOPS SDS Running Buffer (20×) NP0001 Thermo Fisher Scientific
NuPAGE 4-12% Bis-Tris Midi Protein Gels, 26-well WG1403BOX Thermo Fisher Scientific
NuPAGE Sample Reducing Agent (10×) NP0004 Thermo Fisher Scienfitic
One Shot Stbl3 chemically competent E. coli C737303 Thermo Fisher Scientific
OneTaq Hot Start 2× Master Mix with Standard Buffer M0484 New England Biolabs
Opti-MEM I Reduced Serum Medium 31985047 Thermo Fisher Scientific
Penicillin-streptomycin 15140122 Thermo Fisher Scientific
Phenol/chloroform/isoamyl alcohol (25:24:1 mixture, pH 8.0) 10306413 Fisher BioReagents
Phosphatase inhibitor tablets, PhosSTOP 4906845001 Roche
PolyFect Transfection Reagent 301105 QIAGEN
Ponceau S P3504 Sigma-Aldrich
Protease inhibitor cocktail, cOmplete ULTRA Tablets,
Mini, EDTA-free, EASYpack
5892791001 Roche
Precision Plus Protein All Blue Prestained Protein Standards 1610373 Bio-Rad
Protein Deglycosylation Mix P6039S New England Biolabs
Protein Deglycosylation Mix II P6044S New England Biolabs
Puromycin dihydrochloride sc-108071 Santa Cruz
QIAamp DNA Mini Kit 51306 QIAGEN
QIAGEN Plasmid Plus Midi Kit 12945 QIAGEN
QIAprep Spin Miniprep Kit 27106 QIAGEN
QIAquick Gel Extraction Kit 28706 QIAGEN
QIAquick PCR Purification Kit 28106 QIAGEN
QIAvac 24 Plus 19413 QIAGEN
QIAzol Lysis Reagent 79306 QIAGEN
Quick-Load 100 bp DNA Ladder N0467 New England Biolabs
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Reagent Catalog # Manufacturer
Radioimmunoprecipitation assay (RIPA) buffer R0278 Sigma-Aldrich
RNeasy Plus Universal Mini Kit 73404 QIAGEN
Roswell Park Memorial Institute (RPMI) 1640 medium 21875 Thermo Fisher Scientific
Sodium chloride (NaCl) 71376 Sigma-Aldrich
Tri-sodium citrate dihydrate 10448610 Fisher Chemical
Sodium dodecyl sulfate (SDS, 10%) 71736 Sigma-Aldrich
Sodium iodate S4007 Sigma-Aldrich
Sudan Black B 199664 Sigma-Aldrich
SuperScript IV Reverse Transcriptase 18090200 Thermo Fisher Scientific
T4 DNA ligase EL0014 Thermo Fisher Scientific
T4 polynucleotide kinase M0201 New England Biolabs
Tris base 30-20-60 Severn Biotech Ltd
Tris-borate-EDTA (TBE) buffer (10×) T4415 Sigma-Aldrich
Tris-HCl (1 M) T2694 Sigma-Aldrich
Triton X-100 X100 Sigma-Aldrich
Trypsin-EDTA (0.25%), phenol red 25200 Thermo Fisher Scientific
TurboFect transfection reagent R0533 Thermo Fisher Scientific
Tween 20 P5927 Sigma-Aldrich
UltraPure Agarose 16500 Thermo Fisher Scientific
Xylene XYL005 Solmedia Ltd
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2.1.2 Solutions
Solution Reagent Amount Stock conc.
Working
conc.
100 bp DNA Ladder (10
ng/µL)
100 bp DNA Ladder 1 µL 1 µg/µL 10 ng/µL
10× BlueJuice Gel Loading
Buffer
10 µL 10× 1×
ddH2O Up to 100 µL
Acid alcohol (1% v/v)
HCl (5 M) 3 mL - 1% v/v
IMS 210 mL - 70% v/v
dH2O Up to 300 mL
Antibody stripping buffer
Glycine 7.5 g - 200 mM
SDS (10%) 5 mL - 0.1% v/v
Tween 20 5 mL - 1% v/v
HCl (5 M) ∼10.5 mL (or to pH 2.2)
ddH2O Up to 500 mL
Citrate-buffered saline
(CBS, 10×, pH 6.0)
Tri-sodium citrate dihydrate 29.4 g 100 mM 10 mM
HCl (5 M) ∼4 mL (or up to pH 6.0)
ddH2O Up to 1 L
Direct-Lyse lysis buffer
(0.5×)
Tris base 0.61 g - 10 mM
EDTA 0.37 g - 2.5 mM
NaCl 5.85 g - 200 mM
SDS (10%) 7.5 mL - 0.15% v/v
Tween 20 1.5 mL - 0.3% v/v
ddH2O Up to 500 mL
DNA extraction cell lysis
buffer (1×)
Tris-HCl (1 M) 5 mL - 10 mM
EDTA (0.5 M) 25 mL - 25 mM
NaCl 2.19 g - 75 mM
SDS (10%) 25 mL - 0.5% v/v
ddH2O Up to 500 mL
Harris’ haematoxylin
Haematoxylin monohydrate 5 g - 15.6 mM
Absolute ethanol 50 mL - -
Aluminium potassium sulfate
dodecahydrate
100 g - 210 mM
ddH2O 950 mL
Sodium iodate 370 mg - 1.87 mM
Glacial acetic acid 4 mL - 70 mM
Mowiol hard set aqueous
mounting medium
Mowiol 4-88 2.4 g - -
Glycerol 6 g/ 4.75 mL - -
ddH2O 6 mL
Tris-Cl (0.2 M, pH 8.5) 12 mL - -
Dabco 33-LV Variable - 2.5% v/v
Ponceau S staining
solution
Ponceau S 2.5 g - 0.5% w/v
ddH2O 495 mL
Glacial acetic acid 5 mL - 1% v/v
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Solution Reagent Amount Stock conc.
Working
conc.
Sodium boric acid (SBA)
buffer (20×)
Boric acid 45 g 730 mM 36.5 mM
Sodium hydroxide 8 g 200 mM 10 mM
ddH2O Up to 1 L
Transfer buffer (10×)
Tris base 30.29 g 250 mM 25 mM
Glycine 144.13 g 1.92 M 192 mM
ddH2O Up to 1 L
Transfer buffer (1×,
working solution)
10× transfer buffer 100 mL 10× 1×
Methanol 200 mL - 20% v/v
ddH2O Up to 1 L
Tris-acetate-EDTA (TAE,
50×, pH 8.3)
Tris base 242 g 2.0 M 40 mM
EDTA (0.5 M) 100 mL 50 mM 1 mM
Glacial acetic acid 57.1 mL 2.0 M 40 mM
ddH2O Up to 1 L
Tris-buffered saline (TBS,
10×, pH 7.6)
Tris base 60.45 g 500 mM 50 mM
NaCl 87.66 g 1.5 M 150 mM
HCl (5 M) ∼81.5 mL (or to pH 7.6)
ddH2O Up to 1 L
TBS-T 0.1%
10× TBS 100 mL 10× 1×
Tween 20 1 mL - 0.1% v/v
ddH2O Up to 1 L
TBS-Tx 0.1%
10× TBS 10 mL 10× 1×
Tritox X-100 100 µL - 0.1% v/v
ddH2O Up to 100 mL
TBS-Tx 0.25%
10× TBS 10 mL 10× 1×
Tritox X-100 250 µL - 0.25% v/v
ddH2O Up to 100 mL
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2.1.3 Primers and oligonucleotides
2.1.3.1 PCR primers




Table 2.1. All PCR primers used. Red font: sequencing primer M13F or M13R.
2.1.3.2 RT-PCR primers








































Table 2.2. All RT-PCR primers used. Red font: sequencing primer M13F or M13R.
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2.1.4 Antibodies
Primary antibody Catalog # Manufacturer
Anti β-actin (clone C4), mouse, monoclonal sc-47778 Santa Cruz
Anti amyloid-β1-16 (clone 6E10) Alexa Fluor 488, mouse,
monoclonal 803013 BioLegend
Anti amyloid-β17-24 (clone 4G8), mouse, monoclonal 800701 BioLegend
Anti human CD68 (clone PG-M1), mouse, monoclonal M087601-2 Dako
Anti mouse CD68/macrosialin (clone FA-11), rat, monoclonal 137001 BioLegend
Anti Erk1/2 (p44/42 MAPK, clone L34F12), mouse, monoclonal 4696 Cell Signalling Technology
Anti phospho-Erk1/2 (p44/42 MAPK) Thr202, Tyr204 (clone
D13.14.4E), rabbit, monoclonal 4370 Cell Signalling Technology
Anti GAPDH, rabbit, polyclonal sc-25778 Santa Cruz
Anti human HLA-DP, DQ, DR (clone CR3/43), mouse,
monoclonal M0775 Dako
Anti I-A/I-E (MHC class II, clone M5/114.15.2), rat, monoclonal 107601 BioLegend
Anti Iba-1, rabbit, polyclonal 019-19741 Wako
Anti Pyk2 (clone 5E2), mouse, monoclonal 3480 Cell Signalling Technology
Anti phospho-Pyk2 Tyr402, rabbit, polyclonal 3291 Cell Signalling Technology
Anti Syk (clone 6A464), mouse, monoclonal sc-73089 Santa Cruz
Anti phospho-Syk Tyr525, Tyr526 (clone C87C1), rabbit,
monoclonal 2710 Cell Signalling Technology
Anti tau, rabbit, polyclonal A0024 Dako
Anti phospho-tau Ser202, Thr205 (clone AT8), mouse,
monoclonal MN1020 Thermo Fisher Scientific
Anti human TREM2, goat, polyclonal AF1828 R&D Systems
Anti human TREM2, rabbit, polyclonal HPA012571 Atlas Antibodies
Anti human/mouse TREM2 (clone 237920), rat, monoclonal MAB17291 R&D Systems
Anti mouse TREM2, rabbit, polyclonal sc-48765 Santa Cruz
Anti mouse TREM2, sheep, polyclonal AF1729 R&D Systems
IgG2B isotype control, rat, monoclonal MAB0061 R&D Systems
Table 2.3. All primary antibodies used for immunohistochemistry, immunoflu-
orescence, and Western blotting.
Secondary antibody Catalog # Manufacturer
Anti mouse IgG, goat, polyclonal, biotinylated E0433 Dako
Anti rabbit IgG, swine, polyclonal, biotinylated E0353 Dako
Anti mouse IgG, goat, polyclonal, Alexa Fluor 488 A11001 Thermo Fisher Scientific
Anti mouse IgG, goat, polyclonal, Alexa Fluor 568 A11004 Thermo Fisher Scientific
Anti mouse IgG, goat, polyclonal, Alexa Fluor 680 A21057 Thermo Fisher Scientific
Anti rabbit IgG, goat, polyclonal, Alexa Fluor 488 A11008 Thermo Fisher Scientific
Anti rabbit IgG, goat, polyclonal, Alexa Fluor 594 A11012 Thermo Fisher Scientific
Anti rat IgG, goat, polyclonal, Alexa Fluor 488 A11006 Thermo Fisher Scientific
Anti sheep IgG, donkey, polyclonal, Alexa Fluor 488 A11015 Thermo Fisher Scientific
Table 2.4. All secondary detection antibodies used for immunohistochemistry,
immunofluorescence, and Western blotting.
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2.2 Methodology for Chapter 3
2.2.1 sgRNA and HDR template design
2.2.1.1 sgRNA
sgRNA sequences were designed using the CRISPR Design Tool (http://crispr.mit.edu)
where mouse Trem2 Exon 2 was used as the input to search for viable sgRNA sequences.
sgRNA targeting sequences, while relatively flexible, require a NGG protospacer adjacent
motif (PAM) sequence next to the 20 nt sgRNA sequence546. A double Cas9 nickase
(Cas9n) design was used and this requires a sgRNA for each nickase. Therefore, a pair of
sgRNA sequences were designed to flank the target region for the knock-in mutation, with
each sgRNA targeting opposite DNA strands to induce a double-stranded DNA (dsDNA)
break546. For this project, 4 design strategies with iterative improvements were employed.
For CRISPR v1, the CRISPR/Cas9 strategy used was based on a published protocol and
adapted for BV2 using the double Cas9 nickase design546. The sgRNA pairs used were
designed to target the AD-associated rs75932628 (human and mouse c.140G>A, p.R47H)
TREM2 variant in mouse (Table 2.5). The location and orientation of the sgRNA targeting
sequences are shown in Figure 2.1.
For CRISPR v2, a new sgRNA pair targeting the p.R47H variant were designed slightly
further apart to check if CRISPR v1 sgRNA pair was ineffective in inducing HDR activity
(Table 2.6, Figure 2.2).
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Table 2.5. CRISPR v1 sgRNA pair targeting the Trem2 p.R47 codon.
Top and bottom ssDNA oligonucleotides were phosphorylated and annealed into dsDNA
fragments for cloning.
Blue font: sgRNA sequences; red font: additional G-C for compatibility with U6 promoter.
CRISPR v1 sgRNA pair design
Figure 2.1. CRISPR v1 sgRNA pairs targeted sequences flanking the Trem2
p.R47 codon to nick on both DNA strands and create a 5’ DNA overhang.
A region of mouse Trem2 Exon 2 sequence showing the sgRNA pair targeting sequences
for CRISPR v1.
Yellow highlight: sgRNA sequence, green highlight: PAM sequence, bold font: targeted
p.R47 codon, underlined font: targeted c.140G, red arrows: Cas9n nicks, and blue dotted
lines: DNA separation after double nicking.
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Table 2.6. CRISPR v2 sgRNA pair targeting Trem2 p.R47 codon.
Blue font: sgRNA sequences; red font: additional G-C for compatibility with U6 promoter.
CRISPR v2 sgRNA pair design
Figure 2.2. CRISPR v2 sgRNA pairs target sequences flanking the Trem2
p.R47 codon.
A region of mouse Trem2 Exon 2 sequence showing the sgRNA pair targeting sequences
for CRISPR v2.
Yellow highlight: sgRNA sequence, green highlight: PAM sequence, bold font: targeted
p.R47 codon, underlined font: targeted c.140G, red arrows: Cas9n nicks, and blue dotted
lines: DNA separation after double nicking.
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For CRISPR v3, sgRNA pairs targeting other dementia-associated rs104894002 (human
c.97C>T, p.Q33X and mouse c.97AG>TA p.R33X) and rs142232675 (human and mouse
c.259G>A, p.D87N) TREM2 variants in mouse were designed to test if the lack of HDR
was unique to the p.R47 loci on Trem2 (v3a). Additionally, a second set (v3b) of sgRNA
pairs targeting the sgRNA-blocking mutations introduced by the v3a HDR templates (see
Chapter 2.2.1.2: HDR template) for p.R47H, p.Q33X and p.D87N variants were designed
to explore the possibility to revert the sgRNA-blocking mutations back to the WT sequence
as described by Paquet et al547 (Table 2.7, Figure 2.3).
For CRISPR v4, only the sgRNA pair targeting the p.R47H variant from CRISPR v2/v3a
were used.
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Table 2.7. CRISPR v3 sgRNA pairs targeting p.R47H, p.Q33X and p.D87N
variants in mouse Trem2.
Blue font: sgRNA sequences; red font: additional G-C for compatibility with U6 promoter;
green font: sgRNA-blocking mutations.
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(a) CRISPR v3 Q33X
(b) CRISPR v3 D87N
(c) CRISPR v3 R47H
Figure 2.3. CRISPR v3 sgRNA pairs targeted sequences flanking Trem2
p.Q33X, p.D87N and p.R47H variants.
Regions within mouse Trem2 Exon 2 sequence showing sgRNA pairs targeting the (a)
p.Q33X, (b) p.D87N, and (c) p.R47H variants for CRISPR v3a and v3b.
Yellow highlight: sgRNA sequence, green highlight: PAM sequence, bold font: targeted
codon, underlined font: targeted base for knock-in mutation, red font: sgRNA-blocking




HDR templates used were single-stranded DNA (ssDNA) oligonucleotides with the knock-in
mutation in the middle with at least 40 nt flanking homology arms as recommended by
Ann Ran et al546. These can correspond to the sense or anti-sense orientation of mouse
Trem2 genomic DNA (gDNA) sequence. The R47H and D87N HDR templates were 181
nt long (90 nt flanking homology arms) and the Q33X was 113 nt long (56 nt flanking
homology arms), which were ordered as Ultramer oligonucleotides from Integrated DNA
Technologies. Upon receiving these, they were reconstituted to 100 µM with nuclease-free
water or endotoxin-free TE buffer.
For CRISPR v1, the HDR template used did not contain any modifications other than
the intended knock-in mutation for the p.R47H variant (Table 2.8). The sense and anti-
sense orientations were made. For CRISPR v2, silent mutations were added into the
HDR template at the PAM sequence (PAM-blocking mutations) to prevent Cas9 from
re-targeting HDR-edited gDNA547 alongside the intended knock-in mutation for the p.R47H
variant (Table 2.8). The sense and anti-sense orientations were used.
For CRISPR v3, instead of PAM-blocking mutations, sgRNA blocking mutations were used
in the HDR templates targeting the p.Q33X, p.D87N and p.R47H variants (v3a). Similar to
PAM-blocking mutations, these prevent Cas9 from re-targeting HDR-edited gDNA. Paquet
et al547 reported that the location of the knock-in mutation relative to the cut site is crucial
for HDR incorporation. Therefore, the sgRNA-blocking mutations were introduced as
close as possible to the nick locations for each of the sgRNA pairs (Table 2.8, Figure 2.3).
Additionally, to revert the sgRNA-blocking mutations back to the WT sequence, a second
set (v3b) of HDR templates targeting the p.Q33X and p.D87N variants were designed to
only contain the intended knock-in mutation, similar to CRISPR v1. The HDR template
targeting the p.R47H variant was re-used from CRISPR v1 (Table 2.8). To decrease the
amount of clones to screen, only the anti-sense orientation for v3a and v3b HDR templates
were designed. It has been reported that the using the anti-sense HDR template would
result in at least similar or better HDR efficiency to the sense orientation548–551.
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CRISPR
























Table 2.8. HDR template sequences used in all CRISPR/Cas9 designs.
Underlined font: knock-in mutations, blue font: target AD-associated variant codon, green
font: PAM/sgRNA-blocking mutation codon.
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2.2.2 Cloning sgRNA into sgRNA-Cas9 expression plasmids
To prepare the sgRNA fragments for cloning into the sgRNA-Cas9 expression plasmids,
ssDNA oligonucleotides were phosphorylated and annealed into dsDNA fragments. To do
this, 1 µL 100 µM (100 pmol) top strand and 1 µL 100 µM (100 pmol) bottom strand
was mixed in a 0.2 mL PCR tube with 1× T4 DNA Ligase Buffer, 1 µL (10 units) T4
polynucleotide kinase (PNK), and nuclease-free water up to 10 µL (Table 2.9). The reaction
mixture was then incubated in a thermocycler at 37°C for 30 min, 95°C for 5 min, and
allowed to cool to RT. The phosphorylated and annealed sgRNA duplex was diluted 1:200
with nuclease-free water to 0.5 µM to prepare for cloning.
The sgRNA-Cas9 expression plasmids containing the eGFP selection marker (pSpCas9n(BB)-
2A-GFP) and puromycin resistance selection marker (pSpCas9n(BB)-2A-Puro) were gifts
from Feng Zhang (Addgene plasmids #48140 and #48141, respectively)546. The reported
plasmid maps for pSpCas9n(BB)-2A-GFP and pSpCas9n(BB)-2A-Puro are shown in Figure
2.4. sgRNA pairs were cloned into the respective plasmids at the BpiI restriction sites
(GAAGAC(2/6)ˆ, Figure 2.5) and the combinations are detailed in Table 2.10.
To clone the sgRNA duplex into pSpCas9n(BB), 100 ng pSpCas9n(BB), 2 µL 0.5 µM
sgRNA duplex (1 pmol), 1 µL 10 mM ATP (10 nmol), 2 µL 10× FastDigest buffer, 1 µL
FastDigest BpiI, 0.5 µL T4 DNA Ligase (2.5 Weiss U), and nuclease-free water up to 20
µL was prepared in a 0.2 mL PCR tube (Table 2.11). The reaction mixture was incubated
in a thermocycler for 6 cycles of 37°C for 5 min and 21°C for 5 min.
Reagent Amount Working amount/concentration
sgRNA top (100 µM) 1 µL 100 pmol
sgRNA bottom (100 µM) 1 µL 100 pmol
T4 DNA Ligase Buffer (10×) 1 µL 1×
T4 PNK (10,000 units/mL) 1 µL 10 units
Nuclease-free water 6 µL
Table 2.9. Reaction mixture to phosphorylate and anneal sgRNA top and




Figure 2.4. Plasmid maps for (a) pSpCas9n(BB)-2A-GFP and (b)
pSpCas9n(BB)-2A-Puro.
sgRNA dsDNA fragments were inserted between the BpiI restriction sites.
CBh: hybrid CMV enhancer/chicken β-actin promoter, NLS: nuclear localisation sequence,
hSpCsn1: human codon-optimised Streptococcus pyogenes-derived Cas9 with D10A muta-
tion gene, T2A: Thoseaasigna virus 2A self-cleaving peptide, GFP: enhanced GFP gene,
PuroR: puromycin resistance gene, bGH polyA: bovine growth hormone polyadenylation
terminator signal, R-ITR: R-inverted terminal repeat, AmpR: ampicillin resistance gene,
pUC ori: pUC origin of replication.
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Figure 2.5. BpiI restriction sites, GAAGAC(2/6)ˆ, within pSpCas9n(BB)
where the sgRNA dsDNA fragments will be cloned.
Green font: part of U6 promoter, red font: part of sgRNA scaffold, bold font: BpiI

























Table 2.10. List of all cloned pSpCas9n(sgRNA) plasmids that were used in
CRISPR v1, v2, v3 and v4.
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Reagent Amount Working amount/concentration
pSpCas9n(BB) Variable 100 ng
sgRNA dsDNA fragments (0.5 µM) 2 µL 1 pmol
ATP (10 mM) 1 µL 10 nmol
FastDigest buffer (10×) 2 µL 1×
FastDigest BpiI 1 µL -
T4 DNA Ligase (5 Weiss U/µL) 0.5 µL 2.5 Weiss U
Nuclease-free water Up to 20 µL
Table 2.11. Reaction mixture to clone sgRNA dsDNA fragments into pSp-
Cas9n(BB) at the BpiI restriction sites.
2.2.3 E. coli transformation
Transformation of competent Stbl3 E. coli (Thermo Fisher Scientific) was performed
following the manufacturer’s protocols with slight modifications. A 50 µL vial was thawed
on ice and split into two 25 µL aliquots in 1.5 mL microfuge tubes, each for individual
transformations. 2 µL of pSpCas9(sgRNA), sgRNA inserted into pSpCas9n(BB), from
Chapter 2.2.2 was added into 25 µL Stbl3 E. coli and gently mixed. The E. coli were
incubated on ice for 10 min, heat-shocked for 45 s at 42°C, and incubated on ice again
for 2 min. 125 µL SOC medium (at RT) was added to each microfuge tube. 75 µL of
each transformated E. coli was plated on a pre-warmed LB agar plate with 100 µg/mL
ampicillin, reserving the remaining cells at 4°C as back up. The LB agar plates were
incubated inverted at 37°C overnight.
The following day, 3 colonies for each pSpCas9n(sgRNA) were picked using a sterile pipette
tip and inoculated on a reference LB agar plate with 100 µg/mL ampicillin and in a 30 mL
Universal tube containing 3 mL LB broth with 100 µg/mL ampicillin. The reference plate
and LB broth culture were incubated overnight at 37°C with the reference plate inverted
and the liquid culture shaking at ∼300 rpm. The next day, reference plates were wrapped
with Parafilm and stored at 4°C. The liquid culture was harvested by pelleting the cells at
6800 ×g for 3 min at RT to check for successful sgRNA insertion.
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2.2.4 Validation of successful sgRNA insertion
pSpCas9n(sgRNA) plasmids were extracted and purified using the QIAprep Spin Miniprep
Kit (QIAGEN) according to the manufacturer’s protocols. The E. coli pellet was re-
suspended in 250 µL Buffer P1 containing RNase A and LyseBlue reagent in a 1.5 mL
microfuge tube. 250 µL Buffer P2 was added and mixed by inverting tube until the cell
suspension turned homogenously blue. 350 µL Buffer N3 was added and mixed immediately
by inverting tube until the cell suspension became colourless. The cell suspension was
centrifuged at 14,500 ×g for 10 min. The supernatant was transferred onto a QIAprep
spin column and centrifuged at 14,500 ×g for 1 min, discarding the flow-through. 0.5 mL
Buffer PB was added to the spin column and centrifuged at 14,500 ×g for 1 min, discarding
the flow-through. 0.75 mL Buffer PE with ethanol was added to the spin column and
centrifuged at 14,500 ×g for 1 min, discarding the flow-through. The spin column was
centrifuged again at 14,500 ×g for 1 min, discarding the flow-through. 50 µL Buffer EB
was added to the spin column and after 1 min, plasmids were eluted into a clean 1.5 mL
microfuge tube by centrifugation at 14,500 ×g for 1 min.
The purified pSpCas9n(sgRNA) plasmids were Sanger sequenced by contract to GENEWIZ
using the U6-Fwd primer (GAGGGCCTATTTCCCATGATTCC) (Figure 2.4).
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2.2.5 Expansion of transformed E. coli and plasmid DNA extraction
Initially, for CRISPR v1 and v2, plasmids were harvested using the QIAGEN Plasmid Plus
Midi Kit (QIAGEN). Plasmids for CRISPR v3 were harvested using the EndoFree Plasmid
Maxi Kit (QIAGEN). Both kits were used following the manufacturer’s protocols.
For the QIAGEN Plasmid Plus Midi Kit, one colony for each validated pSpCas9n(sgRNA)
was picked from the reference plate using a sterile pipette tip and inoculated into 3 mL LB
broth with 100 µg/mL ampicillin in a 30 mL Universal tube as the starter culture. The
starter culture was incubated at 37°C for ∼8 h with ∼300 rpm shaking. 500 µL of the
starter culture was transferred into 500 µL 50% glycerol with LB broth in a cryovial and
frozen at -80°C for long-term storage. The remaining starter culture was transferred into 50
mL LB broth with 100 µg/mL ampicillin and incubated at 37°C overnight with ∼300 rpm
shaking. E. coli was harvested by centrifugation at 6,000 ×g for 15 min at 4°C. Pelleted
E. coli was resuspended in 4 mL Buffer P1 containing RNase A and LyseBlue reagent. 4
mL Buffer P2 was added and mixed by inverting the tube until the cell suspension turned
homogenously blue. This was incubated for 3 min at RT. 4 mL Buffer S3 was added
and mixed immediately by inverting the tube until the cell suspension became completely
colourless. The lysate was immediately transferred to a QIAfilter cartridge and incubated
for 10 min at RT. The cell lysate was passed through the QIAfilter cartridge into a new
tube. 2 mL Buffer BB was added to the filtered lysate and mixed by inverting. The lysate
was transferred into a QIAGEN Plasmid Plus Midi spin column with a tube extender
attached to a QIAvac 24 Plus (QIAGEN) vacuum manifold. The lysate was passed through
the spin column by vacuum suction. The tube extenders were discarded and the spin
columns were transferred into 2 mL collection tubes. 0.7 mL Buffer ETR was added to
the spin column and centrifuged at 10,000 ×g for 1 min, discarding the flow-through. 0.7
mL Buffer PE was added to the spin column and centrifuged at 10,000 ×g for 1 min,
discarding the flow-through. The spin column was centrifuged again at 10,000 ×g for 1 min
to completely remove residual wash buffer. 200 µL Buffer EB was added to the spin column
and after 1 min, eluted into a 1.5 mL microfuge tube by centrifugation at 10,000 ×g for 1
min. Plasmid DNA concentration and purity was determined by 260 nm absorbance on a
NanoDrop spectrophotometer.
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For the EndoFree Plasmid Maxi Kit, validated colonies were inoculated into a starter
culture and cryopreserved bacterial stocks were prepared from the starter culture as
described above. The remaining starter culture was transferred into 250 mL LB broth
with 100 µg/mL ampicillin. The culture was incubated and pelleted as described above.
Pelleted E. coli was resuspended in 10 mL Buffer P1 containing RNase A and LyseBlue
reagent. 10 mL Buffer P2 was added and mixed by inverting until the cell suspension
turned homogenously blue. This was incubated for 5 min at RT. 10 mL cold Buffer P3 was
added and immediately mixed by inverting until the lysate became completely colourless.
The lysate was immediately decanted into the barrel of a QIAfilter cartridge and incubated
for 10 min at RT. The lysate was then passed through the cartridge using the provided
plunger into a 50 mL centrifuge tube. 2.5 mL Buffer ER was added to the filtered lysate
and mixed by inverting, followed by incubation for 30 min on ice. A QIAGEN-tip 500 was
equilibrated by applying 10 mL Buffer QBT and emptied by gravity flow. The filtered
lysate was then transferred into the QIAGEN-tip and passed through by gravity flow. The
QIAGEN-tip was washed with 2× 30 mL Buffer QC and DNA was eluted with 15 mL
Buffer QN into a 30 mL endotoxin-free centrifuge tube. DNA was precipitated with 10.5
mL isopropanol and centrifuged at 15,000 ×g for 30 min at 4°C, discarding the supernatant.
The DNA pellet was washed with 5 mL endotoxin-free 70% ethanol and centrifuged at
15,000 ×g for 10 min, discarding the supernatant. The DNA pellet was air-dried for 5–10
min and DNA reconstituted in endotoxin-free Buffer TE. Plasmid DNA concentration and
purity was determined by 260 nm absorbance on a NanoDrop spectrophotometer.
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2.2.6 Generation of pSpCas9n(BB)-2A-mCherry2
pSpCas9n(BB)-2A-mCherry2 was made by replacing the puromycin resistance gene in
pSpCas9n(BB)-2A-Puro with the mCherry2 fluorescent protein gene. This was contracted
to GENEWIZ. Briefly, the T2A-puromycin resistance gene was excised from the plasmid
at the EcoRI sites flanking the region (Figure 2.4b) by EcoRI restriction endonuclease
digestion, leaving sticky ends. T2A-mCherry2 sequence with compatible sticky ends was
ligated into the linearised plasmid. Successful cloning was validated by GENEWIZ through
Sanger sequencing. Prepared pSpCas9n(BB)-2A-mCherry2 was received as a endotoxin-free
Maxi-scale purified plasmid. The plasmid map is shown in Figure 2.6.
The expression of mCherry2 protein from the plasmid was validated by electroporation of
5 µg pSpCas9n(BB)-2A-mCherry2 into BV2 cells as described in Chapter 2.2.14.
Figure 2.6. Plasmid map for pSpCas9n(BB)-2A-mCherry2.
sgRNA dsDNA fragments were inserted between the BpiI restriction sites.
CBh: hybrid CMV enhancer/chicken β-actin promoter, NLS: nuclear localisation sequence,
hSpCsn1: human codon-optimised Streptococcus pyogenes-derived Cas9 with D10A mu-
tation gene, T2A: Thoseaasigna virus 2A self-cleaving peptide, mCherry2: mCherry2
fluorescent protein gene, bGH polyA: bovine growth hormone polyadenylation terminator
signal, R-ITR: R-inverted terminal repeat, AmpR: ampicillin resistance gene, pUC ori:
pUC origin of replication.
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2.2.7 Cell culture
BV2 immortalised mouse microglia cell line552 was a kind gift from Dr Jennifer Pocock
(UCL). BV2 were cultured in RPMI-1640 w/ 10% FBS + 1% PS and passaged at a 1:50
split when cells reach ∼80% confluency. To passage, cells were gently rinsed with DPBS
and detached by incubating cells with 0.25% trypsin-EDTA for 5 min at 37°C, followed
by gentle tapping of the culture vessel. Trypsin was inactivated by adding at least an
equal volume of warm RPMI-1640 w/ 10% FBS + 1% PS. Detached cells were pelleted
by centrifugation at 200 ×g for 5 min, discarding the supernatant. The cell pellet was
resuspended in warm RPMI-1640 w/ 10% FBS + 1% PS and seeded into new culture
vessels as appropriate. BV2 cultures were maintained up to passage 25 before discarding,
as their growth characteristics become noticably poorer after this point.
HEK293A human embryonic kidney cell line553 was cultured in DMEM, high glucose,
GlutaMAX, pyruvate w/ 10% FBS + 1% PS and passaged at 1:10 split when cells reach
confluency. Passaging protocols were performed similar to BV2.
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2.2.8 DNA extraction and phenol/chloroform/isoamyl alcohol purifica-
tion
∼1×106-cell pellets were resuspended in 600 µL DNA extraction cell lysis buffer and briefly
vortexed. 600 µL phenol/chloroform/isoamyl alcohol (PCI) was added and briefly vortexed
to mix. The mixture was then centrifuged at 14,500 ×g for 15 min. 500 µL of the top
aqueous layer was transferred into a new 1.5 mL microfuge tube. 500 µL chloroform was
added to the aqueous layer and briefly vortexed to mix. The mixture was centrifuged at
14,500 ×g for 15 min. 400 µL of the top aqueous layer was transferred into a new 1.5 mL
microfuge tube. 200 µL 7.5 M ammonium acetate and 800 µL ice-cold 100% ethanol was
added to the aqueous layer and incubated for at least 1 h at -20°C to precipitate DNA.
DNA was pelleted by centrifugation at 14,500 ×g for 15 min at 4°C. The supernatant was
discarded and the DNA pellet was washed with 150 µL 70% ethanol. Loose DNA was
collected by centrifugation at 14,500 ×g for 2 min at 4°C, discarding the supernatant. The
DNA pellet was air-dried for 10 min at RT and resuspended in 20 µL Buffer EB (QIAGEN).
DNA concentration and purity were determined by 260 nm absorbance on a NanoDrop
spectrophotometer.
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2.2.9 Polymerase chain reaction
PCR reagents per reaction were set up as described in Table 2.12 with the primer pairs
mTREM2_Ex2_M13F(-21)_F1 and mTREM2_Ex2_M13R_R1 (Table 2.13). These were
transferred to a thermocycler and incubated with the cycling conditions described in Table
2.14.
Reagents Amount Working conc.
OneTaq Hot Start 2× Master
Mix with Standard Buffer 5.0 µL 1×
Forward primer (10 µM) 0.2 µL 200 nM
Reverse primer (10 µM) 0.2 µL 200 nM
Nuclease-free water 3.6 µL
Template DNA (10 ng/µL) 1.0 µL 1 ng/µL
Total volume 10.0 µL
Table 2.12. PCR reagent setup per reaction using the OneTaq Hot Start 2×
Master Mix with Standard Buffer.
PCR primer Primer sequence (5’→3’)
mTREM2_Ex2_M13F(-21)_F1 TGTAAAACGACGGCCAGTATTCTAGAGCCCGTCAGGGA
mTREM2_Ex2_M13R_R1 CAGGAAACAGCTATGACTCCCCCTGAAAAAGTCCCAC
Table 2.13. PCR primers used to amplify Trem2 Exon 2.
Red font: sequencing primer M13F or M13R as indicated.
Step Temperature Time Cycles
Initial denaturation 94°C 30 s –
Denaturation 94°C 30 s
40Annealing 65°C 60 s
Extension 68°C 60 s
Final extension 68°C 5 min –
Hold 4°C Untilcollection –
Table 2.14. Thermocycling conditions for PCR.
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2.2.10 Agarose gel electrophoresis and Sanger sequencing
Agarose gel was prepared by dissolving 2 g UltraPure Agarose in 100 mL 1× sodium
boric acid (SBA), Tris-acetate-EDTA (TAE), or Tris-borate-EDTA (TBE) buffer to obtain
a 2% gel. 3 µL 10,000× GelRed was added to the dissolved agarose. The agarose gel
was cast and allowed to set for 30 min at RT or 10 min at 4°C. Once set, the gel was
transferred into the electrophoresis tank containing the same buffer used to make the gel.
Unless indicated otherwise, 1 µL PCR products were mixed with 4 µL 1.25× BlueJuice
Gel Loading Buffer before loading into the wells alongside 100 ng 100 bp DNA Ladder
(Thermo Fisher Scientific) or 2 µL Quick-Load 100 bp DNA Ladder (New England Biolabs)
for DNA size reference. Electrophoresis was performed at 300 V (15 V/cm) for 45 min for
SBA buffer, 100 V (5 V/cm) for 60 min for TAE buffer, or 200 V (10 V/cm) for 90 min
for TBE buffer. DNA bands were visualised and imaged on a ChemiDoc XRS+ System
(Bio-Rad).
For sequencing, remaining PCR product was purified using the QIAquick PCR Purification
Kit according to the manufacturer’s protocols or purified by contract to GENEWIZ before
Sanger sequencing, also by GENEWIZ.
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2.2.11 RNA extraction and purification
RNA was extracted and purified using the RNeasy Plus Universal Mini Kit (QIAGEN)
according to the manufacturer’s protocols. BV2 cell pellets or C57BL/6 mouse brain tissue
were lysed in 900 µL QIAzol Lysis Reagent, vortexed for 1 min and incubated for 5 min at
RT. 100 µL gDNA Eliminator Solution was added and mixed vigorously for 15 s. 180 µL
chloroform was added and mixed vigorously for 15 s. The sample was incubated for 2-3 min
at RT before centrifuging at 12,000 ×g for 15 min at 4°C. 600 µL of the top aqueous layer
was transferred into a new 1.5 mL microfuge tube, to which 600 µL 70% ethanol was added
and briefly vortexed. 700 µL of the mixture was transferred into an RNeasy Mini spin
column in a 2 mL collection tube, centrifuged at 8,000 ×g for 15 s at RT, discarding the
flow-through. The remaining sample was similarly passed through the spin column. 700 µL
Buffer RWT was added to each spin column, centrifuged at 8,000 ×g for 15 s, discarding
the flow-through. 500 µL Buffer RPE was added to each spin column, centrifuged at 8,000
×g for 15 s, discarding the flow-through. Another 500 µL Buffer RPE was added to each
spin column, centrifuged at 8,000 ×g for 2 min and collection tube discarded. The spin
columns were placed in a new 2 mL collection tube and centrifuged at 14,500 ×g for 1
min. Spin columns were transferred into new 1.5 mL microfuge tubes. 30 µL RNase-free
water was added to each spin column and centrifuged at 8,000 ×g for 1 min. Another 30
µL RNase-free water was added to each spin column and centrifuged again to collect any
remaining column-bound RNA. RNA concentration and purity were determined by 260
nm absorbance on a NanoDrop spectrophotometer.
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2.2.12 Reverse transcription-polymerase chain reaction
5 µg of total purified RNA was converted into cDNA using SuperScript IV Reverse
Transcriptase (Thermo Fisher Scientific) according to the manufacturer’s protocol. 5 µg
total RNA template was added to 1 µL 50 ng/µL random hexamers, 1 µL 10 mM dNTP
mix and nuclease-free water up to a total volume of 13 µL. These were gently mixed and
briefly centrifuged to collect. The mixture was incubated for 5 min at 65°C and then
transferred onto ice to chill for at least 1 min. Meanwhile, the reverse transcriptase reaction
mixture was prepared by combining 4 µL 5× SSIV Buffer, 1 µL 100 mM DTT, 1 µL 40
U/µL RNaseOUT, and 1 µL SuperScript IV Reverse Transcriptase per reaction. 7 µL of
the reaction mixture was added to each chilled RNA template, gently mixed and briefly
centrifuged. The reaction was incubated at 23°C for 10 min, 50°C for 10 min, 80°C for 10
min, and held at 4°C until collection.
Targets of interest were amplified by PCR as described in Chapter 2.2.9, in a 10 µL reaction
volume. 1 µL cDNA was used as the template. Primer pairs and annealing temperatures
used are listed in Table 2.15. RT-PCR products were resolved by agarose gel electrophoresis
as described in Chapter 2.2.10.
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Table 2.15. RT-PCR primers used to analyse mouse gene expression in BV2.
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2.2.13 Transfection into BV2 by chemical-based transfection reagents
Lipofectamine 2000 (Thermo Fisher Scientific), Lipofectamine 3000 (Thermo Fisher Sci-
entific), TurboFect (Thermo Fisher Scientific), PolyFect (QIAGEN), and FuGENE 6
(Promega) were explored as possible transfection reagents. ∼4×105 BV2 cells were seeded
into each well of a 12-well culture plate containing 1 mL warm RPMI-1640 w/ 10% FBS
and allowed to adhere for a few hours in a humidified incubator at 37°C/5% CO2. Trans-
fection was performed according to the manufacturer’s protocols using the CRISPR v1
pSpCas9n(mTREM2_R47H_sgRNA-A_R1a)-2A-GFP plasmid. Table 2.16 shows the setup
for the transfection reagents. When used in other culture well plate sizes, the amount of
cells, transfection reagents, and plasmid DNA was scaled linearly relative to the surface
area of wells.
After the transfection reagents were prepared, transfection complexes were left to incubate
for 20 min at RT. During the incubation, old culture medium was replaced with fresh warm
1 mL RPMI-1640 w/ 10% FBS. After the incubation, transfection complexes were added
dropwise directly into the respective wells. The 12-well culture plate was gently gyrated to
ensure even coverage of transfection complexes and incubated in a humidified incubator at
37°C/5% CO2 overnight. Transfection efficiency was assessed by counting the number of
GFP-positive cells counterstained with DAPI at 10× objective magnification field of view.
Transfection reagent DNA:transfection reagent ratio Diluent
Lipofectamine 2000 1 µg plasmid DNA:3 µL Lipofectamine 2000 100 µL Opti-MEM
Lipofectamine 3000 1 µg plasmid DNA:2 µL P3000 Reagent:3 µL Lipofectamine 3000 100 µL Opti-MEM
TurboFect 1 µg plasmid DNA:2 µL TurboFect 100 µL Opti-MEM
PolyFect 1 µg plasmid DNA:10 µL PolyFect 50 µL Opti-MEM
FuGENE 6 1 µg plasmid DNA:3 µL FuGENE 6 100 µL Opti-MEM
Table 2.16. 12-well culture plate setup of transfection reagents used to optimise
the best transfection conditions for BV2.
pSpCas9n(mTREM2_R47H_sgRNA-A_R1a)-2A-GFP was transfected into BV2.
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2.2.14 Transfection into BV2 by electroporation
The Nucleofector 2b (Lonza) system was used for electroporation with the Cell Line
Optimization Nucleofector Kit for Nucleofector 2b Device (Lonza) to determine optimal
electroporation parameters according to the manufacturer’s protocol.
During optimisation (CRISPR v1 and v2), 1×106 cells were resuspended in 100 µL
Nucleofector Solution L or V. 2 µg pmaxGFP alone or 5 µg of each plasmid pair (total
10 µg) was combined and added with 100 pmol sense or anti-sense HDR template to
the cell suspension. The cell suspension was transferred into a Nucleofector cuvette and
electroporated using the recommended programs A-030, A-033, A-020 or D-023.
After optimisation (CRISPR v3 onwards), 2×106 cells were resuspended in 100 µL Nucleo-
fector Solution L and electroporated with 2.5 µg of each plasmid pair (total 5 µg) combined
with 100 pmol anti-sense HDR template using program A-030.
After electroporation, 500 µL warm RPMI-1640 w/ 10% FBS was gently added to the
cuvettes and incubated for 10 min at 37°C. The cell suspension was transferred into 6-well
culture plates containing 1.5 mL warm RPMI-1640 w/ 10% FBS and incubated in a
humidified incubator at 37°C/5% CO2 overnight. Transfection efficacy was estimated by
observing GFP expression by fluorescence microscopy or by flow cytometry.
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2.2.15 Puromycin treatment
24 h post-transfection of BV2 or HEK293A with sgRNA-Cas9 expression plasmid pairs
and HDR template using Lipofectamine 3000, old cell culture medium was replaced with
fresh warm culture medium containing puromycin dihydrochloride between 0–5 µg/mL.
Cells were incubated with puromycin for 48 h in a humidified incubator at 37°C/5% CO2.
After the incubation period, cells were imaged at 100× magnification and cell viability was
compared to determine optimal puromycin concentration.
2.2.16 Nocodazole treatment
5×105 BV2 cells were seeded into each well of a 6-well culture plate and allowed to adhere
for 7 h in a humidified incubator at 37°C/5% CO2. Old culture medium was replaced with 0
ng/mL, 10 ng/mL, 100 ng/mL, 200 ng/mL, 500 ng/mL, or 1000 ng/mL nocodazole in warm
RPMI-1640 w/ 10% FBS. Cells were incubated with nocodazole for 17 h in a humidified
incubator at 37°C/5% CO2. Culture medium containing nocodazole was discarded and
cells were immediately electroporated as described in Chapter 2.2.14.
2.2.17 Nuclei staining in BV2
1.6×105 electroporated BV2 cells were seeded onto 13 mm diameter coverslips in 24-well
culture plates with RPMI-1640 w/ 10% FBS + 1% PS and allowed to adhere. Culture
medium was replaced with 200 µL of 5 µM CellTracker Red CMTPX Dye in RPMI-1640
and incubated for 45 min in a humidified incubator at 37°C/5% CO2. Stained cells were
fixed with 500 µL 10% neutral buffered formalin (NBF) for 5 min and gently rinsed 3× 5
min with DPBS. Fixed cells were stained with 1 µg/mL Hoechst 33342 in water for 5 min
and gently washed with dH2O for 5 min. The coverslips were mounted onto glass slides
with Mowiol hard set aqueous mounting medium and allowed to set for at least 30 min at
RT. Slides were viewed and imaged using a Leica DM5000 B fluorescence microscope.
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2.2.18 Fluorescence-activated cell sorting
Before performing FACS, transfected cells were gently rinsed with DPBS, detached with
0.25% trypsin-EDTA and pelleted at 200 ×g for 5 min, discarding the culture medium
supernatant. Cell pellet was resuspended in 1 mL warm 10% FBS in DPBS or 500 µL
warm phenol red-free RPMI-1640. Cells were passed through a 40 µm cell strainer and
kept on ice until FACS.
Transfection efficiency was determined by the percentage of GFPhi (excitation laser 488
nm, emission detection 525/50 nm) and/or mCherry2hi (excitation laser 561 nm, emission
detection 610/20 nm) cells during FACS on a BD FACS Aria (BD Biosciences). Gates
were set according to untransfected controls.
For CRISPR v1 and v2, 24 h post-electroporation, transfected cells were clonally isolated
by single-cell sorting GFPhi cells into each well of a 96-well culture plate with 100 µL
RPMI-1640 w/ 10% FBS + 1% PS. The clonal cells were incubated in a humidified
incubator at 37°C /5% CO2. Each well was monitored regularly to ensure growth from a
single cell. Only wells with cell that grew from a single cell were subsequently investigated.
On average, it took 2 weeks for each BV2 clonal line to reach confluency in a 96-well
culture plate.
For CRISPR v3 onwards when pSpCas9n(sgRNA)-2A-Puro was replaced with pSpCas9n
(sgRNA)-2A-mCherry2, at 24 h post-electroporation, transfected cells were first enriched
by sorting GFPhi and mCherry2hi double-positive cells into 1 mL RPMI-1640 w/ 10%
FBS + 1% PS (Figure 2.7b). Enriched cells were allowed to recover in T75 flasks with 15
mL RPMI-1640 w/ 10% FBS + 1% PS for a week in a humidified incubator at 37°C /5%
CO2. Before single-cell sorting, cells were detached and pelleted as described above. Just
before resuspension in warm phenol red-free RPMI-1640, cells were resuspended in 1 mL 5
µg/mL Hoechst 33342 in RPMI-1640 + 10% FBS + 1% PS and incubated for 15 min at
37°C. Excess Hoechst 33342 was removed by pelleting the cells again and discarding the
supernatant. Mononucleated cells were then single-cell sorted by forward scatter (FSC)lo
and side scatter (SSC)lo only (Figure 2.7c) or in combination with Hoechstlo (Figure 2.8)
into 96-well culture plates as described above.
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(a) Untransfected BV2 (b) CRISPR v3 transfected BV2
(c) Mononucleated cells
Figure 2.7. Gating parameters for FACS used in CRISPR v3.
(a) Untransfected BV2 to establish threshold for GFPhi and mCherry2hi gating. (b) GFPhi
and mCherry2hi BV2 transfected with CRISPR v3 plasmids and HDR templates. (c)
FSClo-SSClo gating to single-cell sort mononucleated cells.
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(a) Total cell population
(b) Mononucleated cell population
(c) Multinucleated cell population
Figure 2.8. Gating parameters for mononucleated cells using Hoechst 33342
by FACS.
(a) Smaller and less granulated mononucleated cells (FSClo-SSClo, orange) were gated
from the total cell population (red). (b) Hoechstlo cells were gated from FSClo-SSClo cells
and single-cell sorted. (c) Larger and more granulated cells (green) were more likely to be
multinucleated with higher Hoechst 33342 fluorescence intensity.
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2.2.19 Cryopreservation in 96-well culture plates
Old culture medium was discarded and cells were gently rinsed with DBPS. DPBS was
discarded and cells in the 96-well culture plate were detached by incubation with 25 µL
0.25% trypsin-EDTA for 5 min at 37°C, followed by gentle tapping. The cell suspension
was gently mixed by pipetting to break cell clumps and 20 µL was transferred into 20
µL 2× freezing medium (20% DMSO in FBS) in a replicate 96-well culture plate. The
remaining 5 µL cell suspension was transferred into 10 µL 0.5× Direct-Lyse lysis buffer
in a replicate 96-well PCR plate for crude DNA extraction (Chapter 2.2.20). Both plates
were sealed with MicroAmp Clear Adhesive Film (Thermo Fisher Scientific) plate sealing
films. The 96-well culture plate was covered with its lid and wrapped in a thick layer of
paper towels before transferring into a thick polystyrene box. The polystyrene box was
transferred into a -80°C freezer. Cells cryopreserved in this manner were found to be viable
for up to a month, allowing sufficient time for successfully edited clonal lines to be screened
for further expansion and characterisation.
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2.2.20 Crude DNA extraction
This crude DNA extraction protocol was adapted from Ramlee et al. (2015)554. The 5 µL
cell suspension in 10 µL 0.5× Direct-Lyse lysis buffer in 96-well PCR plates from Chapter
2.2.19 were incubated in a thermocycler according to the conditions in Table 2.17. The














Table 2.17. Thermocycling conditions for crude DNA extraction from cells in
96-well PCR plates.
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2.2.21 DNA purification of crude DNA extracts
Crude DNA extracts were purified using the QIAamp DNA Mini Kit (QIAGEN) following
the manufacturer’s protocols. Crude DNA extracts were reconstituted to 200 µL with
DPBS and transferred to individual 1.5 mL microfuge tube containing 20 µL proteinase K.
200 µL Buffer AL was added and mixed by vortexing for 15 s. Samples were incubated for
10 min at 56°C and briefly centrifuged. 200 µL ethanol was added to the samples, mixed by
vortexing for 15 s and briefly centrifuged. Samples were transferred into a QIAamp Mini
spin column in a 2 mL collection tube and centrifuged at 6,000 ×g for 1 min, discarding
the flow-through. 500 µL Buffer AW1 was added to the spin column and centrifuged at
6,000 ×g for 1 min, discarding the flow-through. 500 µL Buffer AW2 was added to the
spin column and centrifuged at 14,500 ×g for 3 min, discarding the flow-through. The spin
column was centrifuged again at 14,500 ×g for 1 min and transferred into a clean 1.5 mL
microfuge tube. 200 µL Buffer AE was added into the spin column and incubated for 1
min at RT, followed by centrifugation at 6,000 ×g for 1 min to elute DNA.
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2.2.22 Competitive allele specific PCR
A custom competitive allele specific PCR (KASP) assay kit (KASP on Demand + KASP
V4.0 2×Master mix, High ROX) was designed and validated by LGC Genomics to genotype
the rs75932628 R47H variant in mouse Trem2. The assay was performed following the
manufacturer’s protocols. Positive control DNA was prepared by using combinations of
the HDR templates in the sense or anti-sense orientation with the WT or R47H variant
(CRISPR v1, Table 2.8) at the appropriate molar ratios to simulate the homozygous WT
(GG) alleles, homozygous R47H variant (AA) alleles, or the heterozygous R47H variant (GA)
alleles (Table 2.18). These positive control DNA were validated to work with the primers
of the custom KASP assay.
The assay reagents: 2.5 µL DNA template of various formats (e.g. undiluted crude DNA,
1:10 diluted crude DNA, 1:10 diluted Trem2 amplicons), 2.5 µL KASP V4.0 2× Master
mix, High ROX, and 0.07 µL KASP on Demand primers per reaction, were prepared
in 384-well PCR plates (Table 2.19). The plate was sealed using a MicroAmp Optical
Adhesive Film (Thermo Fisher Scientific). The assay was performed and read on a 7900HT
Real-Time PCR System (Applied Biosystems) with the recommended 61-55°C Touchdown
















Table 2.18. Molar ratios of the individual ssDNA HDR template used to make
up positive control DNA for the KASP genotyping assay.
These simulate the mouse Trem2 homozygous WT (GG) alleles, homozygous p.R47H variant
(AA) alleles, or heterozygous p.R47H variant (GA) alleles.
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Reagents Volume
DNA template 2.5 µL
KASP V4.0 2× Master mix, High ROX 2.5 µL
KASP on Demand primers 0.07 µL
Table 2.19. Reagent setup per reaction for KASP assay in a 384-well PCR
plate format.
Description Temperature Duration No. ofcycles









Cool 24 °C 60 s 1
Table 2.20. Recommended thermocycling conditions for KASP assay.
2.2.23 Karyotyping
Cells were prepared at ∼40–50% confluency in T25 flasks and shipped to Cell Guidance
Systems Ltd filled to the neck with warm RPMI-1640 w/ 10% FBS + 1% PS for karyotyping.
Karyotyping reports and representative images were received and analysed.
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2.2.24 Expansion and cryopreservation of clonal cell lines
Cryopreserved clonal cell lines of interest in 96-well culture plates were thawed in a 37°C
incubator for ∼10 min. After thawing, the outside of the plates was sprayed with 70%
IMS. 200 µL warm RPMI-1640 w/ 10% FBS + 1% PS was added to each well to dilute
DMSO from the freezing medium. The cells were allowed to recover overnight in a 37°C/5%
CO2 incubator. The following day, culture medium was replaced with 100 µL fresh warm
RPMI-1640 w/ 10% + 1% PS. Clonal lines were allowed to grow to confluence in the
96-well culture plate.
Old culture medium was discarded and cells were gently rinsed with DPBS. Cells were
detached by incubation with 25 µL 0.25% trypsin-EDTA for 5 min at 37°C, followed by
tapping of the plate. Cell suspension was directly transferred into 25 mL warm RPMI-1640
w/ 10% FBS + 1% PS in a T175 flask. Clonal lines were allowed to expand until confluent
in the T175 flasks in a humidified incubator at 37°C/5% CO2, replacing culture medium
as necessary.
After reaching confluency, old culture medium from each flask was transferred into individual
50 mL centrifuge tubes to collect non-adherent cells. Remaining adherent cells were gently
rinsed with DPBS and the DPBS was transferred into the respective 50 mL centrifuge
tubes. Cells were detached with 0.25% trypsin-EDTA and incubated for 5 min at 37°C,
followed by tapping of the flask. Cell suspension was transferred into the respective 50
mL centrifuge tubes and centrifuged at 200 ×g for 5 min, discarding the supernatant.
Cell pellets were resuspended at 1×106 cells/mL in RPMI-1640 w/ 10% FBS + 1% PS
+ 10% DMSO. 1 mL aliquots were added into cryovials, which were transferred into Mr
Frosty (Thermo Fisher Scientific) freezing containers containing isopropanol. The freezing
containers were kept at -80°C overnight and the cryovials were transferred into liquid
nitrogen for storage.
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2.3 Methodology for Chapter 4
2.3.1 Source of brain tissue and selection criteria
Hippocampal brain sections were obtained from various tissue banks, including the MRC
London Neurodegenerative Diseases Brain Bank (King’s College London, UK), Queen
Square Brain Bank for Neurological Disorders (University College London, UK), Oxford
Brain Bank (John Radcliffe Hospital, UK), Southampton Brain Bank (BRAIN UK), and
the Netherlands Brain Bank (Netherlands Institute for Neuroscience, Royal Netherlands
Academy of Arts and Sciences).
The inclusion criteria was that all cases with disease-associated TREM2 variants, previously
identified by Dr Angela Hodges, were considered (Table 2.21). There were 6 non-AD controls
with TREM2 variants that were not included in the study as meaningful statistics cannot
be performed with large data variation between cases. Each AD case with TREM2 variants
were pair-matched for age at death and gender with a non-AD control and an AD case
without TREM2 variants.
Cases were excluded if they did not have available tissue sections containing the posterior
hippocampus. Besides that, AD cases that were not Braak tau stage77 IV–VI and non-AD
controls that were not Braak tau stage 0–I were also excluded.
Following the inclusion and exclusion criteria, 16 AD cases with disease-associated TREM2
variants (AD/TREM2var), 21 AD cases (AD/TREM2wt) and 18 non-AD control cases
(Control/TREM2wt) without disease-associated TREM2 variants were selected.
Informed consent was obtained from all tissue donors in accordance with the Declaration
of Helsinki (1991) and protocols and procedures were approved by the relevant local ethical






death (y) Sex Source
A220/11 Include p.R47H (rs75932628) AD Braak IV 71 Female MRC London
A166/04 Include p.R47H (rs75932628) AD Braak VI 43 Male MRC London
A191/07 Include p.Q33X (rs104894002) AD Braak VI 69 Female MRC London
A341/11 Include p.R47H (rs75932628) AD Braak VI 76 Male MRC London
P03_09 Include p.R47H (rs75932628) AD Braak VI 64 Male QSBB
P07_09 Include p.R47H (rs75932628) AD Braak VI 66 Female QSBB
P1405/06 Include p.R47H (rs75932628) AD Braak VI 76 Female BRAIN UK
P19_06 Include p.D87N (rs142232675) AD Braak VI 71 Male QSBB
P59_03 Include p.R47H (rs75932628) AD Braak VI 41 Female QSBB
S00/318 Include p.D39E (rs200392967) AD Braak VI 72 Female TNBB
S05/265 Include p.G58A (novel) AD Braak VI 64 Male TNBB
S96/204 Include p.D87N (rs142232675) AD Braak VI 91 Female TNBB
A013/03 Include p.R47H (rs75932628) AD Braak V–VI 89 Male MRC London
A025/03 Include p.T96K (rs2234253), p.W191X (rs2234258),
p.L211P (rs2234256)
AD Braak V–VI 72 Female MRC London
A112/96 Include p.R98W (rs147564421) AD Braak V–VI 78 Female MRC London
C33/88 Include p.R47H (rs75932628) AD Braak V–VI 76 Female OBB
A228/96 Exclude (non-AD, no hip-
pocampus)
p.T96K (rs2234253), p.W191X (rs2234258),
p.L211P (rs2234256)
Control 81 Female MRC London
A008/97 Exclude (non AD) p.A105V (rs145080901) Control 33 Female MRC London
A358/99 Exclude (non AD) p.R47H (rs75932628) Control 55 Female MRC London






death (y) Sex Source
P23_07 Exclude (non AD) p.R47H (rs75932628) Control 77 Male QSBB
05/023 Exclude (non AD) p.R47H (rs75932628), p.D87N (rs142232675) MCI 80 Female OBB
S01/283 Exclude (no hippocampus) p.D87N (rs142232675) AD Braak IV 86 Female TNBB
04/021 Exclude (no hippocampus) p.R47H (rs75932628) AD Braak VI 93 Female OBB
93/1074 Exclude (no hippocampus) p.R47H (rs75932628) AD Braak V–VI 78 Female OBB
Table 2.21. Cases with disease-associated TREM2 variants previously identified by Dr Angela Hodges prior to this project.
6 non-AD controls with TREM2 variants were not included as meaningful statistics cannot be performed with large data variation between cases.
Cases were excluded if hippocampal tissue were unavailable. AD cases that were not Braak tau stage IV–VI or non-AD controls that were not Braak
tau stage 0–I were also excluded.
MRC London: MRC London Neurodegenerative Diseases Brain Bank (King’s College London, UK); QSBB: Queen Square Brain Bank for Neurological
Disorders (University College London, UK); BRAIN UK: Southampton Brain Bank (BRAIN UK); TNBB: the Netherlands Brain Bank (Netherlands
Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences); OBB: Oxford Brain Bank (John Radcliffe Hospital, UK).
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2.3.2 Immunohistochemistry
5–7 µm thick formalin-fixed paraffin-embedded (FFPE) sections of the entorhinal cortex
containing the hippocampus were cut from tissue blocks and mounted on charged microscope
slides by the various tissue bank providers. Sections were deparaffinised with xylene for 2×
5 min and rehydrated in decreasing concentrations of industrial methylated spirit (IMS;
100%, 95%, 70% v/v) for 5 min each. Endogenous peroxidase were quenched with 0.7%
v/v hydrogen peroxide (H2O2) in methanol for 30 min. Sections were washed in running
tap water and distilled water (dH2O) for 5 min each. Heat-induced epitope retrieval
(HIER) was performed with citrate-buffered saline (CBS, pH 6.0) in a microwave for 15
min followed by washing in running tap water until the slides were cool. For Aβ staining,
sections were also treated with 80% v/v formic acid for 1 h followed by washing in running
tap water for 10 min. Sections were washed in dH2O for 5 min while a hydrophobic barrier
was drawn around the sections. Sections were washed in 1× TBS-T 0.1% for 2× 5 min.
Non-specific binding was blocked with 10% v/v normal serum (from the same species that
the secondary antibodies were raised in) in 1× TBS-Tx 0.25% for 1 h at RT. Blocking
solution was discarded and the primary antibody solution with 1% v/v blocking serum
in TBS-Tx 0.1% was immediately applied and incubated overnight at 4°C. Sections were
washed in 1× TBS-T 0.1% for 2× 5 min. The secondary antibody solution in TBS-T
0.1% was applied on the sections and incubated for 1 h at RT. Sections were washed in
1× TBS-T 0.1% for 2× 5 min. Sections were visualised with the VECTASTAIN Elite
ABC HRP Kit (Vector Laboratories) for 1 h, washed in 1× TBS-T 0.1% for 2× 5 min,
followed by incubation with activated 3,3’-diaminobenzidine tetrahydrochloride (DAB;
0.024% H2O2 in DAB dissolved in 1× TBS-T 0.1%). Sections were washed in running tap
water and dH2O for 5 min each. Sections were counterstained in Harris’ haematoxylin
for 40 s, washed in running tap water to remove excess staining, differentiated in 1% acid
alcohol, and followed by blueing of haematoxylin in running tap water for 5 min. Sections
were washed in dH2O for 5 min. Sections were dehydrated in increasing concentrations of
IMS (70%, 95%, 100%, 100% v/v) for 5 min each and cleared with xylene for 2× 5 min.
Sections were coverslipped with DPX and left to set overnight.
Combinations of blocking, primary antibody and secondary antibody solutions used are
shown in Table 2.22.
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Blocking
solution Primary antibody Dilution
Manufac-
turer Cat# Secondary antibody Dilution
Manufac-
turer Cat#
NGS Anti human CD68 (clone PG-M1), mouse 1:50 Dako M087601-2 Anti mouse IgG, goat, biotinylated 1:200 Dako E0433
NGS Anti human HLA-DP, DQ, DR (clone CR3/43), mouse 1:100 Dako M0775 Anti mouse IgG, goat, biotinylated 1:200 Dako E0433
NSS Anti Iba-1, rabbit 1:1000 Wako 019-19741 Anti rabbit IgG, swine, biotinylated 1:200 Dako E0353
NGS Anti amyloid-β17-24 (clone 4G8), mouse 1:1200 BioLegend 800701 Anti mouse IgG, goat, biotinylated 1:200 Dako E0433
NGS Anti phospho-tau Ser202, Thr205 (clone AT8), mouse 1:1000 TFS MN1020 Anti mouse IgG, goat, biotinylated 1:200 Dako E0433
Table 2.22. Combinations of blocking solution, primary antibodies, and secondary antibodies that were used for immunohisto-
chemistry.
NGS: normal goat serum, NSS: normal swine serum, TFS: Thermo Fisher Scientific.
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2.3.3 Immunofluorescence
Adjacent FFPE sections used in immunohistochemistry were used for immunofluorescence.
Sections were deparaffinised with xylene for 2× 5 min and rehydrated in decreasing
concentrations of IMS (100%, 95%, 70% v/v) for 5 min each. Sections were washed in
dH2O for 5 min. HIER was performed with CBS in a microwave for 15 min followed
by washing in running tap water until the slides were cool. For Aβ staining, sections
were also treated with 80% v/v formic acid for 1 h followed by washing in running tap
water for 10 min. Sections were washed in dH2O for 5 min while a hydrophobic barrier
was drawn around the sections. Sections were washed in 1× TBS-T 0.1% for 2× 5 min.
Non-specific binding was blocked with 10% v/v normal serum (from the same species that
the secondary antibodies were raised in) in 1× TBS-Tx 0.25% for 1 h at RT. Blocking
solution was discarded and the primary antibody solution with 1% v/v blocking serum
in TBS-Tx 0.1% was immediately put on and incubated overnight at 4°C. Sections were
washed in 1× TBS-T 0.1% for 2× 5 min. The secondary antibody solution in TBS-T 0.1%
was put on the sections and incubated for 1 h at RT. Sections were washed in 1× TBS-T
0.1% for 2× 5 min. Autofluorescence was quenched in 0.3% Sudan Black B in 70% IMS for
10 min. Sections were washed in 1× TBS-T 0.1% for 2× 5 min. Nuclei were stained with
1 µg/mL Hoechst 33342 in dH2O for 10 min. Sections were washed in dH2O for 5 min.
Sections were coverslipped with Mowiol hard set aqueous mounting medium and left to set
in the dark overnight at RT.
Combinations of blocking, primary antibody and secondary antibody solutions applied
sequentially or simultaneously for multiplex staining are shown in Table 2.23. For sequen-
tially applied antibodies, the first primary and secondary antibodies were applied as usual,
followed by application of the second blocking and primary antibody solutions.
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Blocking
solution Primary antibody Dilution
Manufac-





Anti human CD68 (clone PG-M1), mouse 1:50 Dako M087601-2 Anti mouse IgG, goat, AF488 1:200 TFS A11001
Anti Iba-1, rabbit 1:1000 Wako 019-19741 Anti rabbit IgG, goat, AF594 1:200 TFS A11012
NGS
Anti human HLA-DP, DQ, DR (clone CR3/43), mouse 1:50 Dako M0775 Anti mouse IgG, goat, AF488 1:200 TFS A11001
Anti Iba-1, rabbit 1:1000 Wako 019-19741 Anti rabbit IgG, goat, AF594 1:200 TFS A11012
NGS
Anti human CD68 (clone PG-M1), mouse 1:50 Dako M087601-2 Anti mouse IgG, goat, AF568 1:200 TFS A11004
Anti tau, rabbit 1:1000 Dako A0024 Anti rabbit IgG, goat, AF488 1:200 TFS A11008
NGS
Anti human HLA-DP, DQ, DR (clone CR3/43), mouse 1:50 Dako M0775 Anti mouse IgG, goat, AF568 1:200 TFS A11004
Anti tau, rabbit 1:1000 Dako A0024 Anti rabbit IgG, goat, AF488 1:200 TFS A11008
NGS
Anti Iba-1, rabbit 1:1000 Wako 019-19741 Anti rabbit IgG, goat, AF594 1:200 TFS A11012
Anti phospho-tau Ser202, Thr205 (clone AT8), mouse 1:1000 TFS MN1020 Anti mouse IgG, goat, AF488 1:200 TFS A11001
Sequentially applied antibodies
NGS Anti human CD68 (clone PG-M1), mouse 1:50 Dako M087601-2 Anti mouse IgG, goat, AF568 1:200 TFS A11004
NMS Anti amyloid-β1-16 (clone 6E10) AF488, mouse 1:100 BioLegend 803013 – – – –
NGS Anti human HLA-DP, DQ, DR (clone CR3/43), mouse 1:50 Dako M0775 Anti mouse IgG, goat, AF568 1:200 TFS A11004
NMS Anti amyloid-β1-16 (clone 6E10) AF488, mouse 1:100 BioLegend 803013 – – – –
NGS Anti Iba-1, rabbit 1:1000 Wako 019-19741 Anti rabbit IgG, goat, AF594 1:200 TFS A11012
NMS Anti amyloid-β1-16 (clone 6E10) AF488, mouse 1:100 BioLegend 803013 – – – –
Table 2.23. Combinations of blocking solution, primary antibodies, and secondary antibodies that were applied simultaneously
or sequentially for multiplex immunofluorescence staining.
AF: Alexa Fluor, NGS: normal goat serum, NMS: normal mouse serum, TFS: Thermo Fisher Scientific.
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2.3.4 Microscopy
DAB-stained whole-slide sections were imaged using a Leica SCN400F (Leica Biosystems)
slide scanner at University College London with a maximum optical magnification of 200×.
Fluorescently labelled sections were imaged using a Leica DM5000 B at the indicated
magnifications. The filters used were: A4 filter for Hoechst 33342, L5 filter for GFP/AF488,
and TX2 filter for mCherry2/AF568/AF594.
2.3.5 Semi-automated computerised quantification
Scanned sections were analysed using a custom-made semi-automated pipeline combining
ImageJ v1.50i (National Institutes of Health, USA) macros and Python scripts as outlined
in Figure 2.9.
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Figure 2.9. Pipeline for a custom made semi-automated quantification of DAB-
stained whole-slide sections that were scanned.
CD68+ microglia were quantified by % area DAB staining. HLA-DP, DQ, DR+ and Iba-1+
whole microglia were quantified by microglial counts. HLA-DP, DQ, DR+ and Iba-1+
whole microglia morphology were quantified by circularity. Aβ and tau pathology burden
were quantified by % area DAB staining.
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2.3.5.1 Generation of randomly sampled field of views
General rectangular regions of interest (ROI) of the hippocampal cornus ammonis (CA) 1
and CA4 were cropped out from the Leica proprietary whole slide scan image using the
“Extract Image Region” function in Aperio ImageScope v12.1.0.5029 (Leica Biosystems).
These regions were selected because of their vulnerability in AD and the pathological
burden between AD cases are relatively consistent. Parameters used were 50% size scaling,
unticking “Thumbnail”, and TIF output with LZW compression. The output image has a
scale of 2 pixels (px):1 µm.
After cropping, the TIF image was opened in ImageJ and the “Record...” function opened.
A more granular ROI selection was done using the “Polygon selections” tool to exactly
outline the CA1 or CA4. Once the polygon selection is complete, the boundary coordinates
of the each specific ROI selection was obtained from the “Record...” window. Boundary
coordinates were saved in separate .txt files and the ROI selection was also saved using the
“ROI Manager”.
The boundary coordinates were input into a Python script and used to generate coordinates
for 5 random non-overlapping squares of 0.5×0.5 mm2 for each ROI and section. The
coordinates of each square were input into the “Specify...” function (Width: 1000 px,
Height: 1000 px, X/Y coordinates as generated, ticked “Centered”) in ImageJ to create
selections of the squares. The square selections were saved using the “ROI Manager” and
also cropped into individual images using the “Duplicate...” function. The cropped squares
were saved as TIF images.
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2.3.5.2 Quantification of % area of DAB staining
For CD68, Aβ, and tau staining, quantification was performed using % area staining. The
number of CD68+ microglia could not be determined because the intracellular punctate
staining pattern did not delineate individual microglia.
The 5 randomly sampled square images were opened in ImageJ. A threshold filter to
distinguish DAB staining from background was achieved using the “Color Threshold...”
function (Hue: 0–30; Saturation: 0–255, adjusted according to background; Brightness:
determined by the “Mean” option under “Thresholding method”) and by clicking on the
“Filtered” followed by “Select”.
A size filter was applied to remove non-specific DAB staining using the “Analyze Particles...”
function (Size: 10–Infinity, tick “Add to Manager”). For anti-Aβ17-24 (clone 4G8) antibody
staining, intracellular APP was excluded by using a size filter of “2000–Infinity”. This
step also separated discontiguous DAB staining into individual ROI selection particles to
perform the size filter. The filtered individual ROI selections particles were combined again
and saved using the “ROI Manager”.
A binary black and white mask was created using “Create Mask”. Quantification options
were selected within “Set Measurements...” (tick “Area fraction” and “Limit to threshold”,
Decimal places: 3). % area of DAB staining was obtained using the “Measure” function.
Data from the “Results” window was saved as a .txt file which can be opened in Excel
(Microsoft) for data processing.
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2.3.5.3 Quantification of microglial abundance
For HLA-DP, DQ, DR and Iba-1 staining, quantification was performed by counting the
number of stained microglia.
Microglial counts were quantified by using a third party ImageJ plugin “Hull And Circle”555,
which has the capability to quantify shape descriptions (e.g. Feret’s diameter) for individual
thresholded particles∗.
The 5 randomly sampled square images were opened in ImageJ. DAB staining was thresh-
olded as described in Chapter 2.3.5.2. A binary black and white mask was created using
“Create Mask”. A size filter was applied to the ROI selections to remove selected non-specific
DAB staining using the “Analyze Particles...” function (Size: 50–Infinity, tick “Exclude on
edges”, “Clear results”, and “Add to Manager”) and separate discontiguous DAB staining
into individual ROI selection particles. The filtered individual ROI selections for each
particle were saved using the “ROI Manager”.
The “Hull And Circle” plugin was launched∗. “Draw Circle” and “Draw Hull” was unticked
in “Settings”. Quantification of Feret’s diameter for each particle was performed by using
the “Scan Roi Manager” button. The resulting data window was saved as a .txt file.
A second size filter was applied to the saved individual ROI selections for each particle
using a Python script that reads the saved data containing the Feret’s diameter. It then
removes particles that have Feret’s diameter smaller than 50 px/25 µm from the saved
individual ROI selections. 25 µm diameter was chosen as the threshold as it matches
the reported smallest average size of a whole microglia556 and therefore avoids counting
microglial processes present in the plane which the section was cut.
Microglial counts was established by counting the number of remaining particles >25 µm
from the data list using Excel.
∗At time of writing the macro, I did not realise that Feret’s diameter was an option in the ImageJ
built-in “Measure” function. This means that for future quantification, “Hull And Circle” is not required.
Instead, at the same point when “Hull And Circle” is used, Feret’s diameter can be quantified by selecting
“Feret’s diameter” in “Set Measurements...” and using the “Measure” function. This can be combined with
quantifying circularity as described in Chapter 2.3.5.4 to generate the data in one step.
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2.3.5.4 Quantification of microglial morphology
Microglia are very plastic cells and can change morphology in response to immune activation.
Morphological analysis was performed by measuring the circularity of microglia. Circularity
values range from 0–1, with 1 representing a perfect circle and values closer to 0 indicate
an increasingly elongated polygon. In other words, microglia with greater circularity values
have a more amoeboid shape indicating functional activation, whereas lower circularity
values represent a more ramified shape indicating a more surveillance state.
The saved individual ROI selection containing only particles >25 µm from Chapter 2.3.5.3
was opened with the corresponding image file in ImageJ. Quantification options were
selected within “Set Measurements...” (tick “Shape descriptors”, Decimal places: 3).
Circularity values for each particle were obtained using the “Measure” function. Data from
the “Results” window was saved as a .txt file.
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2.3.6 Statistical analyses
All statistical analyses were performed using SPSS Statistics 23 (IBM). All tests were
nominally significant for p-values 6 0.05.
Differences in group demographics for age at death and gender were assessed using one-way
ANOVA and binary logistic regression, respectively.
Semi-automated cell counting was compared with manual cell counting by assessing
the Pearson correlation between cell counts for both methods on HLA-DP, DQ, DR-
immunostained sections. Semi-automated cell counting was also compared with the
commonly used % area staining quantification method by assessing the Pearson correlation
between output measures from both methods in HLA-DP, DQ, DR and Iba-1 immunostained
sections.
Individual group differences for % area staining, microglial counts, and circularity were
assessed by calculating the mean measure of the 5 sampled squares and using one-way
ANCOVA with 1000-sample bootstrapping and Sidak correction for pairwise comparisons.
The effects of age at death, sex, APOE ε4 status, CD33 risk variants, years of tissue storage,
and post-mortem delay on outcome measures were assessed as potential confounders.
Only age at death had a significant effect and was included as a covariate in the one-way
ANCOVA tests.
Group differences for amyloid and tau pathology burden were assessed with Student’s
t-test. The associations between microglial abundance and AD pathology were assessed
using Pearson correlation.
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2.4 Methodology for Chapter 5
2.4.1 Cell culture
BV2 cells, including CRISPR/Cas9-edited and control cell lines, were cultured as described
in Chapter 2.2.7, unless specified otherwise. Passage number of CRISPR/Cas9-edited and
control cell lines used are indicated below.
Phenotype Clone ID Passage number









Table 2.24. Passage number of CRISPR/Cas9-edited and control cell lines
used.
2.4.2 DNA sequence verification
∼2×106-cell pellets were prepared in 1.5 mL microfuge tubes for each clonal line. DNA was
extracted and PCI-purified as described in Chapter 2.2.8. PCR, agarose gel electrophoresis
and Sanger sequencing was performed as described in Chapter 2.2.9 and 2.2.10.
2.4.3 Reverse transcription-polymerase chain reaction
Following RNA extraction (described in Chapter 2.2.11), 5 µg of total purified RNA was
converted into cDNA using SuperScript IV Reverse Transcriptase (Thermo Fisher Scientific)
according to the manufacturer’s protocol as described in Chapter 2.2.12.
Exon 2 of protein-coding Trem2 transcripts (NM_031254 & NM_001272078) and Intron
1–Exon 2 of retained intron Trem2 transcript (ENSMUST00000132340.1) were amplified by
PCR using primer pairs mTREM2_cDNA_seq_F1/R1 and mTREM2F4/R4, respectively
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(Table 2.25), as described in Chapter 2.2.9, in a 10 µL reaction volume. 1 µL cDNA was
used as the template.
RT-PCR products were resolved by agarose gel electrophoresis as described in Chapter
2.2.9.







Table 2.25. RT-PCR primers used amplify cDNA generated from Trem2 iso-
form 1 and 2 transcripts.
Red font: sequencing primer as indicated in brackets.
2.4.4 Protein extraction
For the validation of loss of functional TREM2 protein expression in CRISPR/Cas9-edited
TREM2 clonal lines, untreated cells were harvested from T75 flasks by scraping confluent
cells and pelleting them in 50 mL centrifuge tubes by centrifugation at 200 ×g for 5
min. Cell pellets were resuspended in 1 mL DPBS to wash and transferred into 1.5
mL microfuge tubes. The cell suspension was centrifuged at 14,500 ×g for 5 min at
4°C, discarding the supernatant. The cell pellet was resuspended in 100 µL (per 1×106
cells) of RIPA buffer supplemented with cOmplete ULTRA, EDTA-free (Roche) protease
inhibitor cocktail and PhosSTOP (Roche) phosphatase inhibitor made up according to
the manufacturer’s protocols (1 tablet each in 10 mL RIPA buffer). Lysates were briefly
vortexed to complete resuspension and incubated on ice for 3× 10 min, with brief vortexing
in between incubations. Lysates were then passed through a 26-gauge needle syringe several
times to shear DNA. Any remaining DNA was physically removed with the needle syringe.
Lysates were further sonicated for 15 s before being centrifuged at 14,500 ×g for 10 min at
4°C to separate RIPA-insoluble debris. The supernatants were carefully transferred into
new 1.5 mL microfuge tubes on ice.
Protein concentration was determined by BCA protein assay (Thermo Fisher Scientific)
according to the manufacturer’s protocols. The Working Reagent was prepared by combin-
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ing Reagent A and Reagent B in a 50:1 ratio to a total volume of 200 µL Working Reagent
per reaction. Aliquots of each sample were diluted 1:10 to bring the concentration of each
protein sample within the reference standard range. 10 µL diluted standards/samples
were added in duplicates to individual wells of a clear, flat-bottomed 96-well assay plate,
followed by 200 µL of Working Reagent per well. The plate was covered with a plate sealer
and agitated at ∼800 rpm on an orbital shaker to mix. The plate was incubated at 37°C for
30 min before measuring absorbance at 562 nm on a PHERAstar FS (BMG LABTECH)
plate reader.
2.4.5 Protein lysate deglycosylation
Protein lysates were deglycosylated using the Protein Deglycosylation Mix II (New England
Biolabs) with modifications to the manufacturer’s protocol to maintain protein concentra-
tion at >3 µg/µL to enable sufficient loading in Western blots. 90 µg protein lysate was
diluted with ddH2O to a total volume of 24 µL. 3 µL Deglycosylation Mix Buffer 2 was
added and samples were heated to 100°C for 10 min to denature protein. The denatured
protein lysate was chilled on ice for at least 5 min to condense any evaporation, followed
by centrifugation at 14,500 ×g for 2 min at 4°C. 3 µL Protein Deglycosylation Mix II was
added and gently mixed. The reaction was incubated overnight at 37°C. The following day,
the deglycosylated protein lysate was again chilled on ice for at least 5 min to condense
any evaporation, followed by centrifugation at 14,500 ×g for 2 min at 4°C to collect. To
dissolve precipitated proteins, 10.5 µL 4× NuPAGE LDS Sample Buffer (Thermo Fisher
Scientific) and 4.5 µL NuPAGE Sample Reducing Agent (Thermo Fisher Scientific) or 500
mM DTT were added and gently mixed.
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2.4.6 Western blot
Samples were prepared by mixing the desired amount of protein lysate with 4× NuPAGE
LDS Sample Buffer and 10× NuPAGE Sample Reducing Agent (or 500 mM DTT) to 1×
working concentration at a maximum volume of 20 µL. Samples were then heated at 100°C
for 10 min to denature protein. Denatured protein lysates were chilled on ice for at least 5
min to condense any evaporation, followed by centrifugation at 14,500 ×g for 2 min at 4°C
to collect.
Gel electrophoresis was performed by loading the samples into a 26-well NuPAGE 4-12%
Bis-Tris Midi Protein Gel alongside 3 µL Precision Plus Protein All Blue Prestained Protein
Standards (Bio-Rad) in a XCell4 SureLock Midi Cell (Thermo Fisher Scientific). The
Upper and Lower Buffer Chambers were filled with 1× NuPAGE MOPS SDS Running
Buffer and 500 µL NuPAGE Antioxidant was added to the Upper Buffer Chamber (All
NuPAGE products were from Thermo Fisher Scientific). Gel electrophoresis was performed
at a constant 200 V for 55 min.
After completion of the gel electrophoresis, a wet protein transfer was performed. 4 sheets
of grade 3 qualitative filter paper and 1 sheet of Amersham Protran NC nitrocellulose
membrane (GE Healthcare) were cut and pre-soaked in 1× transfer buffer with 20% (v/v)
methanol. The gel was trimmed to remove wells and dye front. The gel was then sandwiched
next to the nitrocellulose membrane in between 2 sheets of filter paper on each side. The
transfer sandwich was gently pressed to remove air bubbles and then put into a transfer
cassette. Wet protein transfer was performed in a Trans-Blot Electrophoretic Transfer Cell
(Bio-Rad) with 1× transfer buffer with 20% (v/v) methanol at a constant 80 V for 1 h.
Once the transfer was complete, the nitrocellulose membrane was briefly rinsed in 1×
TBS-T 0.1%. The TBS-T 0.1% was discarded and Ponceau S staining solution was added
and briefly incubated to visualise protein on the nitrocellulose membrane. Ponceau S was
discarded and the membrane was rinsed twice with ddH2O to improve contrast. Ponceau
S protein staining was imaged on the ChemiDoc XRS+ System for reference. Ponceau S
staining was removed with 3× 5 min washes in 1× TBS-T 0.1%.
The nitrocellulose membrane was incubated in 5% (w/v) BSA for 1 h at RT to block
non-specific antibody binding. The blocking solution was removed before adding the
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diluted primary antibody solution with 1% blocking solution in 1× TBS-T 0.1% and
incubated overnight at 4°C on an orbital shaker. The following day, the primary antibody
solution was removed and the membrane was washed with 3× 5 min in 1× TBS-T 0.1%.
Diluted secondary antibody solution in 1× TBS-T 0.1% was added to the membrane and
incubated while covered for 1 h at RT. The secondary antibody solution was removed
and the membrane was washed with 3× 5 min in 1× TBS-T 0.1%. Antibody binding was
visualised and imaged on the ChemiDoc XRS+ System. Detected protein band intensities
were quantified using ImageJ.
Combinations of primary antibody and secondary antibody solutions used are shown in
Table 2.26.
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Primary antibody Dilution Manufac-turer Cat# Secondary antibody Dilution
Manufac-
turer Cat#
Anti β-actin (clone C4), mouse 1:10000 Santa Cruz sc-47778
Anti mouse IgG, goat, AF568 1:5000 TFS A11004
Anti mouse IgG, goat, AF680 1:5000 TFS A21057
Anti mouse CD68/macrosialin (clone FA-11), rat 1:1000 BioLegend 137001 Anti rat IgG, goat, AF488 1:5000 TFS A11006
Anti Erk1/2 (clone L34F12), mouse 1:2000 CST 4696 Anti mouse IgG, goat, AF488 1:5000 TFS A11001
Anti phospho-Erk1/2 (clone D13.14.4E), rabbit 1:2000 CST 4370 Anti rabbit IgG, goat, AF594 1:5000 TFS A11012
Anti GAPDH, rabbit 1:1000 Santa Cruz sc-25778 Anti rabbit IgG, goat, AF594 1:5000 TFS A11012
Anti Iba-1, rabbit 1:5000 Wako 019-19741 Anti rabbit IgG, goat, AF594 1:5000 TFS A11012
Anti I-A/I-E (MHC class II, clone M5/114.15.2), rat 1:1000 BioLegend 107601 Anti rat IgG, goat, AF488 1:5000 TFS A11006
Anti Pyk2 (clone 5E2), mouse 1:1000 CST 3480S Anti mouse IgG, goat, AF488 1:5000 TFS A11001
Anti phospho-Pyk2, rabbit 1:1000 CST 3291S Anti rabbit IgG, goat, AF594 1:5000 TFS A11012
Anti Syk (clone 6A464), mouse 1:1000 Santa Cruz sc-73089 Anti mouse IgG, goat, AF488 1:5000 TFS A11001
Anti phospho-Syk (clone C87C1), rabbit 1:1000 CST 2710S Anti rabbit IgG, goat, AF594 1:5000 TFS A11012
Anti human TREM2, goat 1:1000 R&D AF1828 Anti sheep IgG, donkey, AF488 1:5000 TFS A11015
Anti human TREM2, rabbit 1:1000 Atlas HPA012571 Anti rabbit IgG, goat, AF488 1:5000 TFS A11008
Anti human/mouse TREM2 (clone 237920), rat 1:1000 R&D MAB17291 Anti rat IgG, goat, AF488 1:5000 TFS A11006
Anti mouse TREM2, rabbit 1:1000 Santa Cruz sc-48765 Anti rabbit IgG, goat, AF488 1:5000 TFS A11008
Anti mouse TREM2, sheep 1:2000 R&D AF1729 Anti sheep IgG, donkey, AF488 1:5000 TFS A11015
Table 2.26. Combinations of primary antibodies and secondary antibodies that were used for Western blotting.
Atlas: Atlas Antibodies; CST: Cell Signalling Technology; R&D: R&D Systems; TFS: Thermo Fisher Scientific.
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2.4.7 TREM2-activating antibody treatment
6-well culture plates were first coated with antibodies. 500 µL 10 µg/mL TREM2 activating
antibody (MAB17291, R&D Systems) or isotype control antibody (MAB0061, R&D
Systems) in sterile DPBS were added to each well. The plates were gyrated to ensure that
the antibody solution covered the bottom of each well evenly. Plate lids were put on and
plates wrapped in Parafilm to prevent evaporation. Plates were left to incubate overnight
at 4°C on a slow orbital shaker for even coating. The next day, the antibody solutions
were transferred into replicate plates. Wells of the original plates were gently rinsed with 1
mL DPBS to remove unbound antibodies and kept in DBPS until ready to use.
The replicate plates were incubated in exactly the same conditions as the original. The
antibody solutions were removed and wells were gently rinsed with 1 mL DPBS to remove
unbound antibodies. Non-specific binding was blocked with 500 µL 5% BSA in each well
on a slow orbital shaker for 1 h. Blocking solutions were discarded and wells were gently
rinsed 3 times with 1 mL DPBS. 100 µL 1:1000 anti rat IgG AF488 (A11006, Thermo
Fisher Scientific) was added to each well and incubated on a slow orbital shaker for 1 h.
Antibody solutions were discarded and wells were gently rinsed 3 times with 1 mL DPBS.
Fluorescence intensities in each well were measured at 485 nm absorption and 520 nm
emission on the PHERAstar FS plate reader.
Clonal cell lines (BV2 WT, CRISPR TREM2 WT, CRISPR TREM2 KO) were cultured in
RPMI-1640 w/ 10% FBS + 1% PS in T75 flasks until 60-70% confluency. Culture medium
was then replaced with RPMI-1640 without FBS to serum-deprive cells for 24 h before
treatment with antibodies. When ready, cells were detached with 0.25% trypsin-EDTA,
pelleted, and resuspended in warm RPMI-1640. Cell density was adjusted to 1×106
cells/mL with warm RPMI-1640. 1 mL cells were gently added to the side of each well
(Uncoated, Isotype control, TREM2-activating) and then gyrated to ensure even dispersion
of cells. The cells were left to incubate for 1 h at 37°C/5%CO2.
At harvest, culture medium was transferred into individual 1.5 mL microfuge tubes on
ice. 100 µL RIPA buffer supplemented with protease and phosphatase inhibitors was
immediately added to each well on ice to harvest cells. Cells were lysed in the wells by
scraping with the reverse end of a micropipette tip. Cell lysates were transferred into
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individual 1.5 mL microfuge tubes on ice and briefly vortexed. Lysates were incubated for
3× 10 min on ice with brief vortexing between incubations. The reserved culture medium
were centrifuged at 14,500 ×g for 10 min at 4°C to pellet any cells/debris. The culture
medium supernatant was transferred into new 1.5 mL microfuge tubes on ice and frozen
at -20°C for future analyses. Cell protein lysates were sonicated for 15 s and centrifuged
at 14,500 ×g for 10 min at 4°C to pellet RIPA-insoluble debris. The supernatant was
transferred into new 1.5 mL microfuge tubes on ice. Protein concentration was determined
by BCA protein assay and Western blot performed as described in Chapter 2.4.6.
2.4.8 Statistical analyses
All statistical analyses were performed using SPSS Statistics 23 (IBM). All tests were
nominally significant for p-values 6 0.05.
Relative fluorescence intensities of plate-bound antibodies were quantified by normalising
to uncoated wells (background fluorescence intensity). Group differences between uncoated,
isotype control antibody and TREM2-activating antibody wells (10 wells each) were assessed
using one-way ANOVA with post-hoc pairwise comparisons (Tukey HSD correction).
Activation of Syk, Pyk2 and Erk1/2 was quantified by calculating band intensity ratio of
the phospho-protein:total protein in 4 different TREM2 WT and TREM KO cell lines and
normalised to the relative amount of plate-bound treatment antibody (isotype control or
TREM2 activating antibody) measured using secondary antibody fluorescence intensity.
CD68 and Iba-1 protein levels were quantified by quantifying protein band intensity in 4
different TREM2 WT and TREM2 KO cell lines and normalised to β-actin band intensity.
Individual group differences between untreated, isotype control and TREM2-activating
antibody treatment in 4 different TREM2 WT and TREM2 KO cell lines were assessed








This project aims to develop an in vitro disease cell model of TREM2 suitable for functional
characterisation and drug screening. Different experimental models have advantages and
disadvantages depending on the hypothesis being tested. To investigate how different cells
work together in a system, animal models would be more suitable than cell culture models
which tend to be of one cell type or in co-culture. On the other hand, cell culture models
are ideal for investigating subcellular molecular pathways or high-throughput screening
assays because they can be isolated from the influences of other cell types, specifically
treated with compounds, and are easily scalable. Various primary cells and cell lines were
considered for their cell type, suitability of underlying biology, and proliferative capacity
to use as a model of TREM2 dysfunction. TREM2 is expressed on myeloid cells including
dendritic cells, monocyte/macrophages, osteoclasts and microglia400,557. Among these cell
types, microglia have been strongly associated with the pathogenesis of AD362. They have
an active role in the maintenance of the CNS and is part of the innate immune system of the
brain198. In disease, increased microglia activity has been associated with the progression
and severity of AD198,238,558. For example, microglia respond to the hallmark pathologies
of AD including neuronal debris and Aβ by releasing cytokines and chemokines as well
as phagocytosis of these material559. Additionally, chronic activation of microglia may be
involved in disease progression of AD. Blocking of microglial proliferation by inhibiting
CSF1R prevents synaptic degeneration in APP/PS1 mice238. With the increasing amount
of literature on TREM2 dysfunction in microglia contributing to the vulnerability of
developing AD, microglia was used as the cell type of choice for functional characterisation
and drug screening. This enables the comparison and validation of the generated disease
cell model with established phenotypes of microglia with TREM2 dysfunction.
To perform functional characterisation and drug screening, the microglial model of choice
would replicate the disease biology of TREM2 dysfunction conveyed by the AD-associated
risk variants in people. Of the in vitro models, primary microglia are considered the gold
standard for experimental models as they are believed to closely resemble endogeneous
biology compared to cell lines that are transformed or modified to achieve immortalisa-
tion560,561. Primary microglia can be derived from human or rodent brains. To harvest
primary human microglia, brain tissue can be obtained as biopsies from patients undergoing
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brain surgery for epilepsy562 or autopsy tissue if there is a short post-mortem delay563–565.
Primary human microglia could be isolated from people with the TREM2 variants of
interest but this is impractical as the variants are very rare (minor allele frequency [MAF]
0.0012–0.0063 in healthy populations110 and 0.009–0.02 in AD cases109). While obtaining
primary microglia from control human or rodent brains566 are potential alternatives, they
have limited in vitro proliferation capacity required for clonal expansion following genome
editing to characterise and provide sufficient cells for experiments.
An alternative to primary human microglia is to generate microglia from induced pluripo-
tent stem cells (iPSCs) derived from people with a TREM2 variant. iPSCs would have the
required proliferative capacity to theoretically proliferate indefinitely, which allow the pro-
duction of sufficient cells to perform various functional characterisation and drug screening
assays. Even if iPSCs cannot be obtained from patients with TREM2 variants, iPSCs from
control patients could be genome edited to knock-in the disease-associated variants before
or after differentiation into microglia-like cells, depending on their proliferative capacity in
the respective states. Genome editing of TREM2 in iPSCs before differentiation may affect
their ability to respond to differentiating factors and differentiate into microglia-like cells.
Osteoclasts derived from NHD patients with TREM2 variants418 and a TREM2-deficient
macrophage cell line have impaired capability to differentiate, which was associated with a
PlexinA1-dependent pathway567. However, microglia from TREM2 KO mice do not appear
to be affected developmentally and can be detected and isolated from the brain452,495,522,
suggesting that the differentiation of microglia was not compromised by the lack of TREM2.
Regardless, protocols to generate microglia from iPSCs were yet to be established at the
start of the project, although a number of groups have since published successful protocols
and characterisation of microglia-like cells derived from iPSCs568–570.
Besides that, immortalised microglia cell lines also have a high rate of proliferation to
theoretically provide limitless numbers of cells. They also are easier to culture compared
to iPSCs. Immortalised cells are derived from spontaneously occurring cancer cells or
transformed with viral oncogenes to obtain their proliferative capacities. Two immor-
talised human microglia cell lines derived from embryonic human microglia, CHME571
and HMO6572 have been previously described. Unfortunately, these cell lines were not
commercially available or for academic sharing at the time of this project. A number of
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rodent microglia cell lines have been extensively studied over many years, including BV2552,
N9573, EOC574, C8-B4575, MG5576, HAPI577, MG6578, and SIM-A9579. Of these, BV2 has
been the most frequently used and studied. The BV2 cell line is generated from 1-week
old C57BL/6 mouse primary microglia cultures and immortalised with the v-raf/v-myc
carrying J2 virus552.
Because primary microglia are considered as the gold standard for in vitro experimental
models, immortalised microglial cell lines have been compared to primary microglia to
assess their validity as an experimental model. Studies by Henn et al. (2009)560 and Das et
al. (2016)580 have investigated and compared the regulation of the transcriptome between
primary microglia and BV2 in response to LPS stimulation. Both studies have found that
primary microglia regulated a far greater number of genes by up to ten times compared
to BV2. There are also a relatively large number of genes, especially key inflammatory
genes such as Tnf, Cxcl10, Il1a, Il1b, Ccl4 and Ccl5, that were similarly regulated by
primary microglia and BV2. Of the 299 genes upregulated in BV2, 264 (88.3%) genes
are also upregulated in primary microglia580. Despite this, almost all proinflammatory
cytokines and chemokines are more highly induced in primary microglia than in BV2580. In
agreement with transcriptomic data, primary microglia and BV2 release TNF-α and IL-6581.
However, there are discrepancies in the expression of some proinflammatory cytokines
such as IL-1β in BV2 although the concentration and duration of LPS treatment used
were similar581,582. Moreover, with relevance to AD, both primary microglia and BV2
respond to fibrillar Aβ1–42 by stimulating phagocytosis and releasing similar cytokines such
as TNF-α583–585. Oligomeric Aβ1–42 also induces TNF-α release but does not stimulate
phagocytosis in both cells583–585.
However, primary microglia may not represent endogeneous physiology as expected. The
isolation of microglia from brain tissue exposes them to large quantities of cell debris which
activate microglia and also potentially cause microglial priming. Priming causes microglia
to be vulnerable to other inflammatory stimuli and result in an exaggerated response327.
This may explain the greater number of genes regulated and the enhanced immune-
related responses such as the expression of proinflammatory cytokines and chemokines
by primary microglia compared to BV2 when stimulated with LPS560,580. On the other
hand, BV2 which is immortalised by transformation with viral oncogenes almost certainly
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have modified physiology due to the transformation. Nevertheless, BV2 appear to replicate
most key inflammatory responses expected from endogeneous microglia such as release of
cytokines/chemokines, chemotaxis and phagocytosis552,560,580,586.
TREM2 expression has been previously detected in BV2 by others412. Mouse and human
TREM2 have a 69% amino acid sequence homology, which appears modest, but the
extracellular domain where most of the disease-associated variants are located has a 73%
homology. Furthermore, most of the amino acids associated with the AD risk variants are
conserved between mouse and human TREM2 (Figure 3.1), which means the introduction of
human AD-associated TREM2 variants into mouse microglia is possible. Mouse and human
TREM2 also share similar downstream signalling pathways, relying on the DAP12 adaptor
protein to initiate phosphorylation and activation of intermediate signalling proteins386,557.
Therefore, BV2 were used for this project because as an immortalised cell line, they
are capable of providing consistent and sufficient amount of cells to perform functional
characterisation and drug screening. BV2 also have exhibited key microglial properties
and endogeneously express intact TREM2 signalling pathways. Thus, various functional
phenotypic or protein expression markers that are affected by TREM2 dysfunction can be
used as outcome measures during characterisation and drug screening. Genome editing
was used to knock-in the equivalent AD-associated TREM2 DNA variants into mouse
Trem2. Various genome editing methods have been used in the past but the four major
systems used were meganucleases, zinc-finger nucleases (ZFNs), transcription activator-
like effector nucleases (TALENs) and clustered regularly interspaced short palindromic
repeats (CRISPR)/Cas nuclease systems. These genome editing methods utilise the same
general principle to generate modifications in the targeted genome involving two steps:
first to create a double-stranded DNA break at the targeted location followed by the
second step to induce endogeneous DNA repair mechanisms587. The DNA break is usually
repaired through an error-prone non-homologous end joining (NHEJ) or a higher fidelity
homology-directed repair (HDR) pathway587 which can be used to generate indels or
knock-in mutations, respectively.
Meganucleases were identified in single-cell eukaryotic introns where they mediate intron
mobility. These are the first major tool used to perform directed genome editing588.
SceI, which is derived from mitochondria of Saccharomyces cerevisiae, is one of the initial
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Figure 3.1. Most amino acids affected by disease-associated TREM2 variants
in humans are conserved in mouse.
Aligned human and mouse TREM2 cDNA and amino acid sequences with 69% amino acid
sequence homology overall and 73% homology in the extracellular domain.
Grey: signal peptide, yellow: extracellular domain, red: transmembrane domain, green:
cytoplasmic domain, bold: codon for affected amino acid variants, underline: disease-
associated DNA variants.
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meganucleases used589. However, meganucleases have limited flexibility for sequence-specific
targeting as its nuclease domain is shared with the DNA-binding domain and modifications
may therefore impact both functions590.
ZFNs were described about a decade later591. ZFNs consist of Cys2-His2 zinc-finger
domains, which are the most common DNA-binding motifs found in eukaryotes592. The
use of ZFNs in genome editing involve the construction of synthetic zinc-finger proteins
that can recognise 9–18 bp of DNA sequences. They are usually linked to a FokI DNA
cleavage domain that performs the endonuclease activity593,594. Modular designs have been
established by using arrays of zinc-finger domains that can recognise nearly all possible
nucleotide triplets595. Thus, for a 18 bp target recognition, 6 zinc-finger domains in tandem
are required. While ZFNs provided the first tool to target almost any sequence in the
genome, this system has poor flexibility. Designing ZFN expression vectors for one target is
relatively straightforward but tedious re-engineering is required to substitute the zinc-finger
domains in the expression vector to target another DNA sequence.
TALENs were subsequently developed as an alternative for ZFNs. TALENs are DNA-
binding proteins derived from plant pathogenic bacteria in the Xanthomonas genus that
contain 33–35 amino acid repeat domains with each recognising a single base pair596,597.
Similar to ZFNs, transcription activator-like effector (TALE) domains have been designed
to fit into a modular construction to recognise various lengths of DNA sequences, typically
12–20 bp. They are also linked to a FokI DNA cleavage domain for nuclease activity598.
Compared to the triplet-recognising ZFNs, the ability for TALEN to recognise single base
pair sequences provided superior targeting flexibility. Moreover, unlike ZFNs, tedious
re-engineering of the linkage between repeats is not required when constructing long
arrays of TALEs598. However, the construction of repeat TALE arrays for targeting of
repeated DNA sequences can be technically challenging due to the large number of identical
repeat sequences required to clone into the expression vector598. Also, despite the various
combinations of TALEs that theoretically allow for the recognition of virtually any sequence,
in practice there are various restrictions such as that TALE binding sites should start with
a T base598.
The most recent tool in genome editing technology is the CRISPR/Cas system. It is derived
from the bacterial immune system whereby foreign genetic material is recognised by RNA-
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guided nucleases to excise invading DNA599. In bacteria, the type II CRISPR/Cas system
involves short fragments of foreign DNA that are stored in the CRISPR loci and processed
into RNA known as CRISPR RNA (crRNA). crRNAs anneal to 25 nt trans-activating
crRNAs (tracrRNA), which are complementary to the CRISPR repeat and coded on the
opposite strand upstream of the CRISPR loci. They form RNA duplexes and are processed
by RNase III. The processed crRNA:tracrRNA duplexes then associate with Cas nucleases,
forming ribonucleoprotein complexes that recognise DNA sequences complementary to
the crRNA599. Unlike ZFN and TALEN, CRISPR/Cas can be easily reprogrammed by
just changing the crRNA sequence without the need to synthesize large fragments of DNA
oligonucleotides. The crRNA, also known as the guide/short guide RNA (gRNA/sgRNA),
are usually 20 bp in size enabling them to be easily and precisely synthesized. While the
crRNA can be made to target any 20 bp sequence in the genome, crRNA-binding sites
on DNA require an upstream protospacer adjacent motif (PAM) for binding of the Cas
nuclease600, which in the case of Cas9, requires a NGG PAM sequence to be present next
to the target DNA sequence601,602. In practice, the this is a relatively common motif in
the human genome that occurs every 8 bp on average602. An advantage of CRISPR/Cas
over previous tools for genome editing is the uncoupling of the DNA recognition system
and the nuclease, which can be individually assembled. This allows the crRNA sequence
to be easily substituted by simple cloning if the target DNA sequence has to be changed.
Additionally, CRISPR/Cas can be multiplexed to simultaneously edit multiple targets at
once by introducing an array of crRNA sequences in the expression vector.
Detailed methods and tools for the CRISPR/Cas9 system are readily available with
many successful examples published546. Once the workflow is optimised for a cell line,
changing DNA targets is expected to be easy without the need to perform tedious re-
engineering and validation of expression vectors. Only 20 bp crRNA/sgRNA oligonucleotide
sequences against the new target followed by a simple one-step cloning into the vector
are required. Validation only requires Sanger sequencing to check for successful insertion
of the crRNA/sgRNA fragment into the expression vector. Besides that, the uncoupling
of CRISPR/Cas9 components mean greater flexibility in the design choice. The Cas9
nuclease can be delivered into target cells using expression vectors (plasmid, viral)546, Cas9
mRNA603, or protein603 depending on the feasibility of delivery method and the desired
duration of Cas9 activity. crRNA/sgRNA sequences can also be delivered through various
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formats, such as incorporation of DNA sequences into an expression vector (plasmid, viral)
that is subsequently transcribed into RNA or inserted together on the same Cas9 expression
vector546. Alternatively, crRNA/sgRNA can also be pre-assembled and processed with
tracrRNA for delivery with Cas9 mRNA or pre-associated to Cas9 protein and delivered
as ribonucleoprotein complexes603. Therefore, the CRISPR/Cas9 system was chosen and
used for this project.
3.2 Aims
• To generate a disease cell model of microglia carrying different AD-associated TREM2
variants suitable for functional characterisation and therapeutic drug screening.
• To introduce the variants using CRISPR/Cas9-mediated genome editing.
• To optimise methods for transfection, clonal isolation and screening.
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3.3 Methodology overview
This Chapter explored and optimised various steps in the CRISPR/Cas9-mediated genome
editing workflow (Figure 3.2) depending on the results of the previous CRISPR design. The
different approaches are briefly described here in each method section. Detailed methods
are outlined in Chapter 2.2.
Figure 3.2. Schematic flow diagram representing the CRISPR/Cas9-mediated
genome editing workflow performed on BV2.
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RT-PCR
RT-PCR was performed by extracting total RNA from BV2 cell pellets and converted into
cDNA by reverse transcription. Target transcripts of interest were PCR-amplified using
primer pairs spanning across exons to avoid amplification of genomic DNA.
sgRNA and HDR template design
20 bp sgRNA sequences in mouse Trem2 gene were identified using the CRISPR Design
Tool (http://crispr.mit.edu). HDR templates were designed with the intended DNA variant
in the middle with 56–90 nt flanking homology arms (total length 113–181 nt) corresponding
to the sense or anti-sense orientation.
Preparation of sgRNA-Cas9n expression plasmids
sgRNA oligonucleotides were phosphorylated and annealed into dsDNA fragments for
cloning into the expression plasmid to be expressed together with Cas9n. Each sgRNA in a
pair were cloned into the pSpCas9n(BB)-2A-GFP or pSpCas9n(BB)-2A-Puro (CRISPR v1
& v2)/pSpCas9n(BB)-2A-mCherry2 (CRISPR v3 & v4). pSpCas9n(BB)-2A-mCherry2 was
made by replacing the puromycin resistance gene with the mCherry2 fluorescent protein
gene. Cloned sgRNA-Cas9n expression plasmids [pSpCas9n(sgRNA)] were transformed into
E. coli for expansion. 3 colonies were selected to validate successful cloning by Miniprep and
Sanger sequencing of the purified plasmids. Validated pSpCas9n(sgRNA) were expanded
in large cultures and harvested by Midiprep (CRISPR v1 & v2) or EndoFree Maxiprep
(CRISPR v3).
Transfection into BV2
In CRISPR v1, various transfection methods were explored for optimal co-transfection
of CRISPR plasmids and HDR templates. Several chemical-based transfection reagents
and electroporation were compared. Electroporation reagents and parameters were also
optimised. Transfection efficiencies were established by fluorescence microscopy or during
FACS. Subsequent transfections in CRISPR v2–v4 were performed by electroporation.
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Puromycin treatment
In CRISPR v1, negative selection of Lipofectamine 3000-transfected BV2 and HEK293A
cells with puromycin was tested as one of sgRNA-Cas9n expression plasmids contained
a puromycin resistance gene [pSpCas9n(BB)-2A-Puro]. 24 h post-transfection, cells were
treated with 0–5 µg/mL puromycin in culture medium for 48 h. Puromycin resistance was
established by microscopy.
Nuclei staining in BV2
Before CRISPR v3, BV2 cells were stained with CellTracker Red CMTPX Dye and Hoechst
33342 to assess multinuclearity.
Nocodazole treatment
In CRISPR v4, BV2 were treated with 0–1,000 ng/mL nocodazole in culture medium for
17 h to synchronise cell cycle before electroporation.
FACS
For CRISPR v1 and v2, 24 h post-electroporation, transfected GFPhi cells were clonally iso-
lated by single-cell FACS. In CRISPR v3, CRISPR v3a-transfected GFPhi and mCherry2hi
cells were first enriched and allowed to recover for 1 week before transfection of CRISPR
v3b plasmids and HDR template. CRISPR v3b-transfected cells were similarly enriched
and allowed to recover before clonal isolation by single-cell FACS with or without Hoechst
33342 staining of cells. In CRISPR v4, enrichment and recovery of transfected GFPhi and
mCherry2hi cells were only performed once and followed by clonal isolation by single-cell
FACS with Hoechstlo staining.
Screening of CRISPR/Cas9-edited clonal lines
After clonal isolation, cells were allowed to recover and grow to confluence in the 96-well
culture plates. Confluent clonal lines were then split for cryopreservation and crude DNA
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extraction. Clonal lines were temporarily cryopreserved in 96-well culture plates while
screening was performed. Crude DNA was extracted from each clonal line and Trem2
Exon 2 was PCR-amplified. Positive clones were screened by agarose gel electrophoresis
and Sanger sequencing.
KASP genotyping
In CRISPR v1, a KASP genotyping assay was tested as an alternative screening method.
Karyotyping
Karyotyping was performed by sending a sample of early passage (P8) BV2 culture to Cell
Guidance Systems Ltd.
Expansion and cryopreservation of clonal cell lines
Positive Trem2 -edited BV2 clones with homogeneous editing (with DNA insertions or
deletions) were revived from cryopreservation in the 96-well culture plates and expanded
into larger cultures for proper cryopreservation and archiving in liquid nitrogen.
146
3.4 Results
3.4.1 Characterisation of BV2
To characterise BV2 for the expression of TREM2 and genes relevant to its function, genes
co-expressed with Trem2, microglia-specific genes, and expression of cytokines genes were
investigated by RT-PCR. In normal culture conditions, BV2 expressed transcripts from
genes selected from the TREM2 co-expression network in human brain402: Aif1, Cd68,
Cx3cr1, Dap12, Trem2, but not Ciita (Figure 3.3a). Furthermore, BV2 expressed cytokines
associated with TREM2 function: Tnf, Il1b, and Il6 (Figure 3.3a). BV2 also expressed the
microglial enriched genes Cx3cr1, Hexb and P2ry12 (Figure 3.3a) as expected by microglia
derived from a young 1-week old mouse552.
Before performing CRISPR/Cas9-mediated genome editing, the target Trem2 gene in BV2
was sequenced to confirm it was identical to the WT mouse reference sequence. This was
to ensure there were no variants which might affect the sgRNA design. Sanger sequencing
revealed that Trem2 Exon 2 in BV2 and the mm9 mouse reference sequence were identical
(not shown).
3.4.2 Validation of sgRNA-Cas9 expression plasmids
Three E. coli colonies for each plasmid containing sgRNA were extracted and sequenced.
At least one colony for each sgRNA was correctly cloned into the plasmid (Figure 3.4).
These were used to make further plasmid preparations and for archiving.
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(a) BV2
(b) WT mouse brain
Figure 3.3. BV2 express transcripts of genes co-expressed with TREM2 in
human brain, microglia-specific genes, and cytokines associated with TREM2
function.
RT-PCR amplicons from (a) BV2 of genes from a TREM2 co-expression network in human
brain402 (Aif1, Cd68, Ciita, Cx3cr1, Dap12, Trem2 ), cytokines that are associated with
TREM2 function (Tnf, Il1b, Il6 ), or are established microglia-specific genes (Cx3cr1, Hexb,
P2ry12 ). (b) Mouse brain was used as a positive control to identify specific RT-PCR
amplicon bands as indicated in magenta boxes.
Expected amplicon sizes are Aif1 : 193 bp, Cd68 : 185 bp, Ciita: 187 bp, Cx3cr1 : 493 bp,
Dap12 : 386 bp, Hexb: 673 bp, Il1b: 914 bp, Il6 : 633 bp, P2ry12 : 979 bp, Tnf : 130 bp,




Figure 3.4. sgRNA dsDNA fragments were successfully cloned into pSp-
Cas9n(BB).
Sequencing chromatograms of CRISPR v1 plasmids performed using the U6-Fwd primer.
Blue highlighted sequence indicate the sgRNA sequence.
3.4.3 Optimisation of BV2 transfection
Optimal transfection of the sgRNA-Cas9 expression plasmids into BV2 were compared using
chemical-based transfection reagents Lipofectamine 2000, Lipofectamine 3000, TurboFect,
FuGENE 6, and PolyFect. Assessing GFP expression 24 h post-transfection, Lipofectamine
3000 had the highest transfection efficiency with 14 GFP+ in ∼1,000 cells (∼1.4%) in a 100×
magnification field of view. The transfection efficiencies of the other transfection reagents
were considerably lower with PolyFect at ∼0.9%, FuGENE 6 at ∼0.4%, Lipofectamine
2000 at ∼0.2% and TurboFect at ∼0.1% (Figure 3.5, Table 3.1).





Lipofectamine 2000 2 ∼0.2%
Lipofectamine 3000 14 ∼1.4%
TurboFect 1 ∼0.1%
FuGENE 6 4 ∼0.4%
PolyFect 9 ∼0.9%
Table 3.1. Lipofectamine 3000 had the highest transfection efficiency between
the chemical-based transfection reagents tested.
Transfection efficiencies of CRISPR v1 pSpCas9n(mTREM2_R47H_sgRNA-A_R1a)-2A-
GFP using chemical-based transfection reagents in approximately 1,000 BV2 cells.
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Figure 3.5. Transfection using Lipofectamine 3000 resulted in the highest
number of GFP+ cells compared to other transfection reagents.
BV2 cells transfected with 1 µg CRISPR v1 pSpCas9n(mTREM2_R47H_sgRNA-A_R1a)-
2A-GFP using Lipofectamine 2000, Lipofectamine 3000, TurboFect, FuGENE 6, and
PolyFect and nuclei stained with DAPI.
Fluorescence images were captured at 100× magnification and the number of GFP-positive
cells in a single field of view were counted. There were approximately 1,000 cells in each
field of view.
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The transfection efficiency of Lipofectamine 3000 was still far too low to generate sufficient
positive transfected cells for subsequent steps. Therefore, electroporation was explored
as an alternative transfection method. Using pmaxGFP, transfection efficiency and cell
viability using the recommended electroporation programs (A-030, A-033, A-020, D-023)
were first compared by qualitative analysis of GFP-expressing cells in a microscopic field
of view. Program A-030 resulted in the highest transfection efficiency with acceptable cell
viability when used with Nucleofector Solution L and V (not shown).
Next, the transfection efficiency of the CRISPR v1 pSpCas9n(mTREM2_R47H_sgRNA-
A_R1a)-2A-GFP plasmid by electroporation with Nucleofector Solution L was compared to
Nucleofector Solution V using program A-030. Transfection efficiency of the plasmid with
Nucleofector Solution L (14.0%) was 1.97 fold higher than with Nucleofector Solution V
(7.1%) as determined by percentage of GFPhi cells using flow cytometry (Figure 3.6). Hence,
Nucleofector Solution L with program A-030 was used in subsequent electroporations.
(a) Nucleofector Solution L
(b) Nucleofector Solution V
Figure 3.6. Electroporation using Nucleofector Solution L resulted in approx-
imately two-fold higher transfection efficiency compared to Nucleofector Solu-
tion V.
Flow cytometry of BV2 transfected with CRISPR v1 pSpCas9n(mTREM2_R47H_sgRNA-
A_R1a)-2A-GFP using Nucleofector Solution L or V with electroporation program A-030.
Transfection efficiency was determined by the percentage of GFPhi cells.
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3.4.4 Optimisation of puromycin for negative selection
To enrich for BV2 cells transfected with the sgRNA-Cas9 expression plasmid, the optimal
concentration of puromycin to use for negative selection was investigated. Puromycin
(0–5 µg/mL) was tested on BV2 transfected with the CRISPR v1 plasmid pair and HDR
templates using Lipofectamine 3000. After 48 h, only untreated BV2 remained alive
whereas even the lowest (1 µg/mL) puromycin concentration resulted in almost complete
cell death (not shown).
HEK293 cells transfected with the puromycin resistance gene by Lipofectamine 3000 have
been reported tolerate up to 3 µg/mL puromycin over a 48–72 h treatment period546.
Therefore, to rule out the possibility that the poor puromycin resistance in BV2 was due to
the low transfection efficiency using Lipofectamine 3000, HEK293A cells were transfected
with pSpCas9n(BB)-2A-Puro using Lipofectamine 3000 and 0–3 µg/mL puromycin. Al-
though HEK293A cells had relatively higher puromycin resistance compared to transfected
BV2, they too were sensitive to puromycin regardless of whether they had been transfected
with a plasmid containing the puromycin resistance gene (Figure 3.7).
Subsequently, it was found that the pSpCas9n(BB)-2A-Puro plasmid obtained from Addgene
contained a SNP in the puromycin resistance gene that affected its efficacy604. Therefore,
only positive GFPhi selection was used in CRISPR v1 and v2. In practice, most cells that
were transfected with pSpCas9n(BB)-2A-GFP were also transfected with pSpCas9n(BB)-
2A-Puro as described later. Eventually the puromycin resistance gene in pSpCas9n(BB)-
2A-Puro was replaced with the mCherry2 fluorescent protein gene and used in CRISPR v3
and v4.
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Puromycin treatment (48 h)
Figure 3.7. After transfection with pSpCas9n(mTREM2_R47H_sgRNA-B_F1a)-2A-Puro using Lipofectamine 3000, HEK293A
and especially BV2 cells were unexpectedly vulnerable to puromycin treatment.
HEK293A or BV2 cells were treated with puromycin for 48 hours 24 hours post-transfection.
Images were captured after puromycin treatment at 100× magnification. Control: untransfected cells, PuroR: Cells transfected with pSp-
Cas9n(mTREM2_R47H_sgRNA-B_F1a)-2A-Puro containing the puromycin resistance gene.
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3.4.5 Optimisation of clone screening
The efficiency of knocking in the Trem2 c.140G>A DNA variant to result in the p.R47H
variant using CRISPR/Cas9 was expected to be low at ∼5%605. Therefore, a large number
of clones were required to be screened. Different high-throughput screening methods
were explored using CRISPR v1 plasmid pairs and HDR templates. The efficiency of
HDR with the sense or anti-sense oriented HDR templates was also compared. Plasmid
transfection efficiencies were slightly higher than previously achieved with the sense HDR
template-transfected BV2 achieving 18.0% and the anti-sense HDR template-transfected
BV2 23.8% (Figure 3.8). Overall, these transfection efficiencies were 8.2 and 10.8 fold,
respectively, higher than achieved with Lipofectamine 3000 and sufficient for FACS.
(a) Sense HDR template
(b) Anti-sense HDR template
Figure 3.8. Transfection efficiency of CRISPR v1 plasmids with sense or anti-
sense HDR template by electroporation were similar as expected.
Flow cytometry of BV2 transfected with CRISPR v1 plasmid pair and (a) sense or (b)
anti-sense HDR template using Nucleofector Solution L with electroporation program
A-030. Transfection efficiency was determined by the percentage of GFPhi cells.
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As standard DNA extraction and purification using PCI was not feasible in 96-well plates
and with large number of clones, crude DNA from GFPhi-sorted clones was prepared.
Crude DNA extracts (undiluted, 1:10 diluted, and purified) were tested in PCR reactions.
Undiluted crude DNA was successfully amplified without further processing (Figure 3.9)
and therefore used in all subsequent screening.
Figure 3.9. Undiluted crude DNA extracts were successfully PCR-amplified
without additional processing.
Trem2 Exon 2 amplicons from various formats of crude DNA extracts resolved on a 2%
TAE-agarose gel to optimise for PCR amplification.
Control: clones transfected with control plasmids without sgRNA inserted; CRISPR: clones
transfected with CRISPR v1 plasmids; H2O: no template PCR.
DNA from 96 clones transfected with the CRISPR v1 sense HDR template were genotyped
with the expectation that ∼5 clones (∼5%) might carry the edited DNA variant. Agarose
gel electrophoresis of Trem2 Exon 2 amplicons revealed that most of these clones had
varying amplicon sizes and were a mixture of 1–8 bands (Figure 3.10), suggesting that
CRISPR/Cas9 editing was not specific as expected. To understand what had happened,
they were Sanger sequenced. 90 of 96 clones were a mixture of indels (Figure 3.11), 2
clones were pure WT Trem2 and 4 clones had homogeneous indels that resulted in a single
amplicon (Table 3.2). The very high rate of clones with edited Trem2 (94/96, 97.9%)
suggested that co-transfection of both plasmids and sorting only for GFPhi cells without
puromycin selection was effective.
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Figure 3.10. Almost all edited clones have mixed Trem2 amplicon sizes within
and between clones.
A selection of Trem2 Exon 2 amplicons from clonal lines transfected with CRISPR v1
plasmids and sense HDR template resolved on 2% TAE-agarose gels at 100 V for 1 h.
The expected amplicon size for WT Trem2 is 646 bp. Positive and negative control lanes
are not shown. DNA ladder is indicated in base pairs.
Figure 3.11. Most CRISPR v1 clones have mixed DNA sequences on Sanger
sequencing chromatograms.
Example clone transfected with CRISPR v1 plasmids and sense HDR template. The
boundary where the DNA sequence differed is shown (red arrow).
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Table 3.2. Transfection using CRISPR v1 plasmids and sense HDR template
resulted in clones with homogeneous indels within Trem2.
Trem2 Exon 2 sequence from positive CRISPR v1 clones.
Black font: Intronic sequence; blue font: Trem2 Exon 2; red font: mismatch base; bold
font: p.R47 codon; underlined font: target c.140G for DNA variant.
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The Trem2 c.140G>A DNA variant was not found in any of the 96 clones sequenced, which
suggested HDR had not occurred and the rate of HDR is <5% and a lot more than 96
clones would need to be screened. Furthermore, the mixed DNA sequences in individual
clones meant that screening for the edited DNA variant from sequencing chromatograms
will be technically challenging. Together, these meant that screening by Sanger sequencing
would not be time and cost efficient.
To improve the cost and efficiency of screening, a competitive allele specific PCR (KASP)
genotyping assay was used to screen for clones with the DNA variant. Initially, undiluted
crude DNA from 96 clones transfected with the CRISPR v1 anti-sense HDR template was
tested. While the synthetic control DNA amplified, none of the sample DNA did (Figure
3.12a), suggesting inhibitors might be present in the crude DNA extracts. A 1:10 dilution
of crude DNA did not improve sample amplification (not shown). Therefore, Trem2 was
pre-amplified by standard PCR from individual crude DNA and diluted by 1:10 to lower
the concentration of inhibitors and PCR buffer salts. The concentration of the synthetic
control DNA was also optimised to improve the assay with 1 µM resulting in better signal
compared to 0.01 µM and 0.1 µM (Figure 3.12b).
Thus, using 1 µM control DNA and 1:10 diluted Trem2 amplicons from 96 clones transfected
with the CRISPR v1 anti-sense HDR template, the KASP assay successfully amplified. From
this, 9 clones with homozygous DNA variant (AA alleles) and 11 clones with heterozygous
DNA variant (GA alleles) were identified (Figure 3.12c). When resolved on an agarose
gel, some of these clones and an additional 3 clones that failed to amplify in the KASP
assay (potentially due to indels) showed mixed amplicon sizes for each clone (Figure 3.13).
Subsequent Sanger sequencing of 14 amplicons thought to have a single band (Figure
3.13) revealed that all of these clones have mixed DNA sequences on the sequencing
chromatogram. This meant that the method of interpreting results on the agarose gel
were not optimal. Furthermore, inspection of the sequencing chromatograms suggested
the different products within each clone differed by only a few base bairs which cannot be
easily resolved or seen by agarose gel electrophoresis (Figure 3.14). Therefore to assess
subsequent clones, 2% TBE-agarose gels were used instead of 2% TAE-agarose gels and




Figure 3.12. Optimisation of DNA template and control DNA in KASP geno-
typing assays.
(a) Undiluted crude DNA extracts from 96 clones transfected with CRISPR
v1 plasmids and anti-sense HDR template failed to amplify. Two concentrations
of positive control DNA were tested.
(b) 1 µM positive control DNA resulted in optimal signal. 3 concentrations of
positive control DNA (0.01, 0.1, 1 µM) were compared.
(c) 1:10 diluted Trem2 amplicons from 96 clones transfected with the CRISPR
v1 plasmids and anti-sense HDR template successfully amplified. Amplicons from
clones marked as potential AA and potential GA were subsequently resolved on an agarose
gel and Sanger sequenced.
Blue points: homozygous WT (GG) control DNA, red points: homozygous DNA variant
(AA) control DNA, green points: heterozygous DNA variant (GA) control DNA, cyan points:
no template negative control, black points: sample DNA template.
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Figure 3.13. Some clones with potential homozygous (AA) and heterozygous
(GA) DNA variants identified from the KASP genotyping assay and 3 addi-
tional clones that failed KASP amplification (unlabeled) had mixed Trem2
Exon 2 amplicon sizes.
Amplicons were resolved on a 2% TAE-agarose gel at 100 V for 1 h to check for indels. Se-
quencing of clones thought to have a single band (+) revealed that they had heterogeneous
amplicons with small indels.
Expected WT Trem2 amplicon size is 646 bp. Positive and negative controls are not shown.
DNA ladder is indicated in base pairs.
Figure 3.14. Multiple poly-A tails from sequencing chromatograms indicated
mixed DNA sequences were from mixed amplicon species of varying sizes.
Although the sequence was difficult to read, it was possible to see the end of each amplicon
within the mixture because the DNA polymerase adds an extra A at the end of each cycle.
This example from a clone transfected with CRISPR v1 plasmids and sense HDR template
shows a mixture of 4 amplicons differing by 3–55 bp.
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These results also suggested cycles of repeated cut and repair events were occurring in
daughter cells even after clonal isolation. It was further established that the expression
of GFP persisted several days after single-cell FACS (not shown), indicating that sgRNA
and Cas9n were still present and could target HDR-edited Trem2 until NHEJ-mediated
indels removed the sgRNA target sequences. It also explained why the KASP genotyping
results were ambiguous and therefore the assay was not used for subsequent screening.
CRISPR/Cas9 constructs and assay conditions were also redesigned to improve HDR-
mediated editing and its detection.
3.4.6 Introduction of PAM-blocking mutations into HDR template
(CRISPR v2 design)
The generation of BV2 expressing the TREM2 p.R47H variant was unsuccessful in CRISPR
v1. Two potential options for improvement in experimental design were considered. First,
to prevent Cas9 from re-targeting HDR-edited DNA and causing repeated cut and repair
events, PAM-blocking silent mutations were introduced into the HDR template547. Second,
because the relative position of the sgRNA target pairs is crucial in determining double-
nicking and HDR activity605, a new sgRNA pair targeting the p.R47H variant was designed
(CRISPR v2) to test if the CRISPR v1 pair was ineffective. As expected, transfection
efficiencies of the new CRISPR v2 plasmid pairs were similar to the previous electroporation
experiments, achieving 20.2% for sense and 20.5% for anti-sense HDR template (Figure
3.15). 34 clones using sense HDR template and 14 clones using anti-sense HDR template
were generated and screened. As seen previously, Trem2 Exon 2 amplicons from most
clones were heterogeneous. Only 3 clones had homogeneous amplicons (Figure 3.16) and
subsequent Sanger sequencing revealed that 2 of these had homogeneous deletions (clone
B4 and C8, Table 3.3) while the other (clone B6) had mixed amplicon sequences that
was not apparent on the agarose gel. The introduction of PAM-blocking mutations did
not improve the rate of homogeneous editing events nor succeeded in incorporating the
targeted DNA variant.
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(a) Sense HDR template
(b) Anti-sense HDR template
Figure 3.15. Similar to CRISPR v1, transfection efficiency of CRISPR v2
plasmids with sense or anti-sense HDR template was almost equal.
Flow cytometry of BV2 transfected with CRISPR v2 plasmid pair and (a) sense or (b)
anti-sense HDR template using Nucleofector Solution L with electroporation program
A-030. Transfection efficiency was determined by the percentage of GFPhi cells.
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Figure 3.16. 3 clones co-transfected with CRISPR v2 plasmids with sense or anti-sense HDR template had homogeneous Trem2
amplicons while most still resulted in mixed amplicons in each clone.
48 clonal lines were generated and screened from CRISPR v2. Trem2 Exon 2 amplicons were resolved on a 2% TBE-agarose gel at 100 V for 3.5 h.
Amplicons from clones B4, B6, and C8 which contained a single band were purified and Sanger sequenced.
WT Trem2 amplicon (646 bp), labelled “WT”, was used to compare amplicon sizes from clones. DNA ladder size is indicated in base pairs.
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Table 3.3. Positive CRISPR v2 clones with homogeneous indels in Trem2
Exon 2.
Their Trem2 Exon 2 DNA sequence are as shown.
Black font: Intronic sequence; blue font: Trem2 Exon 2; bold font: p.R47 codon, underlined
font: target c.140G for DNA variant.
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The presence of heterogeneous editing events in the clonal population suggested more than
one copy of Trem2 gene existed in BV2 cells. Closer investigation of BV2 revealed that
there was a low frequency of multinucleated cells, with up to 4 nuclei per cell (Figure 3.17).
However, this frequency did not match the rate of multiple Trem2 amplicons occurring.
Nevertheless, smaller and less granulated mononucleated cells were gated in subsequent
cell sorting.
Figure 3.17. BV2 typically exhibit a low frequency of multinucleated cells in
culture which slightly increases on immune activation606.
BV2 cells were electroporated with only the HDR template and stained with CellTracker
Red CMTPX Dye and Hoechst 33342.
Green arrows indicate multinucleated cells. Fluorescence microscopy images were taken at
630× magnification.
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3.4.7 CRISPR/Cas9 targeting additional gene variants in Trem2 (CRISPR
v3 design)
It is possible that the targeting and editing to knock in the p.R47H variant was ineffi-
cient. Therefore, other disease-associated loci in the Trem2 gene resulting in the p.Q33X
(rs104894002) and p.D87N (rs142232675) variants were targeted. Both variants have been
described in AD and Nasu-Hakola patients109,342 with a few examples in people without
AD333. Of these variants, only the p.D87 amino acid residue is conserved between human
and mouse TREM2. Mouse TREM2 contains the p.R33 instead of p.Q33 residue but as
the variant results in an early stop codon, this did not matter. The possibility to revert
sgRNA-blocking mutations back to the WT sequence while retaining the intended DNA
variants with a two-step editing547 (CRISPR v3a and v3b) was also explored. Transfection
efficiencies of plasmid pairs ranged between 17.6–25.6% (CRISPR v3a) and 7.2–10.4%
(CRISPR v3b) (Table 3.4).
58 clones from p.Q33X-targeted CRISPR/Cas9 and 41 clones from p.D87N-targeted
CRISPR/Cas9 were obtained at the end of the second editing step (CRISPR v3b). While
many crude DNA extracts from these clones did not amplify, those that did still showed
mixed amplicon sizes in individual clones with no single-band amplicons (Appendix Figure

















Table 3.4. Transfection efficiencies of CRISPR v3a plasmids were similar to
CRISPR v1 and v2 but were lower with CRISPR v3b.
Transfection efficiency was determined by the percentage of GFPhi and mCherry2hi cells
using flow cytometry.
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131 clones from the p.R47H-targeted CRISPR/Cas9 were also screened. A total of 27
single-band amplicons were identified after agarose gel electrophoresis (Appendix Figure
A2c,d). Sanger sequencing revealed that only one clone had a single amplicon containing a
17 bp insertion and 11 bp deletion (net 6 bp insertion) (Table 3.5) and another clone that
failed to be sequenced.




















Table 3.5. Only one positive clone from CRISPR v3 R47H resulted in a net
small insertion in Trem2 Exon 2.
Trem2 Exon 2 sequence as Sanger sequenced is shown.
Black font: Intronic sequence; blue font: Trem2 Exon 2; red font: mismatch/insertion;
bold font: p.R47 codon; underlined font: target c.140G for DNA variant.
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3.4.8 Improving selection of mononucleated cells using Hoechst 33342
The frequency of mixed amplicon sizes detected on agarose gels did not decrease even
after sorting for smaller and less granulated cells to avoid large multinucleated cells. This
suggests that cell sorting based on size (FSC) and granularity (SSC) alone was insufficient
to gate for mononucleated cells. As multinucleated cells have more DNA content per
cell, they are expected to have higher fluorescence intensity when stained with Hoechst
33342 compared to mononucleated cells. Hence, Hoechst 33342 was used to gate for
mononucleated cells during single-cell FACS. Using CRISPR v3b p.R47H-targeted clones,
there was a higher rate of single-band amplicons in Hoechstlo cells (20/59, 33.9%) compared
to unstained cells (23/142, 16.2%) when screened on agarose gels (Table 3.6) which initially
looked promising.
Two clones with homogeneous indels were identified from the screen, one each from unstained
and Hoechstlo clones (Table 3.7). However, despite enriching for mononucleated cells, mixed
amplicon sizes in individual clones were still present in the majority of clones and the other
single bands were WT Trem2 (Appendix Figure A3). This suggested multinuclearity is






Unstained 142 23 16.2% One net 142 bp insertion
Hoechstlo 59 20 33.9% One 82 bp deletion
Table 3.6. Hoechst 33342 was used to select mononucleated cells and reduced
editing heterogeneity in BV2 clones.
BV2 transfected with CRISPR v3b p.R47H-targeted plasmids and HDR template were
stained with Hoechst 33342 before single-cell sorting Hoechstlo cells. Overall, only two
clones with homogeneous indels were obtained and the remainder single amplicon clones
had WT Trem2.
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Table 3.7. Two clones with a homogeneous insertion or deletion in Trem2
following single-cell sorting of unstained or Hoechstlo CRISPR v3b clones.
Trem2 Exon 2 sequence for each clone as Sanger sequenced is shown.
Black font: Intronic sequence; blue font: Trem2 Exon 2; red font: mismatch/insertion;
bold font: p.R47 codon; underlined font: target c.140G for DNA variant.
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3.4.9 Determining hyperploidy in BV2 by karyotyping
Heterogeneous editing by CRISPR/Cas9 in clonal lines could also potentially result from
editing of multiple copies of Trem2 due to hyperploidy. To establish this in BV2, a
sample culture was karyotyped. On average, BV2 have a triploid set of chromosomes with
heterogeneity between individual cells with some missing or having additional chromosomes
(Figure 3.18). More importantly, there were up to 4 copies of chromosome 17 where the
mouse Trem2 locus is, which may explain the high rate of mixed amplicon sizes in clones
following CRISPR/Cas9 editing. This makes the probability of homogeneous editing,
regardless of NHEJ-mediated indels or HDR-mediated knock-in mutations, very low and
difficult to achieve in these cells and highlights the need for wider consideration when
genome editing transformed cell lines.
(a) BV2 karyotype 1 (b) BV2 karyotype 2
(c) BV2 karyotype 3
Figure 3.18. BV2 cells on average were triploid with further instability in the
chromosome number between individual cells.
Chromosome 17, where the mouse Trem2 locus is, has up to 4 copies. Karyotyped BV2
cells were cultured in normal conditions.
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3.4.10 Cell cycle synchronisation of BV2 before transfection (CRISPR
v4 design)
It may be possible to improve the rate of HDR so that all copies of Trem2 in a cell
would incorporate the same knock-in mutation. Lin et al has reported that cell cycle
synchronisation using nocodazole was able to increase the efficiency of HDR by up to 31%548.
Therefore, in a further attempt to generate BV2 with the p.R47H variant, BV2 were treated
with nocodazole before electroporation. Transfection efficiencies of the plasmid pairs and
HDR template for each concentration of nocodazole and untreated control cells resulted in
lower transfection efficiencies than previously obtained (1.8–6.0%, Table 3.8). On screening,
CRISPR/Cas9 editing was heterogeneous with mixed amplicon sizes in individual clones
regardless of nocodazole treatment (Appendix Figure A4). Only untreated BV2 (4/57,
7.02%), 10 ng/mL (9/59, 15.25%), and 1000 ng/mL (11/37, 29.73%) nocodazole-treated
BV2 resulted in any single-band amplicons which of those sequenced, turned out to be
WT Trem2 while 100 ng/mL (0/51), 200 ng/mL (0/16) and 500 ng/mL (0/46) nocodazole-
treated BV2 resulted in mixed amplicon sizes as before (Table 3.9). Overall, cell cycle
synchronisation by nocodazole treatment did not improve the rate of HDR sufficient to











Table 3.8. Transfection efficiencies with CRISPR v4 plasmids and HDR tem-
plate in BV2 treated with or without various concentrations of nocodazole
were lower than previously achieved.











0 57 4 7.02%
10 59 9 15.25%
100 51 0 0%
200 16 0 0%
500 46 0 0%
1000 37 11 29.73%
Table 3.9. Nocodazole treatment did not appear to shift cells towards a higher
rate of HDR editing.
BV2 treated with different concentrations of nocodazole were transfected with CRISPR
v4 R47H plasmids and HDR template. Mononucleated cells were positively gated during
single-cell sorting. No clones were found to carry the p.R47H variant. Of those containing
single bands which were sequenced, all were WT.
3.4.11 Trem2 -edited BV2 clonal lines suitable for functional character-
isation
The majority of 9 homogeneous Trem2 -edited clonal BV2 cell lines containing an indel
were expected to result in functional loss of TREM2 and thus were potentially useful in
mechanistic and drug screening studies where a loss of TREM2 function was relevant.
Although there were several clones with indels leading to frameshift generated from the
different CRISPR designs, only clones from CRISPR v1 when transfected with the sense
HDR template (C1G10, C1E2, C1C4, C1G4) and the CRISPR v3b clones with Hoechst
33342-mediated selection of mononucleated cells (C3bB10, C3bC4) successfully revived
from cryopreservation in the 96-well culture plates (Table 3.10). Additionally, 5 WT clones
which had undergone CRISPR/Cas9 editing alongside the others were revived to be used
as procedure controls (Table 3.10). Characterisation of these clones is described in Chapter
5.
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Table 3.10. Homogeneous clones with a single insertion or deletion predicted to
result in a functional TREM2 knockout and able to be grown are summarised.
Trem2 Exon 2 sequence for each clone as Sanger sequenced is shown.
Black font: Intronic sequence; blue font: Trem2 Exon 2; red font: mismatch/insertion;
bold font: p.R47 codon; underlined font: target c.140G for DNA variant.
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3.5 Discussion
In CRISPR v1, multiple Trem2 amplicons edited at a similar target site were observed on
agarose gels and by sequencing. It was initially thought that the design of CRISPR v1
which did not stop Cas9n retargeting Trem2 after successful HDR led to continuous editing
until NHEJ-mediated indels disrupted the sgRNA targeting sequences. Furthermore, GFP
expression in transfected BV2 was observed to last over several days (data not shown),
suggesting that the sgRNA-Cas9 expression plasmid persisted long enough for extended
expression of Cas9n and activity after clonal isolation by single-cell FACS. This would mean
as BV2 proliferated, daughter cells that have undergone HDR would still have viable sgRNA
target sequence in Trem2 and each could undergo independent editing events from Cas9n,
resulting in a genotypically heterogeneous population with slightly different indels. Thus,
PAM-blocking mutations and sgRNA-blocking mutations were introduced into CRISPR v2
and v3 design, respectively. These silent blocking mutations on the HDR template would
alter the sgRNA targeting sequences on Trem2 after successful incorporation by HDR and
disrupt further Cas9n targeting and editing547,607. Others have shown that PAM- and
sgRNA-blocking mutations similarly improved accurate HDR events with no additional
indels being generated in iPSCs and HEK293 cells by up to 10-fold547.
However, multiple Trem2 amplicons were still observed after the introduction of PAM-
and sgRNA-blocking mutations in CRISPR v2 and v3, respectively. This suggested that
repeated cutting was not the cause of heterogeneous editing of Trem2. An alternative
explanation for this is that there were multiple copies of Trem2 in each cells for Cas9n
to target and cut, leading to the detection of heterogeneous NHEJ-mediated indels in
clonal lines. There are two possibilities that result in multiple copies of Trem2 to occur:
multinuclearity or hyperploidy. Indeed, some multinucleated BV2 cells were observed
at a low frequency when nuclei were stained in BV2 that is consistent with findings by
others606. Microglia have been observed to form multinucleated cells upon stimulation
by various inflammatory factors in vitro, including IL-3, IL-4, IL-13, TNF-α, granulocyte
macrophage-colony stimulating factor (GM-CSF), phorbol myristate acetate (PMA), and
phagocytosis of cell debris606,608–610. Although BV2 were not stimulated with most of
these inflammatory factors and cytokines during CRISPR/Cas9-mediated genome editing,
electroporation of BV2 induced a high amount of cell death (data not shown) and hence cell
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debris. The rigours of FACS shortly after electroporation may also exacerbate cell stress
and activation. These crucial steps in the CRISPR/Cas9 workflow may have increased the
occurrence of multinucleated BV2. Unfortunately, this is unavoidable as other methods of
transfection do not yield sufficient transfection efficiency.
Considering the low frequency of multinucleated cells relative to the frequency of multiple
amplicons observed in each clone, it appears that multinuclearity was not the major
contributing factor of multiple copies of Trem2. Regardless, the contribution of multin-
ucleated cells was minimised by positively gating for mononucleated cells during FACS.
Multinucleated cells induced by cell debris have been shown to have high granularity (SSC)
in by flow cytometry610 and hence, smaller and less granular cells were sorted with stricter
FSC-SSC gating in CRISPR v3 and v4. However, the changes in FSC-SSC gating alone did
not drastically improve the frequency of single-band amplicons observed. Additionally, seg-
regation of multinucleated cells could be improved by using a nuclear stain such as Hoechst
33342 as they would have more intense fluorescence staining compared to mononucleated
cells. The use of DNA-binding stains like Hoechst dyes to stain nuclei of live cells may
impact genomic integrity as it is potentially mutagenic and carcinogenic. It can result in
endoreduplication leading to polyploidy611 and decrease in DNA synthesis612. Nevertheless,
it has been shown that live cell staining with Hoechst 33342 for flow cytometry does not
result in mutagenesis, at least in boar spermatozoa613. When Hoechstlo cells were single-cell
sorted in the present study, the rate of obtaining single homogeneous Trem2 amplicons
improved by almost two-fold compared to sorting unstained BV2 by FSC-SSC gating only.
Multiple heterogeneous editing of Trem2 is more likely caused by hyperploidy of BV2.
BV2 is a cell line infected with a v-raf /v-myc oncogene-carrying J2 retrovirus to achieve
immortalisation552. This resulted in cancer-like proliferative properties with an indefinite
and high rate of proliferation which would likely accumulate chromosomal instability in
the cells614. These cells were established ∼27 years ago552 and therefore likely to have
accumulated chromosomal abnormalities since. Although BV2 has been widely used in the
research of microglia, its genomic abnormalities and karyotype have been under-reported.
Karyotyping a sample of early passage (P8) BV2 culture revealed heterogeneous aneuploidy
between individual cells and importantly, there were up to 4 copies of chromosome 17 where
Trem2 is located. Most cells that were characterised had >2 copies of chromosome 17 and
176
this is consistent with the frequency of multiple amplicons observed after CRISPR/Cas9
editing. A recent paper described BV2 to be hypertriploid615, similar to the observations
here. Despite this, homogeneously edited clonal lines with a single edited Trem2 amplicon
were generated in the project. Considering the heterogeneity of chromosome copy numbers
observed, it is possible that these cells had only one copy of chromosome 17 and hence
only had one CRISPR/Cas9-mediated cut and repair event dominated by NHEJ.
In this project, it appears that CRISPR/Cas9-mediated genome editing to introduce Trem2
gene variants by HDR was not successful. Even after 4 different experimental designs with
iterative improvements, BV2 clones with the p.R47H, p.Q33X or p.D87N variants were
not observed. After CRISPR v1 and v2, the p.R47H loci within Trem2 was thought to
be inefficient at inducing HDR. Thus, Trem2 p.Q33X and p.D87N variants, in addition
to p.R47H, were targeted in CRISPR v3 but this was still unsuccessful with multiple
amplicons in each clone observed from agarose gels and Sanger sequencing. Some amplicons
were similar in size to the WT amplicons which may be successful HDR event occurring in
at least one copy of Trem2. Nonetheless, distinguishing the overlapping DNA sequences in
sequencing chromatograms at the p.R47H (c.140G>A) loci to identify if any of the clonal
lines had at least one allele with the variant was difficult. It would be possible to isolate
the individual amplicons by cloning them into plasmids and sequencing. However, this
would be extremely time consuming, especially when the expected frequency of HDR is
extremely low. It also would not resolve the problem of having a mixed genotype in the
clonal line where only some of the copies were edited with the desired variant.
Successful genome editing by CRISPR/Cas9 and HDR in immortalised cell lines have been
reported, although all of them have been screened at a population level and not in clonal
lines547,548,605,616–619. For example, HEK293 cells were frequently used as a control when
editing iPSC, but were only genotyped on the population level through next generation
sequencing or base mismatch endonucleases which does not account for the number of
gene copies present in individual cells. HEK293 cells are known to be tetraploid553 and if
these cells were to be single-cell sorted for clonal isolation and genotyped, it is likely that
multiple NHEJ-mediated indels arising from multiple edited events at a given target would
be detected and homozygous HDR events in individual clones would be difficult to identify.
DNA repair by NHEJ or HDR is largely dependent on the phase of the cell cycle. NHEJ is
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dominant through a large portion of the cell cycle especially in the G1, S, and G2 phases
whereas HDR is limited to the late S and G2 phases after DNA replication and at the point
where sister chromatids are available for use as repair templates620. The HDR mechanism
at this point prevent telomere fusion in the M and G1 phases621. Because HDR is restricted
to a small window and is also in competition with the dominant NHEJ in the S and G2
phases622, it is not surprising that the rate of HDR is so low. There have been attempts
to skew DNA repair occurring in the S and G2 phases from NHEJ towards HDR by
suppression of NHEJ pathways using inhibitors or gene expression knockdown623. However,
inhibition of any DNA repair mechanisms could contribute to further genomic instability
and chromosomal abnormalities especially in cells already having unstable genomes due to
their immortalisation.
Cell cycle synchronisation is another method that has been employed to maximise HDR
efficiency for genome editing548. When inhibitors to different phases of the cell cycle
were tested, it was surprising that nocodazole which inhibits the cell cycle at the late
G2/M phase achieved the highest rate of HDR, up to 31% HDR efficiency which is higher
than that achieved with inhibitors targeting the late G1/S phase when HDR begins548.
In that publication, the authors attributed the high rate of HDR to the action of Cas9
on two sets of chromosomes in each cell during the M phase when DNA is replicated.
However, in CRISPR v4 of this project, homogeneous HDR events were not detected in any
clones treated with nocodazole regardless of concentration, likely due to poor transfection
efficiency. The rate of HDR was measured at a population level may not directly translate
to successful single cell targeting. Nonetheless, the possibility that HDR occurred at an
appreciable rate cannot be ruled out because neither genotyping or sequencing could resolve
where this may have happened on a subset of targets.
Future CRISPR/Cas9 designs include the addition of selectable markers on the HDR
template to improve clonal cell selection. Ideally, a positive selectable marker (fluorescent
protein gene) should be used instead of a negative selectable marker (antibiotic resistance
gene) to avoid inducing cell death and the generation of cell debris that can activate BV2.
A population of cells with successful HDR can then be enriched by FACS and clonal cell
lines with the desired genotype can be established from this population. However, the
selectable marker gene would need to be removed from the target gene after screening and
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clone selection as it could lead to disruption of the open reading frame or dysfunctional
protein folding due to the additional amino acids. The removal can be performed using
the piggyBac system, which results in scarless excision of the selectable marker624.
For this, the HDR template should be designed with the selectable marker gene flanked
by the piggyBac inverted terminal repeats which will be recognised by the transposase on
incorporation into gDNA alongside the intended knock-in variant. Cells with successful
HDR can be enriched by FACS and followed by removal of the fluorescent protein gene
using the excision-only piggyBac transposase. Successful excision can be gated from loss-
of-fluorescence and followed by clonal isolation using single-cell FACS. While this method
does not improve the rate of HDR, it greatly reduces the amount of clones to screen as
it enriches for cells with successful HDR and homogeneous editing events will be more
likely to be detected. Alternatively, as NHEJ-mediated indels were so prevalent, it may
be possible to screen for a clonal line with at least one copy of Trem2 with the desired
variant and have the remainder copies knocked out. This would result in the functional
expression of only the TREM2 variant protein and not a heterogeneous expression of
WT and variant proteins. Caveats to this method is that the fluorescent protein gene
would need to be incorporated directly after an endogeneous TTAA sequence for scarless
excision of the fluorescent protein gene, which may not be present close to the targeted
DNA sequences.
Moreover, instead of using immortalised rodent cell lines, microglia-like cells from human
iPSCs could be established with published protocols available now568–570. iPSCs could
be obtained from patients with a TREM2 variant to be used as the disease cell model.
Isogenic control cell lines could be generated using CRISPR/Cas9-mediated genome editing
to edit the variant into the WT sequence. An advantage to genome editing patient-derived
iPSC is that the DNA variant provides specificity for sgRNA targeting. If the variant is
heterozygous, CRISPR/Cas9 can be designed to only specifically target the variant allele
and modifying it to become WT while avoiding any unwanted editing in the other WT
allele. If patients with a TREM2 variant cannot be found, iPSCs from control patients
could still be used. Again, genome editing can be used to introduce the variants into iPSCs
similar to immortalised cell lines. A benefit to using iPSCs over immortalised cell lines is
that iPSCs would be ensured to not have chromosomal abnormalities unlike immortalised
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cell lines. With only two copies of Trem2 to target and edit, it is far more likely to detect
successful homogeneous HDR editing. Regardless of iPSC approach, the CRISPR/Cas9
workflow would be the same as established in this project and the suggestions made to
improve screening can be implemented. Successful editing of iPSCs using CRISPR/Cas9
by others has been demonstrated547. Therefore, this is a promising approach to obtain a
cell model that is more disease relevant as these microglia-like cells are of human origin and
have a transcriptome profile and functional physiology that are highly similar to human
adult microglia568–570.
To conclude, achieving homogeneous CRISPR/Cas9-mediated genome editing of immor-
talised cell lines with hyperploidy and multiple copies of the target gene is challenging.
Clones with homogeneous NHEJ-mediated events resulting in insertions or deletions that
are predicted to result in functional loss of TREM2 were generated. On the other hand,
clones with HDR-mediated knock-in of DNA variants could not be detected. This is likely
due to the very low rate of HDR in combination with multiple copies of Trem2 in each
cell. Thus, obtaining clones with specific disease-associated variants was not achieved.
Nevertheless, a TREM2-deficient model has a number of valuable applications such as to
investigate the mechanism and signalling pathways of TREM2 function or the effects of











Various in vitro studies have implicated the loss of TREM2 function with dysfunctional
phagocytosis, chemotaxis, cell survival and proliferation383. These are key innate immune
responses mediated by microglia against disease pathology. TREM2 function also appears
to modulate inflammatory responses mediated by the activation of immune receptors such
as TLRs381,394,428,495,497,501. Consequently, TREM2 activation can skew microglia function
towards anti-inflammatory responses associated with debris clearance by phagocytosis and
tissue repair384,394,412.
In vivo studies using TREM2-deficient AD mouse models reported mixed findings with
amyloid and tau pathology burden depending on the AD mouse model used (Chapter 1.6.5.4
and 1.6.5.6). For example, cortical insoluble Aβ1–42 and Aβ1–40 load is increased in 8 m old
TREM2-deficient APP/PS1 mice468 but not in 8.5 m old TREM2-deficient 5XFAD mice438
compared to TREM2-expressing control mice. On the other hand, hyperphosphorylated
tau is decreased in 4 m old TREM2-deficient APP/PS1 mice239 but is increased in TREM2-
deficient 5XFAD mice of unreported age241 compared to TREM2-expressing control mice.
Despite differences in pathology burden that is likely due to age-dependent effects and
AD mouse models, these implicate the role of dysfunctional TREM2 in microglia and how
these cells may modulate the severity of pathology leading to the onset and progression of
AD.
Nevertheless, TREM2 deficiency consistently decrease the density of plaque-associated
microglia239,241,438,468,470,472 and it has been shown that these microglia may be involved in
limiting the neurotoxic effects of oligomeric and protofibrillar Aβ species in the periphery
of amyloid plaques470,474 (Chapter 1.6.5.3). Put together, these suggest that the role of
microglia is vital in the pathogenesis of AD and its function is compromised by dysfunctional
TREM2.
The various disease-associated variants appear to affect TREM2 function differently (Chap-
ter 1.6.4). Variants such as p.R47H, p.R62H, p.D87N and p.T96K located on the exposed
extracellular region of the protein affect ligand binding106,108,378. Besides that, variants like
p.Y38C and p.T66M are located within the Ig-fold and disrupt normal protein folding of
TREM2. This causes TREM2 to accumulate in the endoplasmic reticulum and increase its
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degradation, which prevents its trafficking to the cell surface378,379,432,452,453. Additionally,
some variants including the p.R47H appear to impair protein maturation by affecting
post-translational modifications such as glycosylation379,382,452 and degradation435.
Despite the increasing number of experimental in vitro and in vivo studies on the role of
TREM2 in disease, these findings need to reflect the disease in people. Studies involving
people with a TREM2 variant have been very limited because of the rarity of the variants.
Even the most common and established AD-associated p.R47H variant has a MAF of
0.0012–0.0063 in healthy populations110 and 0.009–0.02 in populations with AD109. This
means that very large AD cohorts need to be screened to identify sufficient number of
cases for analysis.
A cohort consisting of 16 post-mortem cases with disease-associated TREM2 variants (9
p.R47H, 7 other variants) has been identified and requested from various UK and European
brain banks by Dr Angela Hodges. These cases were identified from AD donors to the
brain banks by sequencing TREM2 Exon 2 and screened for the disease-associated TREM2
variants. In this study, the effects of disease-associated TREM2 variants on microglial
dysfunction in post-mortem AD brain tissue was investigated by labelling microglia with
various functional microglia-specific markers.
Traditionally, markers specific to microglial function were used to identify microglia in
tissue. These markers include CD68, human leucocyte antigens (HLAs) and ionised calcium-
binding adaptor molecule 1 (Iba-1). CD68 is a lysosome-associated protein and is used as
a marker of phagocytosis625,626, which is a key function of microglia to clear pathology and
tissue debris. HLA genes are clustered on chromosome 6 and the cluster can be divided
into 3 regions: class I, II and III. HLA class I genes consist of HLA-A, HLA-B and HLA-C
whereas class II genes include the HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1,
HLA-DRA and HLA-DRB1. On the other hand, HLA class III genes encode for several
components of the complement system627. The HLA class II genes encode for combinations
of the α- and β-subunits of the MHC class II molecule. HLA class II, especially HLA-DP,
-DQ and -DR, are associated with antigen presentation628. Antibodies against HLA-DP,
-DQ or -DR have been commonly used to label “activated” microglia629–631, although the
activation states have been poorly defined. In fact, microglia with ramified morphology,
associated with a “resting” or surveillance state, were also shown to constitutively express
183
HLA-DR632. On the other hand, Iba-1 is associated as a pan-macrophage marker633 and in
normal brains include all microglia. Iba-1 is an actin-binding634 and calcium-binding635
protein involved in membrane ruffling and formation of phagocytic cups, which are early
processes of phagocytosis636.
Microglial activation in its most basic form is recognised as microgliosis, described by the
proliferation of the local microglial population to increase cell numbers637,638. Activated
microglia also tend to transform from a ramified into an amoeboid morphology639,640.
These two measures can be quantified from labelled microglia in post-mortem tissue to
determine their overall activation state.
Besides investigating the effects of disease-associated TREM2 variants on microglia, this
study presents the opportunity to identify functional microglial markers of TREM2 dys-
function in human AD. These markers can then be used as outcome measures during
characterisation of the in vitro TREM2 model generated in Chapter 3 to establish if its
phenotype reflects TREM2 dysfunction in human AD.
4.2 Aims
• To investigate the effects of disease-associated TREM2 variants on microglia using
different functional activation markers in post-mortem human brains of AD cases
with and without disease-associated TREM2 variants.
• To establish microglial markers from dysfunction conveyed by disease-associated
TREM2 variants in people, which can be used to characterise and compare the
generated in vitro TREM2 model to the human disease.
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4.3 Methodology overview
Detailed methods are outlined in Chapter 2.3.
AD cases with a disease-associated TREM2 variant (AD/TREM2var) were identified prior to
this project (A. Hodges) (Table 2.21). They were pair-matched for age at death and gender
with a non-AD control (Control/TREM2wt) and AD cases without a disease-associated
TREM2 variant (AD/TREM2wt). Cases without hippocampal tissue sections, AD cases
that were not Braak tau stage IV–VI, or non-diseased controls that were not Braak tau
stage 0–I were excluded from analyses.
To investigate the effects of TREM2 variants on microglia, immunohistochemistry was
performed using antibodies against frequently used microglia-specific functional markers:
CD68 and HLA-DP, -DQ, -DR (henceforth called HLA) as well as the pan-microglial marker
Iba-1. Microglial abundance and morphology were used as measures of activation which are
commonly observed changes in microgliosis. To make the groups comparable with respect to
the degree of pathology, AD cases with similar Braak tau staging were selected. Additionally,
sections were immunostained for amyloid and tau pathology. For high-throughput analyses,
immunostained sections were imaged using a microscope slide scanner and quantification
performed using a semi-automated computerised pipeline. CD68-immunostained microglia
were quantified by % area staining whereas HLA- and Iba-1–immunostained microglia were
quantified by cell counts.
To identify if microglia immunolabelled by CD68, HLA or Iba-1 represent similar mi-
croglial subpopulations or not, double staining immunofluorescence was performed using
combinations of antibodies against these markers (Table 2.23). Additionally, to observe
any dysfunction of microglial association to amyloid or tau pathology, double staining
immunofluorescence was also performed on a small subset of cases using combinations of
antibodies against the microglial markers with antibodies against amyloid and tau pathol-





The cases for each group in the cohort for this study were selected to match age at death,
gender and Braak tau stage (IV–VI) as best as possible. Age at death was not significantly
different between the 3 groups (ANOVA: F=0.731, p=0.487; Table 4.1). Gender was also
comparable across the 3 groups (binomial logistic regression: χ2=1.117, p=0.572; Table
4.1), although there was a slightly higher female:male (10:6) ratio in the AD/TREM2var
group. The AD/TREM2var group contained cases with several different disease-associated

















Table 4.1. Demographics of the research cohort used in this study.
Age at death and gender were balanced between the experimental groups.
IQR: interquartile range, Control/TREM2wt: non-AD control cases without disease-
associated TREM2 variants, AD/TREM2wt: AD cases without disease-associated TREM2












(rs2234253, rs2234258, rs2234256) 1
Table 4.2. List of disease-associated TREM2 variants in AD/TREM2var.
p.R47H was the most frequent variant. One case contained 3 variants in TREM2 which
are in linkage disequilibrium.
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4.4.2 Comparison between manual and semi-automated cell counting
methods
While manual counting is commonly used to quantify cell abundance or density in im-
munostained tissue, it is laborious. Therefore, to perform high-throughput quantification of
immunostained cells in a ROI, a semi-automated analysis pipeline utilising a combination
of Python scripts and ImageJ macros compatible for use on scanned slide images was
developed. Results were compared to manual cell counts from micrographs of the same
sections and ROI performed by an experienced neuropathologist (Dr Andrew King) on
HLA-immunostained images from randomly selected cases from each group in the cohort.
As HLA and Iba-1 have similar staining patterns, the comparison between semi-automated
quantification and manual counting was only performed on HLA-immunostained images.
There was a strong correlation between the number of HLA+ microglia counted manually
and those counted by the semi-automated method (Pearson correlation: R=0.849, p<0.001,
n=110; Figure 4.1a).
Cell counts were used to quantify HLA+ or Iba-1+ microglial abundance instead of the
commonly used % area staining because cell counts better reflect microglial cell density.
Microglia have highly dynamic morphology depending on activation states. Surveil-
lance/resting microglia have a ramified morphology with small cell body whereas activated
microglia have an amoeboid morphology and larger cell body due to retraction of microglial
processes. Nevertheless, to check that cell counts were not significantly different from the
commonly used % area staining and still represented cell density, semi-automated cell
counts were compared to the % area staining method using HLA- and Iba-1-immunostained
images. Cell counts strongly correlated with % area staining for both HLA- (Pearson
correlation: R=0.856, p<0.001, n=585; Figure 4.1b) and Iba-1-immunostained (Pearson
correlation: R=0.941, p<0.001, n=330; Figure 4.1c) images. These strong correlations
show that these high-throughput quantification methods are comparable to commonly used
methods.
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(a) Manual vs semi-automated (b) HLA
(c) Iba-1
Figure 4.1. Semi-automated quantification of cell density strongly correlated
with commonly used standard quantification methods in the same tissue sec-
tions.
Scatter plots showing strong correlation between (a) manual and semi-automated HLA+
cell counts (R=0.849, p<0.001, n=110 total images across a sample of cases), (b) HLA %
area stained and HLA+ cell counts (R=0.856, p<0.001, n=585 total images across a sample
of cases), (c) Iba-1 % area stained and Iba-1+ cell counts (R=0.941, p<0.001, n=330 total
images across a sample of cases).
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4.4.3 AD cases with disease-associated TREM2 variants have fewer func-
tionally activated microglia
To investigate the effects of the disease-associated TREM2 variants on the overall microglia
population in the hippocampal CA1 and CA4, the abundance of cells expressing the
pan-microglia marker Iba-1 were assessed. Iba-1+ microglia abundance was not statis-
tically different in the CA1 and CA4 between Control/TREM2wt, AD/TREM2wt and
AD/TREM2var groups. However, there was a small trend towards fewer Iba-1+ microglia
in AD/TREM2var cases compared to AD/TREM2wt in both the CA1 and CA4 (Figure
4.2).
Microglia can perform various immune-related functions when activated. Therefore, the
effects of disease-associated TREM2 variants on the number of cells expressing these
functional markers were investigated. Microglia have been associated with the ability to clear
neuronal debris and AD pathology such as Aβ through phagocytosis. Phagocytic microglia
were stained for CD68, a lysosome-associated protein marker. CD68 immunostaining
resulted in a punctate pattern frequently near small and intense haematoxylin staining,
which represent glial cell nuclei. There was significantly lower CD68 staining in the
CA4 of AD/TREM2var cases compared to AD/TREM2wt (pairwise comparison ANCOVA:
p=0.030) and Control/TREM2wt (pairwise comparison ANCOVA: p=0.015) (Figure 4.3b,d).
There was a trend towards lower CD68 staining in the CA1 of AD/TREM2var compared
to AD/TREM2wt (Figure 4.3a,c).
Activated microglia have been commonly labelled with antibodies against HLA-DP, -
DQ or -DR629–632, which function is associated with antigen presentation628. When
immunostained for HLA, there were trends towards fewer HLA+ microglia in the CA1 and
CA4 of AD/TREM2var compared to AD/TREM2wt (Figure 4.4). The number of HLA+
microglia in the CA1 and CA4 were similar to or lower than that of Control/TREM2wt
(Figure 4.4). As expected, there was increased HLA+ microglia in AD/TREM2wt compared
to Control/TREM2wt, which was significant in the CA1 (pairwise comparison ANCOVA:
p=0.009) and a trend in the CA4 (Figure 4.4).
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(a) Iba-1 CA1 (b) Iba-1 CA4
(c) Iba-1 CA1
(d) Iba-1 CA4
Figure 4.2. Iba-1+ microglia abundance were not statistically different between
the 3 experimental groups in the CA1 and CA4 but there was a small trend
towards fewer Iba-1+ microglia in the CA4 of AD/TREM2var.
Box plots showing Iba-1+ microglial abundance in the (a) CA1 and (b) CA4 of 18
Control/TREM2wt, 21 AD/TREM2wt and 16 AD/TREM2var cases. Means and standard
deviations are shown in Appendix Table A1.
Representative images from p.R47H cases illustrating Iba-1+ microglial abundance in the
(c) CA1 and (d) CA4 between experimental groups. Antibody binding was visualised with
the dark brown DAB staining. Microscopy images are at 400× magnification.
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(a) CD68 CA1 (b) CD68 CA4
(c) CD68 CA1
(d) CD68 CA4
Figure 4.3. Significantly fewer CD68+ microglia were found in the CA4 of
AD/TREM2var compared to AD/TREM2wt with a similar trend in the CA1.
Box plots showing CD68 % area staining in the (a) CA1 and (b) CA4 of 18
Control/TREM2wt, 21 AD/TREM2wt and 16 AD/TREM2var cases. Means and stan-
dard deviations are shown in Appendix Table A1. *: p<0.05
Representative images from p.R47H cases illustrating CD68 staining in the (c) CA1 and
(d) CA4 between experimental groups. Antibody binding was visualised with the dark
brown DAB staining. Microscopy images are at 400× magnification.
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(a) HLA CA1 (b) HLA CA4
(c) HLA CA1
(d) HLA CA4
Figure 4.4. HLA+ microglia abundance trended towards fewer HLA+ mi-
croglia in the CA1 and CA4 of AD/TREM2var compared to AD/TREM2wt.
Box plots showing HLA+ microglial abundance in the (a) CA1 and (b) CA4 of 18
Control/TREM2wt, 21 AD/TREM2wt and 16 AD/TREM2var cases. Means and standard
deviations are shown in Appendix Table A1. **: p<0.01
Representative images from p.R47H cases illustrating HLA+ microglial abundance in the
(c) CA1 and (d) CA4 between experimental groups. Antibody binding was visualised with
the dark brown DAB staining. Microscopy images are at 400× magnification.
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To investigate the relationship between functional markers used to label microglia, double
staining immunofluorescence was performed. Due to limitations with the species that
the antibody pairs were raised in, sections could only be stained with CD68+Iba-1 and
HLA+Iba-1 combinations. Many Iba-1+ microglia were not CD68+ (Figure 4.5) or HLA+
(Figure 4.6), indicating that only a subset of cells stained with the pan-microglial Iba-1
marker were activated with a functional phenotype. Additionally, there were also CD68+
and HLA+ microglia that were not Iba-1+ (Figure 4.5,4.6), suggesting that other cell
types expressing these markers were also present. Alternatively, some of these functionally
activated microglia may differentiate into a phenotype that do not express Iba-1. This
may explain the different observations in the cell densities of CD68+, HLA+ and Iba-1+




Figure 4.5. Only a subset of Iba-1+ microglia were stained with CD68. Con-
versely, not all CD68+ cells were stained with Iba-1.
Double staining immunofluorescence of CD68+ (green) and Iba-1+ (red) microglia sub-
populations in the CA1 and CA4 of (a) AD/TREM2wt and (b) AD/TREM2var (p.R47H)
cases.
CD68+–Iba-1+ microglia are indicated with filled arrows. CD68+ only or Iba-1+ only
microglia are indicated with empty arrows. Cell nuclei were stained with Hoechst 33342
(blue). Images on the left panels were captured at 200× magnification. Right panels are
images of the dotted squares at 400× magnification. Separate fluorescence channels are




Figure 4.6. Only a subset of Iba-1+ microglia were stained with HLA. Con-
versely, not all HLA+ cells were stained with Iba-1.
Double staining immunofluorescence of HLA+ (green) and Iba-1+ (red) microglia subpop-
ulations in the CA1 and CA4 of (a) AD/TREM2wt and (b) AD/TREM2var (p.R47H)
cases.
HLA+–Iba-1+ microglia are indicated with filled arrows. HLA+ only or Iba-1+ only
microglia are indicated with empty arrows. Cell nuclei were stained with Hoechst 33342
(blue). Images on the left panels were captured at 200× magnification. Right panels are
images of the dotted squares at 400× magnification. Separate fluorescence channels are
shown in Appendix Figure A6.
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4.4.4 Microglia were morphologically activated in AD cases, including
those with disease-associated TREM2 variants
To assess morphological changes in microglia that is indicative of the extent of activa-
tion639,640, cell morphology of functionally activated HLA+ microglia and pan-Iba-1+
microglia was measured using circularity (cell area to perimeter ratio). Iba-1+ microglia
morphology was not statistically different between the 3 groups in the CA1 and CA4
(Figure 4.7a,b). However, there was a trend towards more amoeboid Iba-1+ microglia
in AD/TREM2var cases compared to AD/TREM2wt and Control/TREM2wt in both
hippocampal regions (Figure 4.7a,b).
Cell morphology between AD/TREM2wt and AD/TREM2var groups in the CA1 and CA4
were not statistically different (Figure 4.7c,d). As expected, HLA+ activated microglia
were significantly more amoeboid in AD/TREM2wt (pairwise comparison ANCOVA in
CA1: p=0.014, CA4: p=0.004) and AD/TREM2var (pairwise comparison ANCOVA in
CA1: p=0.011, CA4: p=0.005) compared to Control/TREM2wt (Figure 4.7c,d).
As HLA and Iba-1 staining appear to label slightly different microglia, the differences in
HLA+ and Iba-1+ cell morphology further support that they may be different microglial
subpopulations. For this, only HLA+ and Iba-1+ microglia could be assessed as CD68 have
a punctate staining pattern which does not delineate cell morphology.
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(a) Iba-1 CA1 (b) Iba-1 CA4
(c) HLA CA1 (d) HLA CA4
Figure 4.7. HLA+ microglia, but not Iba-1+ microglia, were more amoeboid
in AD cases than non-AD control cases, but there was no significant difference
in cell morphology in those with a TREM2 variant.
Box plots showing average circularity of (a,b) Iba-1+ and (c,d) HLA+ microglia in 0.5×0.5
mm2 areas of the (a,c) CA1 and (b,d) CA4 of 18 Control/TREM2wt, 21 AD/TREM2wt
and 16 AD/TREM2var cases. Means and standard deviations are shown in Appendix Table
A2.
*: p<0.05, **: p<0.01.
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4.4.5 AD pathology does not appear to be affected by the presence of
disease-associated TREM2 variants
AD cases with comparable pathology (Braak tau stage IV–VI) were selected for comparison.
Additionally, the abundance of amyloid and hyperphosphorylated tau pathology was
measured in adjacent tissue sections of the CA1 and CA4 between AD/TREM2wt and
AD/TREM2var cases. Thus as expected, amyloid and tau pathology were not statistically
different in the CA1 and CA4 between the two groups (Figure 4.8), although there was a
trend towards lower tau burden in the CA4 of AD/TREM2var compared to AD/TREM2wt
cases.
(a) Aβ CA1 (b) Aβ CA4
(c) Phospho-tau CA1 (d) Phospho-tau CA4
Figure 4.8. The degree of amyloid and tau pathology in the CA1 and CA4
were not affected by the disease-associated TREM2 variants.
Box plots showing AD pathology of (a,b) Aβ (4G8) and (c,d) phospho-tau (AT8) in 0.5×0.5
mm2 areas of the (a,c) CA1 and (b,d) CA4 of 18 Control/TREM2wt, 21 AD/TREM2wt
and 16 AD/TREM2var cases. Means and standard deviations are shown in Appendix Table
A3.
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The abundance of microglia stained with CD68, HLA or Iba-1 was not significantly
correlated with amyloid or tau burden in the AD group as a whole (Table 4.3). As
TREM2 variants may influence AD pathology, this was tested for the AD/TREM2wt and
AD/TREM2var groups separately. There was no significant correlation between microglial
abundance and AD pathology, except in AD/TREM2wt cases in the CA1 where there was
a significant negative correlation between the number of Iba-1+ microglia and the degree of
tau pathology (Pearson correlation: R=-0.570, p=0.007) (Table 4.3). Overall, this suggests
that the number of functionally activated microglia or total microglia was not influenced
by AD pathology in the hippocampus.
Correlations Region
Combined AD AD/TREM2wt AD/TREM2var
R p R p R p
CD68 vs tau CA1 0.096 0.571 0.355 0.114 -0.196 0.468
CA4 0.289 0.087 0.315 0.165 -0.311 0.260
HLA vs tau CA1 0.169 0.324 0.235 0.305 -0.074 0.793
CA4 0.116 0.500 0.004 0.987 0.124 0.660
Iba-1 vs tau CA1 -0.292 0.080 -0.570 *0.007 0.016 0.954
CA4 -0.152 0.368 -0.276 0.226 -0.124 0.648
CD68 vs Aβ CA1 -0.029 0.863 -0.060 0.795 -0.044 0.871
CA4 0.062 0.719 0.400 0.072 -0.226 0.418
HLA vs Aβ CA1 0.029 0.868 0.147 0.524 -0.340 0.214
CA4 -0.154 0.370 -0.354 0.116 0.125 0.657
Iba-1 vs Aβ CA1 0.178 0.291 0.395 0.076 -0.311 0.260
CA4 -0.195 0.248 -0.347 0.123 -0.027 0.922
Table 4.3. Overall microglial abundance was not affected by the degree of AD
pathology in the CA1 or CA4.
Pearson correlations between microglial abundance and AD pathology burden in the CA1
and CA4 of all AD cases or separated by the presence/absence of disease-associated TREM2
variants. The only significant correlation found was between Iba-1+ microglia abundance
and tau pathology burden in the CA1 of AD/TREM2wt cases.
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To visualise the the interaction between microglia and AD pathology, double staining
immunofluorescence was performed. Although microglial abundance and AD pathology
burden were not statistically correlated, CD68+ and HLA+ microglia were more frequently
seen to cluster around amyloid plaques in the CA1 and CA4 of AD/TREM2wt and
AD/TREM2var cases (Figure 4.9a,4.10a). Some Iba-1+ microglia were also found adjacent
to amyloid plaques but at a lower extent compared to CD68+ and HLA+ microglia (Figure
4.11a). Microglia co-localisation with tau pathology was less obvious. Microglia tended
to only cluster around regions of intense hyperphosphorylated tau staining, which are
suspected to be neuritic plaques where hyperphosphorylated tau within dystrophic neurites




Figure 4.9. CD68+ microglia were clustered around amyloid and suspected
neuritic plaques in both AD/TREM2wt and AD/TREM2var cases.
Double staining immunofluorescence of (a) CD68+ microglia (red) and Aβ pathology
(green) or (b) CD68+ microglia (red) and tau pathology (green) in the CA1 and CA4 of
AD/TREM2wt and AD/TREM2var (p.R47H) cases.





Figure 4.10. HLA+ microglia strongly colocalised around amyloid and sus-
pected neuritic plaques in both AD/TREM2wt and AD/TREM2var cases.
Double staining immunofluorescence of (a) HLA+ microglia (red) and Aβ pathology
(green) or (b) HLA+ microglia (red) and tau pathology (green) in the CA1 and CA4 of
AD/TREM2wt and AD/TREM2var (p.R47H) cases.





Figure 4.11. Unlike CD68+ and HLA+ microglia, Iba-1+ microglia were not
preferentially clustered around amyloid and suspected neuritic plaques in ei-
ther AD/TREM2wt or AD/TREM2var cases.
Double staining immunofluorescence of (a) Iba-1+ microglia (red) and Aβ pathology
(green) or (b) Iba-1+ microglia (red) and tau pathology (green) in the CA1 and CA4 of
AD/TREM2wt and AD/TREM2var (p.R47H) cases.
Cell nuclei were stained with Hoechst 33342 (blue). Images were captured at 200× magni-
fication.
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4.4.6 Analysis of AD cases with TREM2 p.R47H variant only
The different AD-associated TREM2 variants may affect the function of TREM2 and
therefore AD vulnerability differently. Therefore to investigate if the effects of the most
common and established AD-associated TREM2 p.R47H variant only are consistent with
previous findings, analyses were repeated on these cases (AD/TREM2R47H) only. In
contrast to AD/TREM2var, there were significantly fewer HLA+ microglia in the CA4
of AD/TREM2R47H cases compared to AD/TREM2wt (pairwise comparison ANCOVA:
p=0.012) and Control/TREM2wt (pairwise comparison ANCOVA: p=0.030) cases (Figure
4.12f).
Conversely, HLA+ microglia morphology was no longer significantly different between
AD/TREM2R47H and Control/TREM2wt cases in the CA1 (Figure 4.13c).
Otherwise, observations between the analyses of only TREM2 p.R47H cases and all cases
with a disease-associated TREM2 variant remained similar (Figure 4.12, 4.13). These
findings suggest that disease-associated TREM2 variants other than the p.R47H may have
different effects on HLA+ microglia. As the number of the other TREM2 variants were
limited, this could explain the relatively small difference in the results of both analyses.
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(a) Iba-1 CA1 (b) Iba-1 CA4
(c) CD68 CA1 (d) CD68 CA4
(e) HLA CA1 (f) HLA CA4
Figure 4.12. CD68+ and HLA+ but not Iba-1+ microglia were significantly
fewer in the CA4 of AD/TREM2R47H compared to AD/TREM2wt cases, with
similar trends for Iba-1+ microglia in the CA1 and CA4 as well as CD68+ and
HLA+ microglia in the CA1.
Box plots showing (a,b) Iba-1+, (c,d) CD68+ and (e,f) HLA+ microglia abundance in
the (a,c,e) CA1 and (b,d,f) CA4 of 18 Control/TREM2wt, 21 AD/TREM2wt and 9
AD/TREM2R47H cases. Means and standard deviations are shown in Appendix Table A4.
*: p<0.05.
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(a) Iba-1 CA1 (b) Iba-1 CA4
(c) HLA CA1 (d) HLA CA4
Figure 4.13. Microglial morphology in cases with the TREM2 p.R47H variant
only was largely comparable to all cases including a disease-associated TREM2
variant. However, HLA+ microglia in the CA1 were no longer significantly
more amoeboid in AD/TREM2R47H than Control/TREM2wt cases.
Box plots showing average circularity of (a,b) Iba-1+ and (c,d) HLA+ microglia in 0.5×0.5
mm2 areas of the (a,c) CA1 and (b,d) of 18 Control/TREM2wt, 21 AD/TREM2wt and 9
AD/TREM2R47H cases. Means and standard deviations are shown in Appendix Table A5.
*: p<0.05, **: p<0.01.
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4.5 Discussion
Microglia in end-stage AD cases in the present study appear to be activated with increased
numbers of HLA-DP, -DQ, -DR-expressing microglia in the hippocampus. In contrast,
AD cases with a disease-associated TREM2 variant, particularly the p.R47H variant, had
significantly fewer cells expressing functionally activated markers of HLA-DP, -DQ, -DR
and CD68 in the hippocampal CA4, with similar or fewer of these microglia compared to
non-AD cases. Meanwhile, the overall microglia population appears to be unaffected by
disease or the presence of disease-associated TREM2 variants as there were similar numbers
of cells stained with the pan-microglial marker Iba-1 in the hippocampus of elderly controls
and AD cases with and without disease-associated TREM2 variants. Similar findings with
Iba-1-expressing microglia have been reported by others in the middle frontal gyrus of AD
cases with and without the TREM2 p.R47H variant470 and in TREM2-deficient APP/PS1
mice468.
In contrast to the present study, Iba-1-expressing microglia in the CA1 and CA4 has also
been reported to be decreased in AD cases with the TREM2 p.R47H variant compared to
AD cases without TREM2 variants473. In addition, in TREM2-deficient 5XFAD mice, the
total brain myeloid cells is also decreased compared to mice with normal TREM2241,438.
While the inconsistencies between the studies in mice can be attributed to the different
AD model used, it may be that the patient cohort studied had different demographic
characteristics. Indeed, in the study that found fewer Iba-1-expressing microglia in the
hippocampus, the median age at death of cases is 13.5 years older than those in the present
study473. Moreover, % area staining and cell counts in the present study were significantly
affected by age at death and were included as covariates in statistical analyses. This
suggests an overall failure of microglia to respond adequately to inflammatory stimuli and
undergo microgliosis despite having significant AD pathology.
Phagocytosis is one of the first functional phenotype found to be impaired by TREM2
dysfunction384. It is a key function of microglia to clear debris from tissue injury followed
by tissue repair mediated in combination with the release of trophic factors192,194,195. Mi-
croglial phagocytosis can be induced through phagocytic receptors associated with pro- or
anti-inflammatory responses. Activation of receptors that recognise foreign microorganisms
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such as TLRs lead to the removal of invading pathogens and a proinflammatory response in
these phagocytes642. On the other hand, stimulation of receptors like phosphatidylserine re-
ceptors that recognise apoptotic cell components result in the clearance of cell debris and the
induction of anti-inflammatory responses for tissue repair642. Phagocytosis of material result
in proteolytic degradation in the lysosome643. CD68 is a lysosomal/endosomal-associated
glycoprotein and predominantly localises to these organelles which are present during
phagocytosis644. Therefore, CD68 has been widely used as a marker of phagocytosis645.
Our findings of decreased CD68 immunostaining in AD cases with a disease-associated
TREM2 variant is consistent with the existing literature on the impairment of phagocytosis
by the loss of TREM2 function. TREM2 deficiency has been reported to impair the
phagocytosis of various substrates including apoptotic neurons106,384,412,429, bone compo-
nents418,488, whole bacteria or bacterial components381,432,442,452, lipids108,393 and Aβ1–42
fibrils417,452,489. Furthermore, CD68 immunostaining is lower in TREM2-deficient mouse
models of AD470 and stroke429 compared to TREM2-expressing control mice. Conversely,
increased TREM2 function and signalling result in increased phagocytosis384,394,417. Sup-
porting this, it appears that TREM2 expression levels correlate with the phagocytic
capabilities of microglia428. In studies of AD-associated TREM2 variants, the p.R47H and
p.R62H have been shown to impair microglial phagocytosis108,435. Together, these and
our findings indicate that disease-associated TREM2 variants convey a loss of function to
TREM2 which negatively impacts overall levels of phagocytosis by microglia in response to
AD pathology.
The increased number of HLA-DP, -DQ, -DR-expressing cells in AD cases compared
to non-AD cases seen in the present study have been previously observed in various
neurodegenerative diseases including AD646–649, Parkinson’s disease649 and Huntington’s
disease650 as well as in brain injury650–652. The number of HLA-DP, -DQ, -DR-expressing
microglia in the hippocampus appear to positively correlate with the severity of AD653.
HLA or MHC class II has been used as a marker to label activated microglia629–631. In AD,
microglial stimulation by Aβ increase cell surface expression of MHC class II and release of
proinflammatory mediators such as IL-1β, IL-6, TNF-α and IL-8654. This suggests that
increased MHC class II expression may also be a marker of proinflammatory activation by
microglia. Our findings are consistent with observations in TREM2-deficient AD mice which
have decreased MHC class II expression compared to AD mice with normal TREM2438.
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Interestingly, the study by Korvatska et al. (2015)473 reported that MHC class II expression
in human post-mortem brain is not affected by the AD-associated TREM2 p.R47H variant.
MHC class II staining is significantly increased in hippocampal CA1 and CA4 of AD cases
but there is no difference between AD cases with or without the variant473. This is contrast
to the present study with decreased numbers of HLA-DP, -DQ, -DR-expressing microglia
especially in the CA4 of AD cases with the TREM2 p.R47H variant. Again, this difference
may be due to their cohort being much older. Indeed, aging has been associated with the
increased expression of MHC class II655–659 and age at death was found to significantly
affect the number of HLA-DP, -DQ, -DR-expressing microglia in the CA1 and CA4 in the
present study.
The underlying mechanisms of TREM2 dysfunction by disease-associated variants resulting
fewer HLA-DP, -DQ, -DR-expressing cells are still unknown. The loss of TREM2 function
as a DAMP recognition receptor may result in microglia unable to respond to pathogenic
stimuli to become activated and therefore unable to increase the expression of HLA-DP, -DQ,
-DR. A network analysis study reported an association between TREM2 expression and
several HLA class II genes (HLA-DMA, HLA-DMB, HLA-DPA1, HLA-DPB1, HLA-DQA2
and HLA-DRA)402. Indeed, TREM2 signalling appears to induce MHC class II expression
and antigen presenting function of dendritic cells, macrophages and microglia430,660. On
TREM2 activation, immature dendritic cells increase the expression of antigen presenting
molecules including MHC class II, CD40, B7.1, B7.2 and CCR7380. Microglia are also
capable of expressing antigen presentation-associated adhesion or co-stimulatory molecules
such as CD11a, CD40, CD54, CD58, CD80 and CD86 which are required to activate
T cells661,662. TREM2 activation in BV2 microglia cause some of these genes to be
upregulated, especially MHC class II but not CD40660. This suggests that TREM2 induces
a different antigen presentation phenotype compared to dendritic cells. Nevertheless, an in
vitro co-culture study using BV2 microglia overexpressing TREM2 saw increased CD4+
T cell activation associated with increased MHC class II expression compared to BV2
expressing lower levels of TREM2428.
These indicate that antigen presentation by microglia may be impaired by the loss of
TREM2 function. However, there have been limited evidence for antigen presentation by
microglia in the brain. Under normal physiological conditions, a very low number of T
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cells are present in the CNS663–668. In contrast, increased T cell invasion into the brain is
detected in neurodegenerative diseases, especially in multiple sclerosis and equivalent animal
models667–673. Normally, antigen presentation to T cells does not occur within tissues674.
Dendritic cells that phagocytose and process antigens migrate to the lymph nodes for
antigen presentation to T cell receptors660. However, microglia do not leave the CNS and
hence do not present antigens to T cells in the lymph nodes675. Even so, in a mouse model
that antigen-presenting function is limited to injected cells, both antigen-primed dendritic
cells and microglia injected intracerebrally could recruit T cells into the CNS675, which
suggests that antigen presentation can occur there. Alternatively, naive T cells that were not
exposed to antigens can also migrate into the CNS attracted by chemokines released from
damaged neurons, activated glia or endothelium676. Microglia expressing MHC molecules
can then mediate antigen presentation to T cells which indicates the target antigen is
nearby677. Besides that, it has been suggested that microglia are not the primary antigen
presenting cells (APCs) to recruit T cells but instead modulate T cell effector function678.
Supporting this, in contrast to infiltrating macrophages and dendritic cells, activated
microglia are not as effective at inducing T cell proliferation which is associated with
microglial production of prostaglandins and NO that inhibit proliferation and expression of
MHC and co-stimulatory molecules679,680. Instead, activated microglia are more effective
at polarising T cells towards the Th1 phenotype than infiltrating macrophages or dendritic
cells679,680. Furthermore, microglia may be involved in resolving T cell responses. Microglia
stimulated with IFN-γ or activated Th1-conditioned medium induce microglial expression
of B7-H1 co-stimulatory molecule that inhibits T cell responses681.
These suggest that there may be a role of the adaptive immune system and T cell involvement
in AD but it is still underexplored. An early study observed Aβ-reactive T cells in PBMC
isolated from AD patients, but plaque-associated T cells have not been detected682. In in
vivo animal studies, only very few CD4+ T cells are seen in the meninges of Aβ-immunised
APP/HLA-DR transgenic mice683. In contrast, a follow up study using APP/IFN-γ
transgenic mice found CD4+ and CD8+ T cells that co-localise with amyloid plaques and
CD11b+ microglia in the hippocampus528. The difference between these two observations
can be attributed to the stimulation by IFN-γ in the latter study528, which is found to
enable T cell migration into the brain684. Although IFN-γ expression is experimentally
induced, IFN-γ level has been reported to be elevated in the plasma of AD patients
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compared to controls685 which could facilitate T cell invasion into the brain. Additionally,
in APP/PS1 mice induced with a Th2 response, plaque-associated microglia express MHC
class II and surprisingly, CD11c which is a characteristic marker of dendritic cells686.
CD11c expression is also found in microglia in several other AD mouse models438,687–689
and in plaque-associated microglia in AD brains690,691. This further supports the view
that microglia can transform into an APC-like phenotype. Some studies have observed
co-localisation and direct contact between plaque-associated CD11c+ microglia and CD3+
T cells686 or not at all691. This could be due to the induction of T cell responses by
glatiramer acetate in the former study686 having the same impact as IFN-γ in allowing T
cell migration into the brain whereas in the latter study, the AD mice were untreated691.
Induction of Th2 responses in AD mice results in fewer amyloid plaques and improved
cognition686, suggesting a key role for microglial antigen presentation mediated by MHC
class II expression and T cell responses in the pathogenesis of AD, which could be impaired
by disease-associated TREM2 variants.
Interestingly, when observed in a few AD cases with and without disease-associated
TREM2 variants in the present study, HLA-DP, -DQ, -DR-expressing microglia appear
to strongly colocalise with amyloid and suspected neuritic plaques regardless of TREM2
variant. However, when quantified across the tissue, AD cases with a disease-associated
TREM2 variant have fewer overall microglia expressing CD68 and HLA-DP, -DQ, -DR.
CD68 staining also tend to colocalise with amyloid and neuritic plaques, but it is not
clear whether these are the same cells expressing HLA-DP, -DQ, -DR. Due to technical
limitations of antibody species compatibility, HLA-DP, -DQ, -DR and CD68 double staining
immunofluorescence could not be performed. Nevertheless, HLA-DP, -DQ, -DR- and CD68-
expressing cells had partial overlap with Iba-1-expressing cells. Similar observations are
also seen in AD and multiple sclerosis brains by others692. Surprisingly, Iba-1-expressing
microglia do not appear to preferentially cluster around amyloid and neuritic plaques to
the same extent as HLA-DP, -DQ, -DR- and CD68-expressing cells in the present study.
This suggests that these cells better reflect functionally activated microglia responding to
AD pathology compared to Iba-1-expressing cells.
In sum, our data highlight shared and distinct mechanisms in microglial response to
AD pathology that involve TREM2 function. It suggests that sufficient numbers of
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properly functioning microglia are required to mitigate the rapid progression of amyloid
and tau pathology occurring in AD. Our findings reflect a very subtle change in microglial
phenotype in individuals with disease-associated TREM2 variants. This includes a decrease
in phagocytosis (lower CD68 immunostaining) and antigen presention (fewer HLA-DP,
-DQ, -DR-expressing cells) by microglia which can be measured as markers to characterise
the generated in vitro TREM2 model. Fewer HLA-DP, -DQ, -DR-expressing microglia
due to disease-associated TREM2 variants may indicate a role for the adaptive immune
system and T cell involvement in AD pathogenesis that has been a relatively underexplored
field. Following our findings, it is important to further confirm if the lower abundance of
functionally activated microglia is due to decreased cell proliferation or the impairment
of resting/surveillance microglia to activate in response to pathology. Besides that, a key
finding would be to check if the differences in the number of CD68- and HLA-DP, -DQ,
-DR-expressing cells are directly due to TREM2 dysfunction by performing double staining
immunofluorescence of these markers with an anti-TREM2 antibody. This could not be
done in this study because a reliable and validated antibody against TREM2 for use in
FFPE human brain tissue is not available during the project. Since then, a very recent
study has successfully performed TREM2 immunostaining on these tissue475. Surprisingly,
they did not detect any microglia expressing TREM2 but only in circulating monocytes
despite careful characterisation and optimisation of immunostaining. This has strong
implications on the role of TREM2 in microglia, including findings by us and others, which
will require replication in our cohort as well.
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This Chapter evaluates the functional consequences of the CRISPR/Cas9-edited BV2 cell
lines containing indels in Trem2 Exon 2 which were generated in Chapter 3. These indels
were either an in-frame deletion expected to cause the removal of a few amino acids at the
ligand-binding site, or insertions/deletions that caused a frameshift and thus changed the
amino acid sequence completely from the point of the indel. Regardless, these indels are
predicted to result in the functional loss of TREM2. Further assessment of these lines is
necessary to see if the predicted effect at the DNA level led to the expected changes at the
transcript and protein level. Additionally, as Cas9 may still persist after screening, the
clonal lines need to be checked to ensure no further Cas9 activity leading to further DNA
cleavage during expansion of the cell lines.
Functional loss of TREM2 in the various clonal lines should result in the lack of activation
of signalling pathways downstream of TREM2 as the cells fail to respond to stimulation
by a TREM2 ligand. Activation of TREM2 has been associated with the induction of
phagocytosis, cell migration, proliferation, cell survival and the production of cytokines
and chemokines383. To mediate all of these functions, TREM2 activation leads to signalling
cascades involving many different pathways which dictate the different outcomes. These
signalling pathways can be activated by a number of different receptors in addition to
TREM2. TREM2 acts via the adaptor protein DAP12, though DAP12 interacts with and
can be activated by a range of other receptor proteins693 such as SIRPβ1694 and complement
receptor 3 (CR3)695 in microglia. While these receptors have diverse ligands, their functional
outcomes are often similar due to convergence on common protein components downstream
of receptor activation388. For example, activation of SIRPβ1 and CR3 have been described
to mediate phagocytosis694,695, similar to TREM2. Hence, TREM2 deficiency would
not result in complete impairment of its associated functions, such as phagocytosis, if
alternative DAP12- or ITAM-associated receptors become activated. Although various
receptors can engage similar signalling pathways, not all of them have been implicated in
disease. Therefore, disease vulnerability conveyed by the decrease in or loss of TREM2
function is expected to only result from impaired innate immune responses against TREM2
ligands.
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Various ligands have been described to bind TREM2 including cell membrane lipids,
lipoproteins and nucleotides (Chapter 1.6.3). However, these do not bind only to TREM2
and therefore it is difficult to differentiate their effects on different receptors (Table 5.1).
For specific receptor activation, antibodies have been commonly used to simulate ligand
binding. A commercially available monoclonal antibody raised against the extracellular
region of TREM2 (MAB17291, R&D Systems) has been previously used and reported to
result in TREM2 activation394. Stimulation of myeloid precursor cells transduced with
TREM2 with this antibody has been shown to increase phosphorylation of Erk compared
to isotype control antibodies394. Erk is a signalling protein known to be downstream of
TREM2 activation (Figure 5.1).
TREM2 ligands Other known receptor(s) Ref.
Cell membrane lipids/phospholipids CD36 696
Lipoproteins CD36, class A scavenger receptor (SR-A) 696,697
Nucleotides Toll-like receptor 9 (TLR9) 698
Table 5.1. Examples of TREM2 ligands that also bind other microglial recep-
tors.
On TREM2 activation, Src-family kinases are recruited to DAP12 and phosphorylate
DAP12 ITAMs693. The phosphorylated ITAMs in turn become docking sites for recruited
Syk699 (Figure 5.1). Syk then becomes activated and phosphorylates several downstream
effectors including Vav700, PLCγ701 and PI3K702, which can initiate their own signalling
cascades699,703 (Figure 5.1). The signalling pathways originating from TREM2 then start
to diverge.
As numerous proteins are involved in these downstream signalling cascades, only a small
number can be practically investigated without resorting to high-throughput experiments.
Therefore, three key signalling proteins downstream of TREM2 that mediate important
cellular functions related to immune responses associated with TREM2 function were
focused on in this Chapter. Syk is a crucial signalling protein in the TREM2 signalling
pathway as it transduces signals from DAP12 to trigger downstream signalling cascades
(Figure 5.1). Some of these include calcium and PKC signalling, Pyk2–Rho-mediated actin-
cytoskeleton reorganisation, ROS production, phagocytosis, PI3K-mediated Tec and Akt
signalling, and Ras–Erk regulation of gene expression703 (Figure 5.1). Syk is a necessary
component in mediating phagocytosis as Syk deficiency result in the complete inhibition of
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phagocytosis in macrophages704. This is associated with inability for arms of the phagocytic
cup to fuse704. Syk is also involved in promoting cell survival through PI3K–Akt signalling
to activate the Wnt–β-catenin signalling pathway533. Akt phosphorylates and inactivates
GSK3β (Figure 5.1), which results in the stabilisation of β-catenin to regulate expression
of genes associated with proliferation (c-Myc, Cyclin D1) and anti-apoptosis (Bcl-2)533.
Moreover, Syk has a role in the induction of cytokine and chemokine production through
the activation of CARD9–Erk/NFκB signalling705 (Figure 5.1).
Besides that, Pyk2 is also an important protein in mediating TREM2–DAP12 function.
Despite no direct evidence of Pyk2 activation by TREM2 signalling, signalling components
downstream of TREM2 have been shown to result in Pyk2 phosphorylation. Pyk2 can
be directly activated by Src-family kinases after recruitment to DAP12 upstream of Syk
activation699,706 or further downstream through Syk–Vav signalling707 (Figure 5.1). Indeed,
DAP12-deficient BMDM had impaired phosphorylation of Pyk2 when stimulated with
CSF-1708. CSF-1 activation of its receptor CSF-1R triggers a signalling pathway that
phosphorylates DAP12 ITAMs and subsequently activates Pyk2709. Pyk2 is a part of the
intracellular calcium signalling that is involved in various immune cell responses710–714.
Pyk2 also mediates actin-cytoskeleton reorganisation for phagocytosis715,716 and cell polarity
for chemotaxis/cell migration717 which are established functions of TREM2383.
Additionally, Erk1 and Erk2 mediate significant functions of TREM2. They are protein
homologues that have 84% sequence homology and share many common functions718.
Therefore, they are considered to be similar effectors here and collectively referred to as
Erk1/2. They have a diverse role in mediating cellular functions as part of the MAPK
signalling cascade719. One of these roles crucial to TREM2 function is to transmit sig-
nals from CARD9 to activate transcription factors and induce cytokine and chemokine
production705 (Figure 5.1). In addition, Erk1/2 mediates cell survival by promoting the
expression of anti-apoptotic Bcl-2720 and inhibit Bcl-2 antagonists (Bad, Bim-EL) by
phosphorylation721,722. Erk1/2 also inhibits caspase 9 to prevent the activation of the
pro-apoptotic caspase 3 and further contribute to cell survival723.
These 3 signalling proteins are involved in almost all TREM2-related functions. Therefore,
functional loss of TREM2 is expected to cause these 3 signalling proteins to not respond
to TREM2 activation.
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Figure 5.1. TREM2 activation initiates signalling through DAP12 to trigger
further activation of various signalling cascades that mediate TREM2 func-
tion.
A simplified illustration of several signalling pathways downstream of activated TREM2.
On TREM2 ligand (TREM2L) binding, Src-family kinases are recruited to DAP12 and
phosphorylate tyrosine residues on DAP12 ITAMs. Syk is then recruited to the phos-
phorylated ITAMs and become activated. Activated Syk then further activates several
intermediate signalling proteins as shown. Key signalling proteins that mediate many of
TREM2 functions focused on in this Chapter are labelled in blue.
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Chapter 4 showed that CD68 expression and HLA-DP, -DQ, -DR-expressing cell abundance
were decreased in hippocampal CA4 of AD cases with a disease-associated TREM2 variant,
particularly the p.R47H. This is despite having similar abundance of Iba-1-expressing cells
between AD cases with or without a disease-associated TREM2 variant, which suggests
that the variants result in loss of microglia function, particularly phagocytosis and antigen
presentation. These variants have also been associated with the loss of or decreased
TREM2 protein function (Chapter 1.6.4). Therefore, it is expected that the generated
TREM2-deficient clonal lines would have decreased CD68 and MHC class II expression
when treated with an AD-related stimulus compared to WT cells. Hence, the response of
these cells can be compared with findings from Chapter 4 to determine if the clonal lines
model aspects of disease due to TREM2 variants in people.
The usefulness of this in vitro disease model of TREM2 and its suitability for high-
throughput screening to identify disease-modifying therapeutic drugs can be established
through these findings. Furthermore, the initial investigation on the changes in activation
of key signalling proteins downstream of TREM2 provides preliminary data on how the
functional loss of TREM2 impact innate immune responses. This may then suggest
potential avenues for therapeutic targeting.
5.2 Aims
• To confirm that the cell lines generated by CRISPR/Cas9-mediated editing of Trem2
have a functional loss of TREM2 protein expression.
• To investigate the effects of TREM2 deficiency on the activation of key signalling
proteins that mediate inflammatory responses associated with TREM2 function.
• To compare the effects of TREM2 deficiency in the generated cell lines with disease-




Detailed methods are outlined in Chapter 2.4.
Expanded cultures of Trem2 -edited (C1G10, C1E2, C1C4, C1G4, C3bB10, C3bC4),
CRISPR WT (C3bA1, C3bA6, C3bA8, C3bA12, C3bB4) clonal BV2 cell lines from
Chapter 3 and BV2 WT cells were established. Cell pellets were harvested to confirm
Trem2 DNA sequence as well as transcript and protein expression. DNA were extracted and
purified from all clonal lines followed by PCR amplification of Trem2 Exon 2. Amplicons
were resolved on an agarose gel to compare any change in size at the target site in Trem2
following CRISPR/Cas9 editing. Purified amplicons were also Sanger-sequenced to confirm
DNA changes and ensure clonal lines had not been mixed during handling and expansion
of cultures.
For RT-PCR, RNA was extracted and converted into cDNA. Exon 2 of protein-coding
transcripts (NM_031254 & NM_001272078) and Intron 1–Exon 2 of the retained Intron
1 transcript (ENSMUST00000132340.1) were PCR-amplified and amplicons resolved on
an agarose gel. Protein lysates were extracted, quantified and deglycosylated. TREM2
protein expression was assessed by Western blot. Various commercially available antibodies
against TREM2 were tested and validated (Table 5.2).
Primary antibody Immunogen Manufacturer Cat#
Anti human TREM2, goat Human TREM2 His19–Ser174 R&D Systems AF1828
Anti human TREM2, rabbit Human TREM2 Gln33–Pro144 Atlas Antibodies HPA012571
Anti human/mouse TREM2
(clone 237920), rat Mouse TREM2 Leu19–Pro168 R&D Systems MAB17291
Anti mouse TREM2, rabbit Mouse TREM2 Met1–Thr227 Santa Cruz sc-48765
Anti mouse TREM2, sheep Mouse TREM2 Leu19–Pro168 R&D Systems AF1729
Table 5.2. Commercially available antibodies against human or mouse TREM2
used to detect functional expression of TREM2 in CRISPR/Cas9-edited clonal
lines.
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Clonal lines were investigated for changes in the activation of signalling mediators down-
stream of TREM2 and functional microglial markers identified from Chapter 4. Four
TREM2 KO (C1G10, C1E2, C3bB10, C3bC4) and four TREM2 WT [three CRISPR con-
trol (C3bA1, C3bA6, C3bA8) and BV2 WT] cell lines were used. 6-well culture plates were
coated with 10 µg/mL isotype control or TREM2-activating antibody (MAB17291) that
binds to the extracellular region of TREM2. Clonal lines were seeded onto antibody-coated
plates and incubated for 1 h. Protein lysates were harvested and changes in phosphorylation




5.4.1 Evaluation of Trem2 DNA sequence at CRISPR/Cas9-targeted
site in expanded clonal cell lines
To ensure that the correct clonal cell lines were selected and that further Cas9 activity
leading to additional DNA cleavage did not occur, Trem2 Exon 2 DNA amplicons from
expanded cultures of Trem2 -edited (C1G10, C1E2, C1C4, C1G4, C3bB10, C3bC4) and
CRISPR WT (C3bA1, C3bA6, C3bA8, C3bA12, C3bB4) clonal lines were compared by
agarose gel electrophoresis and Sanger sequencing. Agarose gel resolution of amplicons
from most clones (C3bA1, C3bA6, C3bA8, C3bA12, C3bB4, C1E2, C3bB10 and C3bC4)
were the same as observed during screening, reflecting size differences due to indels except
for clones C1C4, C1G4 and C1G10 (Figure 5.2a,b). Amplicon sizes from clones C1C4 and
C1G4 appeared to be a mixed population (Figure 5.2b). For clone C1G10, in addition to
the 249 bp amplicon (397 bp deletion) found in the initial Trem2 DNA screening (Chapter
3), an amplicon smaller than the 646 bp Trem2 WT amplicon but larger than the 619 bp
amplicon (27 bp deletion) from clone C1E2 was identified (Figure 5.2a). Therefore, it is
predicted to have a <27 bp deletion.
Subsequently, amplicons from these clones were Sanger sequenced. Clones C1C4 and
C1G4 were not sequenced because they were no longer clonal as observed from agarose gel
electrophoresis. All the sequenced cell lines retained clonality with the same changes in
Trem2 Exon 2 DNA sequence as found from clone screening in Chapter 3. Interestingly,
in clone C1G10, only the smaller amplicon with 397 bp deletion but not the additional
amplicon with <27 bp deletion was observed on sequencing (not shown). This meant that
the exact size of this additional amplicon with <27 bp deletion could not be determined
here. It was later found to have a 13 bp deletion in another copy of Trem2 (Chapter
5.4.2). As a result from these findings, clones C1C4 and C1G4 were excluded from future
experiments due to heterogeneity in Trem2 editing.
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(a) Clonal CRISPR/Cas9-edited cell lines
Trem2 Exon 2 DNA amplicons
(b) C1C4 & C1G4
Figure 5.2. Most cell lines generated from CRISPR/Cas9 editing remained
clonal after culture expansion.
(a) Trem2 Exon 2 DNA amplicons from clonal lines on an agarose gel with expected
changes in Trem2 Exon 2 amplicon sizes after CRISPR/Cas9 editing.
Amplicon sizes are WT Trem2 : 646 bp; C1G10: 633 bp (-13 bp), 249 bp (-397 bp); C1E2:
619 bp (-27 bp); C3bB10: 735 bp (+89 bp); C3bC4: 564 bp (-82 bp).
(b) Trem2 Exon 2 DNA amplicon sizes from clones C1C4 and C1G4 (bold and asterisk)
on an agarose gel were heterogeneous indicating loss of clonality. Negative control lane not
shown.
DNA ladder sizes are indicated in base pairs.
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5.4.2 Expression of Trem2 in CRISPR/Cas9-edited clonal lines
Four mRNA isoforms are produced from murine Trem2. Two of these, NM_031254 and
NM_001272078, are protein-coding430. NM_031254 translates into the full-length 227
amino acid protein. NM_001272078 uses an alternative splice site which results in a
frameshift and the protein lacking the transmembrane domain. The other two isoforms are
not known to translate into protein. ENSMUST00000132340.1 retains Intron 1 whereas
ENSMUST00000148545.1 is a much shorter processed transcript of unknown function. To
investigate the effects of indels on Trem2 transcript expression, RT-PCR was performed. A
primer pair spanning Exon 1–3 was used to detect protein-coding isoform NM_031254 and
NM_001272078 transcripts (Figure 5.3). Expression of these transcripts were completely
disrupted in Trem2 -edited clones (Figure 5.4). None of the resulting cDNA amplicon sizes
observed after agarose gel electrophoresis corresponded to indels generated by CRISPR/Cas9
editing. The indels generated in clones C3bB10 and C1E2 are located in Exon 2 and were
not expected to disrupt transcript expression or exon splicing (Table 5.3). On the other
hand, the 397 bp deletion in clone C1G10 and 82 bp deletion in clone C3bC4 start in
Intron 1 and span into Exon 2 (Table 5.3), which may affect transcript splicing.
The effect of indels on ENSMUST00000132340.1 transcript with the retained Intron 1
was investigated using a primer pair spanning Intron 1–Exon 3 specific for this isoform
only (Figure 5.3). Amplicons consistent with ENSMUST00000132340.1 were detected after
agarose gel electrophoresis in all clones and amplicon sizes corresponded to the indels
generated from CRISPR/Cas9 (Figure 5.5a). For clone C1G10, only the amplicon with
the <27 bp deletion but not 397 bp deletion was detected here (Figure 5.5a). The forward
primer (mTREM2F4) used is located within the 397 bp deletion and was not amplified.
Therefore, this cDNA amplicon was Sanger sequenced to determine the exact deletion. This
revealed a 13 bp deletion directly before the p.R47 codon (Figure 5.5b). This demonstrates
that clone C1G10 has 13 bp and 397 bp deletions in two different copies of Trem2. Both
of these deletions are predicted to result in a frameshift and a functional loss of TREM2
(Table 5.3).
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Figure 5.3. RT-PCR primers designed to specifically target protein-coding transcripts (NM_031254 & NM_001272078) and the
transcript with retained Intron 1 (ENSMUST00000132340.1).
Four mRNA isoforms known to result from Trem2. ENSMUST00000132340.1 and ENSMUST00000148545.1 transcripts are not known to translate
into protein.
Known protein-coding regions are indicated in grey. Locations of forward (⇀) and reverse (↽) primers are as indicated with the corresponding
primer ID.
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Trem2 NM_031254 and NM_001272078 isoform Exon 1–3 cDNA amplicons
Figure 5.4. Indels in Trem2 Exon 2 resulted in complete disruption of protein-
coding NM_031254 and NM_001272078 transcripts.
None of the NM_031254 and NM_001272078 Exon 1–3 cDNA amplicon sizes from Trem2 -
edited clones on an agarose gel corresponded to the indels generated by CRISPR/Cas9
editing. Clones C1G10 and C3bC4 have deletions that start in Intron 1 which may disrupt
exon splicing and transcript expression.
Expected changes in amplicon sizes are WT Trem2 : 515 bp; C1G10: 502 bp (-13 bp), 118
bp (-397 bp); C1E2: 488 bp (-27 bp); C3bB10: 604 bp (+89 bp); C3bC4: 433 bp (-82 bp).
DNA ladder sizes are indicated in base pairs.
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(a) Trem2 ENSMUST00000132340.1 isoform Intron 1–Exon 2 cDNA amplicons
(b) C1G10
Figure 5.5. Only the amplicon with a 13 bp deletion in Trem2 of clone C1G10
was amplified from Trem2 cDNA ENSMUST00000132340.1.
(a) ENSMUST00000132340.1 Intron 1–Exon 2 cDNA amplicons from all clones on an
agarose gel corresponded to the indels generated by CRISPR/Cas9 editing. For clone
C1G10, only the amplicon with the <27 bp deletion was amplified because the forward
primer (mTREM2F4) used is located within the 397 bp deletion of the other copy of Trem2.
Expected changes in amplicon sizes are WT Trem2 : 416 bp; C1G10: 403 bp (-13 bp);
C1E2: 389 bp (-27 bp); C3bB10: 505 bp (+89 bp); C3bC4: 334 bp (-82 bp). DNA ladder
sizes are indicated in base pairs.
(b) Sequencing of Trem2 cDNA ENSMUST00000132340.1 Intron 1–Exon 2 amplicon
from clone C1G10 revealed a 13 bp deletion (dotted box) directly before the p.R47 codon
(highlighted blue).
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5.4.3 Expression of TREM2 protein in CRISPR/Cas9-edited clonal lines
To confirm TREM2 protein expression in the CRISPR/Cas9-edited clonal lines, Western
blots using various commercially available antibodies against human or mouse TREM2
were tested. Their specificity was tested in a range of protein lysates of human and mouse
origin. Mature TREM2 is known to be glycosylated at two predicted N-glycosylation
sites to result in a total molecular weight of ∼40–60 kDa, while unglycosylated TREM2
is predicted to be ∼25 kDa379,452. As the antibodies were raised against recombinant
human or mouse TREM2 peptides that may not be glycosylated, the lysates were also
deglycosylated to remove all N-linked glycans and expose antibody-binding epitopes. Only
antibody AF1729 showed any specificity for TREM2 and only gave a weak signal at the
expected molecular weight ∼25 kDa following deglycosylation of the lysates (Figure 5.6e,f).
As expected, TREM2 was not expressed in N2A mouse neurons and HEK293 human
kidney cell lines whereas TREM2 was detected in BV2 mouse microglia and THP-1 human
monocyte cell lines of myeloid origin (Figure 5.6e,f).
Antibody AF1828 appeared to detect specific protein bands at ∼37 kDa that correspond
close to the molecular weight of glycosylated TREM2 (>40 kDa). However, there was
no shift in molecular weight of protein bands after deglycosylation (Figure 5.6a). This
demonstrates that the protein band detected by antibody AF1828 is not a glycosylated
protein and is unlikely to be TREM2. The other antibodies resulted in a large number
of non-specific protein bands, with or without deglycosylation, with no distinct bands at
the expected molecular weight in lysates from cells expected to express TREM2 (Figure
5.6a–d).
Therefore, antibody AF1729 was used to investigate TREM2 expression in the different
Trem2 -edited and CRISPR WT clonal lines. As expected, TREM2 protein was detected in
lysates from CRISPR WT clonal lines but was undetectable in the Trem2 -edited clonal
lines that have indels predicted to cause the removal of a few amino acids or change in
amino acid sequence (Figure 5.7). Interestingly, TREM2 protein was also not detected in
the clonal line with a small in-frame deletion (C1E2) (Figure 5.7) which was expected to
result in a loss of 9 amino acids spanning across the p.R47 residue, matching observations
from protein-coding transcripts (Table 5.3).
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(a) AF1828 (b) HPA012571
(c) MAB17291 (d) sc-48765
(e) AF1729 (f) AF1729 (∼25 kDa band)
Figure 5.6. Antibody AF1729 showed specificity for TREM2 only after deg-
lycosylation of protein lysates whereas the other antibodies were not specific
for TREM2
30 µg of positive (mouse BV2 & human THP-1) and negative (mouse N2A & human
HEK293), untreated and deglycosylated protein lysates were used to test the specificity of
anti TREM2 antibodies (a) AF1828, (b) HPA012571, (c) MAB17291, (d) sc-48765 and
(e) AF1729 on Western blots.
Molecular weight of glycosylated TREM2 (g): ∼40–60 kDa and unglycosylated TREM2
(ug): ∼25 kDa. Protein molecular weight ladder is indicated in kDa.
(f) TREM2 band intensity at ∼25 kDa from deglycosylated BV2 and THP-1 lysates
detected using AF1729 is distinctively higher than background in negative control lysates.
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(a)
(b) Deglycosylated protein lysates (∼25 kDa band)
Figure 5.7. TREM2 protein was detected in CRISPR WT clonal lines but not
in TREM2 KO clonal lines.
(a) 30 µg of untreated and deglycosylated protein lysates from TREM2 WT cell lines
(BV2 WT and CRISPR WT clones) and TREM2 KO clonal lines were immunoblotted for
TREM2 using anti-mouse TREM2 antibody AF1729. Unglycosylated mouse TREM2 (ug)
is ∼25 kDa. Protein molecular weight ladder is indicated in kDa.
(b) TREM2 band intensity corresponding to blot (a) at ∼25 kDa from deglycosylated
BV2 WT and CRISPR WT clones detected using AF1729 is distinctively higher than
background in negative control lysates and TREM2 KO clonal lines.
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5.4.4 Summary of CRISPR BV2 clones
Table 5.3 summarises Trem2 Exon 2 DNA, full-length Trem2 cDNA and TREM2 amino
acid sequences of TREM2 KO and CRISPR WT clonal lines. Full-length Trem2 cDNA
sequences were predicted from Sanger-sequenced Trem2 Exon 2 DNA or protein-coding
transcripts converted into cDNA. Full-length TREM2 amino acid sequence was translated
from predicted full-length Trem2 cDNA sequence.
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Table 5.3. Trem2 Exon 2 DNA, predicted full-length Trem2 cDNA and pre-
dicted full-length TREM2 amino acid sequences of TREM2 KO and CRISPR
WT clones.
Trem2 Exon 2 DNA sequence was determined by Sanger sequencing. Full-length Trem2
cDNA sequence was predicted from Sanger-sequenced Trem2 Exon 2 DNA or cDNA.
Full-length TREM2 amino acid sequence was translated from predicted full-length Trem2
cDNA sequence. C1G10-1 and C1G10-2 represent the two different deletions identified in
this cell line.
Legend:
DNA: Intron (cyan), Trem2 Exon 2 (black), mismatch/insertion (red), p.R47 codon (bold),
target c.140G for DNA variant (underline).
cDNA: Alternating exons (black/blue), mismatch/insertion (red), p.R47 codon (bold),
target c.140G for DNA variant (underline).
Amino acid: Alternating exons (black/blue), residue overlap splice site (green), p.R47
residue (underline), frameshifted amino acids (orange), first stop codon (red).
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5.4.5 Functional characterisation of TREM2 knockout clonal lines
To characterise the effects of TREM2 deficiency on the activation of signalling mediators
downstream of TREM2, four of each TREM2 KO (C1G10, C1E2, C3bB10, C3bC4) and
TREM2 WT (BV2 WT, C3bA1, C3bA6, C3bA8) cell lines were stimulated with plate-
coated isotype control or TREM2-activating antibodies (MAB17291, R&D Systems) for 1
h. The amount of plate-bound antibodies in each well was checked for consistent antibody
stimulation. As expected, fluorescence intensities were higher in isotype control (pairwise
comparison ANOVA: p<0.001) and TREM2-activating antibody (pairwise comparison
ANOVA: p<0.001) coated wells compared to uncoated wells (Figure 5.8). This indicates
that the isotype control and TREM2-activating antibodies successfully bound to and coated
the plates. TREM2-activating antibody-coated wells had consistently and significantly
higher fluorescence intensity compared to isotype control antibody-coated wells (pairwise
comparison ANOVA: p=0.006) (Figure 5.8), demonstrating a higher concentration of the
TREM2-activating antibody than isotype control antibody were available for binding in
those wells. This have implications for any direct comparison of results obtained between
these two antibodies.
Figure 5.8. Isotype control and TREM2-activating antibody (MAB17291) suc-
cessfully bound to and coated the plates.
More of the TREM2-activating antibody coated the 6-well plates compared to the isotype
control antibody although the same concentration of antibodies (10 µg/mL) was used
during the coating procedure. The relative amount of plate-bound antibodies was deter-
mined using fluorescent secondary antibodies against rat IgG and fluorescence intensity
measured on a plate reader. Error bars indicate standard error of the mean for n=10 wells
per condition.
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Activation of Syk, Pyk2 and Erk1/2 (ratio of phospho-protein:total protein) between
TREM2 KO and TREM2 WT cells when stimulated with the TREM2-activating antibody
or isotype control antibody were not statistically different (Figure 5.9, 5.10a,b,c).
However, Pyk2 activation in TREM2 KO and TREM2 WT cells when treated with the
TREM2-activating antibody were increased compared to isotype control antibody (pairwise
comparison ANOVA: TREM2 KO p=0.001, TREM2 WT p=0.001; Figure 5.9, 5.10b).
Similarly, Erk1/2 activation in TREM2 KO cells was significantly increased (pairwise
comparison ANOVA: p=0.008) and in TREM2 WT cells showed an increasing trend when
treated with the TREM2-activating antibody compared to isotype control antibody (Figure
5.9, 5.10c). Syk activation in TREM2 KO and TREM2 WT cells were not increased by
treatment with TREM2-activating antibody compared to isotype control antibody (Figure
5.9, 5.10a).
Interestingly, Pyk2 activation in TREM2 KO cells when stimulated with the isotype
control antibody was increased compared to uncoated wells (pairwise comparison ANOVA:
p=0.006; Figure 5.9, 5.10b). Nevertheless, as expected, activation of Syk, Pyk2 and Erk1/2
in TREM2 WT cells between treatment of the isotype control antibody and uncoated wells
were not statistically different (Figure 5.9, 5.10a,b,c).
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Figure 5.9. Western blots of all proteins probed from protein lysates of TREM2
KO and TREM2 WT cell lines after stimulation with the TREM2-activating
antibody or isotype control antibody.
1 million cells per TREM2 WT or TREM2 KO cell line were stimulated with the antibodies
for 1 h at 37°C. Total and phospho-proteins were probed on the same membrane using
different fluorescent secondary antibodies for Syk, Pyk2 and Erk1/2. CD68 and Iba-1
were similarly probed on the same membrane. Exposure for each detection antibody was
individually adjusted.
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(a) Syk activation (b) Pyk2 activation
(c) Erk1/2 activation
Figure 5.10. Activation of Syk, Pyk2 and Erk1/2 were not statistically different
between TREM2 KO and TREM2 WT cells when stimulated with the TREM2-
activating antibody.
Overall, activation of (a) Syk, (b) Pyk2 and (c) Erk1/2 were not statistically different
between TREM2 KO and TREM2 WT cells when treated with the TREM2-activating
antibody, isotype control antibody or uncoated wells.
Error bars indicate standard error of the mean for n=4 different cell lines per phenotype.
**: p<0.01
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Differences in activation between the TREM2-activating antibody and isotype control
antibody may be explained by differences in plate-bound antibody titre. Therefore,
activation levels were normalised to the relative amount of plate-bound antibodies. In the
normalised data, activation of Syk, Pyk2 and Erk1/2 between TREM2 KO and TREM2
WT cells when stimulated with the TREM2-activating antibody were still not statistically
different (Figure 5.11a,b,c).
Pyk2 activation when treated with the isotype control antibody was higher in TREM2
KO cells compared to TREM2 WT cells (pairwise comparison ANOVA: p=0.030; Figure
5.11b). Activation of Syk and Erk1/2 when treated with the isotype control antibody were
not different between TREM2 KO and TREM2 WT cells.
Pyk2 activation in TREM2 KO and TREM2 WT cells when treated with the TREM2-
activating antibody remain higher than isotype control antibody (pairwise comparison
ANOVA: TREM2 KO p=0.032, TREM2 WT p=0.016; Figure 5.11b). Activation of Syk and
Erk1/2 in TREM2 KO and TREM2 WT cells after treatment with the TREM2-activating
antibody were not different compared to isotype control antibody (Figure 5.11a,c).
238
(a) Syk activation (b) Pyk2 activation
(c) Erk1/2 activation
Figure 5.11. Activation of Pyk2 but not Syk and Erk1/2 in TREM2 KO and
TREM2 WT cells were higher when stimulated with the TREM2-activating
antibody compared to isotype control antibody.
Activation of (a) Syk, (b) Pyk2 and (c) Erk1/2 (phospho-protein:total protein) were
normalised to the relative amount of plate-bound antibodies.
Error bars indicate standard error of the mean for n=4 different cell lines per phenotype.
*: p<0.05
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Chapter 4 showed that CD68 expression and HLA-DP, -DQ, -DR-expressing cells were lower
in hippocampal CA4 of AD cases with a TREM2 variant, particularly p.R47H, compared
to AD cases without TREM2 variants. This is despite similar numbers of Iba-1-expressing
cells between AD cases with or without a TREM2 variant. Therefore, mouse homologues
of the same functional markers used were investigated in TREM2 KO cells to determine if
the outcome of functional loss of TREM2 were comparable. CD68/macrosialin and Iba-1
expression in TREM2 KO and TREM2 WT cells when stimulated with TREM2-activating
antibody, isotype control antibody or uncoated wells were similar (Figure 5.9,5.12). MHC
class II expression could not be determined as the primary antibody used was unable to
reliably detect MHC class II (not shown).
(a) CD68 (b) Iba-1
Figure 5.12. Functional microglial markers CD68 and Iba-1 in TREM2 KO and
TREM2 WT cells were unaffected by stimulation with the TREM2-activating
antibody or isotype control antibody.
Protein levels of (a) CD68 and (b) Iba-1 were normalised to β-actin band intensities.
Error bars indicate standard error of the mean for n=4 different cell lines per phenotype.
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5.5 Discussion
Four clonal microglia cell lines with functional loss of TREM2 were successfully generated.
In these cell lines, indels in the Trem2 gene led to protein-coding Trem2 transcripts being
completely disrupted and an absence of TREM2 protein expression compared to cell lines
with normal Trem2 gene.
The effects of TREM2 deficiency on the activation of Syk, Pyk2 and Erk1/2 after stimulation
with a TREM2-activating antibody was then investigated. Antibody-mediated TREM2
activation additionally appeared to activate FcγR that signal through the same intermediate
signalling proteins as TREM2. Stimulation of TREM2 KO cells with the TREM2-activating
antibody resulted in similar activation of Syk, Pyk2 and Erk1/2 compared to TREM2
WT cells. This indicates that either the TREM2-activating antibody had no effect on
activating TREM2 or it similarly activates Syk, Pyk2 and Erk1/2 through a TREM2-
independent effect. Since Pyk2 activation was higher in TREM2 WT cells when stimulated
with the TREM2-activating antibody compared to the isotype control antibody even after
normalising for antibody titre, this demonstrates that the TREM2-activating antibody
does have an effect on TREM2 activation.
Normally, non-specific IgG antibodies have limited biological function and thus have been
used as isotype control antibodies in antibody-based receptor activation experiments.
However, immune cells such as microglia express Fc-γ receptors (FcγR) that can bind to the
Fc region of IgG antibodies and trigger FcγR responses. TREM2 and FcγR share common
signal transduction mechanisms downstream of receptor activation. Like TREM2–DAP12,
activated FcγR signals through ITAMs on the Fc receptor γ-chain (FcRγ; not to be confused
with FcγR)724–726. Subsequently, Syk is also recruited to phosphorylated ITAMs on the
FcRγ and activates downstream signalling cascades. As the isotype control and TREM2
activating antibody used in the present study have intact IgG Fc region, this may explain
the activation of Pyk2 and Erk1/2 by the TREM2-activating antibody in TREM2 KO
cells.
Unexpectedly, stimulation with the TREM2-activating antibody or isotype control antibody
resulted in a slight increase (but not statistically significant) of Pyk2 activation and to
a smaller extent Erk1/2 activation in TREM2 KO cells compared to TREM2 WT cells.
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This suggests that not only do these antibodies appear to activate downstream signalling
independent of TREM2 but this effect is enhanced by the loss of TREM2. Considering
that the activation of Pyk2 and Erk1/2 by the antibodies in TREM2 KO cells can be due
to FcγR signalling, the slight increase of this activation in TREM2 KO cells relative to
TREM2 WT cells indicate that TREM2 deficiency enhances FcγR signalling.
This could be due to an inhibitory effect by intact TREM2. As TREM2–DAP12 and FcγR
share downstream signalling proteins such as Src-family kinases and Syk, it is possible
that they compete for these proteins when simultaneously activated. Without TREM2,
there is a higher availability of intermediate signalling kinases to be recruited by FcγR
signals to activate Pyk2 and Erk1/2. However, since TREM2–DAP12 and FcγR signalling
converges at Syk and can similarly activate Pyk2 and Erk1/2, simultaneous activation of
TREM2 and FcγR should still result in activation of Syk, Pyk2 and Erk1/2 regardless
if the signal originated from TREM2–DAP12, FcγR or both, which is not the case here.
Alternatively, expression of TREM2 and FcγR could be co-regulated. Increased signalling
through FcγR suggests that the loss of TREM2 increases the expression or availability of
FcγR. Although not measured here, TREM2-deficient BMDM have been reported with
increased FcγR mRNA and protein expression compared to WT BMDM cells489. On the
other hand, Fcgr1 mRNA expression in TREM2-deficient primary adult microglia has been
reported to be similar to WT primary adult microglia532. These differences may be due
to the isolation of primary microglia involving homogenisation of brain tissue to produce
a large amount of cell debris, which may activate or prime microglia to increase basal
expression of FcγR. Nevertheless, the slight increase in activation of Pyk2 and Erk1/2
in TREM2 KO cells compared to TREM2 WT cells when stimulated with either the
TREM2-activating antibody or isotype control antibody in the present study suggests
increased FcγR expression in TREM2 KO BV2 microglia.
Even if the cells can be activated through TREM2 or FcγR with these antibodies, the lack of
Syk activation by the isotype control antibody (FcγR activation only) or TREM2-activating
antibody (TREM2+FcγR activation) in TREM2 WT and TREM2 KO cells is still not
explained. It is possible that these treatments have a suppressive effect on the activation
of Syk. An interesting property of ITAM signalling is that ligand-binding avidity affects
the recruitment of signalling mediators to ITAMs. Avidity can be defined as the sum of
242
affinities of each ligand-binding interaction to the target receptor727. Strong ligand-binding
avidity to receptors result in high phosphorylation of ITAMs and this leads to the commonly
described recruitment of Syk. However, weak or tonic ligand-binding avidity cause only
partial phosphorylation of ITAMs728 and the recruitment of tyrosine phosphatases SHP1/2,
inositol phosphatase SHIP1 or docking protein DOK3729–731 instead of Syk (Figure 5.13).
This potentially occurs through a preferential interaction between monophosphorylated
ITAMs and single SH2 domain-containing phosphatases compared to dual SH2 domains of
Syk732. The recruitment of phosphatases physically blocks other SH2 domain-containing
protein including Syk from binding to ITAMs396. Besides that, phosphatases like SHP1 can
also dephosphorylate Syk, Vav and PI3K693,733,734 to negatively regulate ITAM-mediated
signalling pathways.
In the present study, the TREM2-activating antibody binding to TREM2 is likely to have
low avidity due to its monoclonal nature which binds to only one epitope site on each
receptor and lead to inhibitory ITAM signalling. In agreement, stimulation of a mouse
monocyte cell line with a different monoclonal antibody against TREM2 was shown to
recruit SHIP1 to DAP12396. The inhibitory ITAM signalling can only occur with intact
TREM2 which explains the lack of significant Syk activation in TREM2 WT cells when
treated with the TREM2-activating antibody compared to uncoated wells in the present
study. Peng et al. (2010) also showed that treatment of osteoclasts with a monoclonal
antibody against TREM2 still resulted in phosphorylation of Syk, which was higher in
SHIP1-deficient osteoclasts396. This suggests that the recruitment of SHIP1 does not
completely prevent Syk phosphorylation. Indeed, in the present study, there was a trend
towards increased Syk activation in TREM2 WT cells when stimulated with the TREM2-
activating antibody (TREM2+FcγR activation) compared to the isotype control antibody
(FcγR activation only).
Likewise, monomeric or multimeric IgG aggregation can affect ligand binding affinity to
FcγR735. Dimeric or multimeric IgG aggregates have enhanced binding affinity to FcγR
compared to monomeric IgG735. In the present study, it is not known if the plate-bound
isotype control or TREM2-activating antibodies are monomeric or multimeric aggregates.
As the plates were coated as evenly as possible with constant agitation, it is likely that
the antibodies were coated as monomers or very small oligomers. This contrasts with
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multimeric aggregations of antigen-bound IgG antibodies in immune complexes. Hence,
this may explain the lack of Syk activation when stimulated with the TREM2-activating
antibody in TREM2 KO cells (FcγR activation only) compared to TREM2 WT cells
(TREM2+FcγR activation), which results in inhibitory ITAM signalling from FcγR (Figure
5.13).
Stimulation of macrophages with a monoclonal antibody against TREM2 also resulted
in intracellular calcium flux, recruitment of PLC-γ and F-actin organisation396. Pyk2 is
involved in this signalling pathway703,717. Indeed, Pyk2 was activated in TREM2 WT cells
by the TREM2-activating antibody in the present study. Pyk2 can be directly activated
by Src-family kinases recruited upstream of Syk activation699,706 and circumvent the
inhibitory action of phosphatase recruitment to partially phosphorylated ITAMs (Figure
5.13). This suggests that the inhibitory ITAM signalling does not significantly affect Pyk2
phosphorylation and activation.
Nevertheless, the interpretation of Syk, Pyk2 and Erk1/2 activation, even with simultaneous
activation of TREM2 and FcγR when stimulated with the TREM2-activating antibody,
shows that there is a difference in signalling pathways downstream of TREM2 caused
by TREM2 deficiency. Furthermore, the current findings highlight the implications of
functional loss of TREM2, which is the increased FcγR signalling potentially caused by
increased levels of FcγR. If the loss of or decrease in TREM2 function caused by disease-
associated TREM2 variants similarly result in increased expression of FcγR, it may result in
exaggerated FcγR-mediated immune responses such as release of proinflammatory cytokines
(e.g. TNF-α and IL-1β)736 that can contribute to disease progression. The increased FcγR
expression will need to be confirmed in the TREM2-deficient cell lines generated in this
project and could also be investigated in post-mortem brain sections in cases with disease-
associated TREM2 variants. Additionally, the effects of TREM2 activation will need to be
separated from FcγR activation in follow-up studies. This could be done by processing
the antibodies prior to use with pepsin to generate F(ab’)2 fragments which lack the
Fc region385. The cells can then be treated with non-specific F(ab’)2 fragments (control
treatment), TREM2-activating F(ab’)2 fragments (TREM2-activating) or non-specific IgG
antibody with Fc region (FcγR-activating).
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Figure 5.13. The lack of significant phosphorylation and activation of Syk and Erk1/2 in TREM2 WT cells after treatment with
monoclonal TREM2-activating antibody may be due to weak ligand-binding avidity on TREM2 or FcγR that result in partial
inhibitory ITAM signalling.
Unlike activating ITAM signalling (left), inhibitory ITAM signalling (right) is mediated by partial phosphorylation of ITAMs, which results in the
recruitment of phosphatases such as SHP1/2 and SHIP1 to ITAMs instead of Syk. Despite the lack of Syk recruitment and activation, Pyk2 can still
be phosphorylated and activated by Src-family kinases that are recruited upstream of Syk.
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The present study also aimed to compare the expression of functional microglial markers
CD68, HLA-DP, -DQ, -DR (MHC class II) and Iba-1 in the generated cell lines to see if
they model the disease caused by TREM2 variants in people. Chapter 4 showed that AD
cases with a disease-associated TREM2 variant had lower expression of CD68 and fewer
HLA-DP, -DQ, -DR-expressing cells with no differences in Iba-1-expressing cell abundance
compared to AD cases without TREM2 variants. Therefore, it was expected that CD68 and
MHC class II expression would have a similar decrease and no difference in Iba-1 expression
when stimulated with an AD pathological mimic in TREM2 KO cells compared to TREM2
WT cells. Unfortunately, the antibody against MHC class II (107601, BioLegend) used
could not detect specific bands during antibody testing and optimisation. Regardless,
CD68 and Iba-1 protein levels between TREM2 WT and TREM2 KO cells when stimulated
with the TREM2-activating antibody were similar. The similar levels of CD68 in cells
stimulated with the TREM2-activating antibody compared to uncoated wells demonstrate
that CD68 expression is not induced by TREM2 or FcγR stimulation. It may be that CD68
expression is not induced without a phagocytic substrate. Therefore, the experimental
setup in this study was insufficient to determine if the generated TREM2-deficient cell
lines model the disease in people or not. To do so, these cells should be stimulated with an
inert phagocytic substrate such as microspheres together with TREM2-activating F(ab’)2
fragments. Alternatively, TREM2-activating F(ab’)2 fragment-conjugated microspheres
can also be used. In addition, the experiments can be combined to investigate the separate
effects of TREM2 and FcγR activation in the TREM2-deficient cell lines and how they
may model the disease in people. This can be done by conjugating non-specific F(ab’)2
fragments, TREM2-activating F(ab’)2 fragments and non-specific IgG antibody with Fc
region onto microspheres and using these for cell stimulation.
In summary, this study shows that the generated Trem2 -edited clonal lines from Chapter
3 have functional loss of TREM2 as predicted from the indels generated in in Trem2 Exon
2. These cells can be used to investigate disease-relevant TREM2-mediated mechanisms
that contribute to AD vulnerability. In addition, these TREM2-deficient microglia cell
lines can also be used to screen for therapeutic compounds that ameliorate effects of
the loss of TREM2 function. Stimulation of these cell lines with the TREM2-activating
antibody demonstrated differences in activation of downstream signalling pathways between
TREM2 KO and TREM2 WT cells. This also revealed a potential vulnerability of TREM2-
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The primary aim of this project was to generate an in vitro TREM2 model that endo-
geneously express the disease-associated variants and with intact signalling pathways
downstream of TREM2. Such a model will be suitable for investigating disease-causing
mechanisms conveyed by TREM2 variants and to screen therapeutic compounds. Most
studies focused on elucidating TREM2 function have shown that TREM2 is involved
in various innate immune responses such as phagocytosis, chemotaxis, cell survival and
proliferation383. These studies often utilise TREM2-deficient or overexpressing models to
elucidate TREM2 function.
On the other hand, studies on the TREM2 variants focused on the effects of the vari-
ants on the protein itself and how they affect functional outcomes in comparison to
TREM2-deficient models. So far, disease-associated TREM2 variants have been shown
to negatively impact expression of full-length protein (p.Q33X, p.W44X), protein folding
(p.Y38C, p.T66M)333,378, protein maturation (p.R47H)379,382,452, and protein trafficking to
the cell membrane (p.Y38C, p.T66M)379,452 as well as ligand-binding (p.R47H, p.R62H,
p.D87N)106,108,378. In these studies, expression vectors were used to overexpress TREM2
with the variants, which meant these models do not have endogeneous regulation of protein
expression levels. This brings the validity of the model into question as overexpressing a
misfolding protein may result in its accumulation in the endoplasmic reticulum (ER)737.
This leads to ER stress and induce the unfolded protein response738,739. There are studies
that used patient-derived primary myeloid cells such as peripheral blood monocytes carrying
a disease-associated TREM2 variant108. These cells would have endogeneous expression
of TREM2 with the variant and could also be used to study disease-causing mechanisms
and pathways. However, they would not be suitable for screening assays because sourcing
sufficient numbers of cells for the scale of such experiments would be practically and
technically challenging.
Cell lines that endogeneously express TREM2 variants and can be cultured in large numbers
have great value to further elucidate disease-causing mechanisms and identify therapeutic
targets. However, the efficiency of knocking in TREM2 variants by CRISPR/Cas9 genome
editing was far too low (Chapter 3). Furthermore, obtaining homogeneously edited clonal
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lines was complicated by hyperploidy in the cell line as HDR-mediated DNA repair occurs
at a rate too low to knock-in the DNA variants in all copies of Trem2. Also, NHEJ-mediated
DNA repair is not precise and results in heterogeneous indels across different copies of
Trem2 (Chapter 3). Regardless, TREM2-deficient cell lines were successfully generated by
indels in Trem2. These can be used to model TREM2 variants that result in the functional
loss of TREM2 expression.
6.1.1 Alzheimer’s disease-associated TREM2 variants may mediate in-
hibitory ITAM signalling
Recent studies have suggested that the disease-causing mechanism of TREM2 variants
is due to decreased or loss of TREM2 protein function. However, our understanding of
how disease-associated TREM2 variants impact underlying signalling pathways remain
unclear. Elucidating disease-causing mechanisms and pathways conveyed by TREM2
variants may enable the identification of potential therapeutic targets, either single proteins
or signalling pathways, to ameliorate the decrease or loss of TREM2 function. TREM2 is
known to signal through DAP12 and its ITAMs. This leads to the recruitment of Syk and
transduction of activating signals. However, it is not apparent in the TREM2 literature
that TREM2 can also mediate inhibitory ITAM signalling through low ligand-binding
avidity and downstream recruitment of phosphatases such as SHIP1 and SHP1/2 to DAP12
ITAMs.
Decreased CD68 expression and fewer HLA-DP, -DQ, -DR-expressing cells were observed in
AD cases with disease-associated TREM2 variants, particularly p.R47H in Chapter 4. This
variant has been found to decrease binding of several ligands including ApoE, proteoglycans
and phospholipids106,108,378,438. The impairment of ligand binding is potentially due to
a slight protein conformational change and change in electrostatic interactions378. Thus,
ligands that normally bind to TREM2 would have weaker binding avidity.
In Chapter 5, the lack of Syk activation in TREM2 WT cells after treatment with a
monoclonal TREM2-activating antibody suggests that that low ligand-binding avidity
on TREM2 results in inhibitory signalling by recruitment of phosphatases to the ITAMs
of DAP12 instead of Syk. Disease-associated TREM2 variants located on the conserved
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extracellular ligand-binding basic patch (p.R47H, p.R62H and p.D87N) appear to decrease
ligand-binding affinity but do not completely abolish binding378. This may be a disease-
causing mechanism mediated by the more frequent AD-associated p.R47H and p.R62H
variants to suppress innate immune activation in response to pathological ligands, such as
cellular debris and protein aggregates. Thus, recognition and clearance of these ligands by
TREM2-expressing cells such as microglia would be impaired.
This mechanism may have far-reaching effects beyond suppressing activation signals of
TREM2 as its downstream signalling pathways are shared with many other immunoreceptors
expressed on innate immune cells like microglia699,703,732,740,741. The phosphatases recruited
to DAP12 can dephosphorylate many components of ITAM-mediated signalling and suppress
signals from other receptors as well733,734.
The suppression of activating signals by TREM2 may explain the decrease in HLA-DP, -DQ,
-DR-expressing microglia in AD cases with the TREM2 p.R47H variant. Although TREM2
has not been directly implicated in antigen presentation, FcγRs are involved in antigen
uptake, endosomal maturation, antigen processing and cellular activation742. In fact, all cell
surface FcγRs, regardless of ITAM- or ITIM-carrying, are capable of internalising opsonised
material or immune complexes742. ITAM-carrying FcγRs mediate the degradation of
antigens for processing and presentation that leads to T cell activation743,744. On the
other hand, ITIM-carrying FcγRs mediate the retention and preservation of antigens
for subsequent transfer to B cells743. Low ligand-binding avidity by TREM2 p.R47H
variant may result in phosphatase recruitment and suppress activation and signals from
FcγRs, especially activating ITAM-carrying FcγRs that utilise Syk to mediate downstream
signalling. Thus, suppression of antigen uptake as well as FcγR-mediated antigen processing
and presentation pathways would not induce HLA-DP, -DQ, -DR expression. This is
consistent with observations in post-mortem hippocampal CA4 with similar numbers of
HLA-DP, -DQ, -DR-expressing cells between AD cases with a disease-associated TREM2
variant and non-AD cases (Chapter 4).
It is also possible that the decreased CD68 expression in AD cases with TREM2 p.R47H
variant may be similarly affected by this. Studies so far have demonstrated increased
TREM2 signalling or overexpression result in increased phagocytosis384,394,417,428. More-
over, other ITAM-associated receptors including FcγR, SIRPβ1 and CR3 can also induce
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phagocytosis through similar ITAM-mediated signalling pathways489,694,695,742. Activat-
ing signals from these receptors may be suppressed by phosphatases recruited from low
ligand-binding avidity of TREM2 p.R47H variant.
This overreaching effect of the TREM2 p.R47H variant on other immunoreceptor signalling
pathways may explain why this rare variant has significant associations to various neu-
rodegenerative diseases. Furthermore, ligands that have been found to bind TREM2 so
far are highly implicated with pathology underlying neurodegenerative diseases. These
include cell components exposed during apoptosis or released in cell debris (e.g. cell
membrane lipids and nucleotides)378,423,429,436–439 and lipoproteins significantly associated
with AD (e.g. ApoE and ApoJ/clusterin)106–108,440. This suggests that TREM2 is highly
likely to be engaged in disease and result in suppression of innate immune activation by
the TREM2 p.R47H variant. Other AD risk genes further highlight the significance of
this ITAM-mediated signalling pathway. INPP5D (SHIP1), PTK2B (Pyk2) and PLCG2
(phospholipase C γ 2)112,117 are involved in this signalling pathway whereas many other risk
genes are related to functional responses to this signalling pathway such as phagocytosis
and cytoskeletal organisation (Figure 1.3).
6.1.2 Decrease or loss of TREM2 function may enhance signalling of
co-regulated receptors
In Chapter 5, TREM2-deficient cells had increased activation of Pyk2 by stimulation
with the TREM2-activating antibody, which could only result in the activation of FcγR,
compared to TREM2 WT cells. It is not clear if the increased activation is due to the loss
of inhibition by TREM2 on FcγR signalling or increased expression of FcγR. Although
not assessed in Chapter 5, TREM2-deficient BMDM is reported to have increased FcγR
expression compared to WT BMDM489, which may explain the increased activation of
Pyk2. If the same occurs in AD patients with disease-associated TREM2 variants, the
increased FcγR signalling in may result in overactivation of innate immune responses such
as the release of proinflammatory TNF-α and IL-1β736. This may activate surrounding
microglia into a M1-like state with a cytotoxic phenotype. Increased FcγR signalling is
also expected to enhance antigen uptake, processing and presentation742. However, CD68
expression and the abundance of HLA-DP, -DQ, -DR-expressing cells were decreased in
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hippocampal CA4 of AD cases with disease-associated TREM2 variants in Chapter 4. This
suggests that AD-associated TREM2 variants, particularly the p.R47H variant, do not
increase FcγR signalling or expression, unlike the effects seen in TREM2-deficient microglia.
Nevertheless, there may be a combined effect of inhibitory ITAM signalling and increased
expression of FcγR, resulting in the observations in Chapter 4.
Furthermore, the decrease or loss of TREM2 function may lead to increased expression
of other receptors co-regulated by TREM2 besides FcγR. The loss of TREM2 signalling
could alter basal ITAM/ITIM signalling and there may be a regulatory feedback loop to
compensate for the decreased or loss of signals from TREM2. Indeed, ITAM signalling
can lead to the regulation of transcription factors via the MAPK signalling pathway719
and may enhance the expression of ITAM-associated receptors. Further confirmation is




In conclusion, 4 individual TREM2-deficient clonal microglia lines with intact signalling
pathways downstream of TREM2 were generated. These cells can be used to model
variants that impair trafficking of TREM2 to the cell membrane (e.g. p.Y38C, p.T66M)
or variants that lead to the functional loss of TREM2 (e.g. p.W14X, p.Q33X, p.W44X).
Through the generation of these cell lines, knock-in of gene variants into immortalised
cell lines using CRISPR/Cas9 was found to be very difficult due to technical limitations,
mainly the tendency for these cell lines to have chromosomal instability and hyperploidy.
The investigation in post-mortem brain tissue revealed decreased expression of CD68
and fewer HLA-DP, -DQ, -DR-expressing microglia in the CA4 of AD cases with disease-
associated TREM2 variants, particularly the p.R47H, despite no differences in the number
of Iba-1-expressing microglia. Using the generated TREM2-deficient microglia cell lines,
characterisation of key signalling proteins downstream of TREM2 in the presence or absence
of functional TREM2 with a TREM2-activating antibody demonstrated differences in
the phosphorylation of intermediate signalling proteins due to TREM2 deficiency. This
also highlighted that signalling pathways downstream of TREM2 is shared with and can
be activated by FcγR. Furthermore, ITAM-associated receptors including TREM2 and
FcγR may suppress these signalling pathways by inhibitory ITAM signalling from low
ligand-binding avidity such as by monoclonal antibody stimulation or protein variants that
reduce ligand-binding avidity. In addition, TREM2 deficiency appear to enhance FcγR
signalling, potentially through co-regulation with TREM2 that result in the increase of FcγR
expression in the absence of TREM2. These suggest potential disease-causing mechanisms
due to dysfunctional inflammatory responses. Suppression of inflammatory responses
may result in the inability of immune cells to mediate clearance of pathology whereas
enhanced or overactive inflammatory responses may lead to bystander damage of healthy
cells. Therefore, potential therapeutic compounds may target and balance dysfunctional




The generation of in vitro cell models endogeneously expressing disease-associated TREM2
variants with intact downstream signalling pathways is still crucial for further investigation
on the disease-causing mechanisms of these variants. Using a positive selectable marker
such as a fluorescent protein gene in the HDR template may significantly improve screening
efficiency for successful HDR in immortalised cell lines with multiple copies of the targeted
gene. Following screening, the selectable marker gene can be removed from the target gene
using transposon systems such as the piggyBac system to ensure scarless excision (discussed
in detail in Chapter 3). Alternatively, patient-derived iPSCs can be used to generate
microglia-like cells carrying the disease-associated TREM2 variant and isogenic control cell
lines can be generated from these using CRISPR/Cas9. iPSCs would be initially screened
to ensure that they would not have chromosomal abnormalities. Thus, to generate isogenic
control lines from iPSCs carrying heterozygous variants like the AD-associated TREM2
variants, only one copy of TREM2 needs to be targeted, which is much more likely to
occur than homogeneous editing of up to four copies of Trem2 in BV2.
The use of these cells in high-throughput assays can accelerate research on disease-causing
mechanisms or pathways, which in turn allows the identification of potential therapeutic
targets. For example, the effects of these variants on signalling pathways downstream of
TREM2 that are shared with other ITAM-associated immunoreceptors can be studied.
Besides that, expression levels of FcγR or other microglial ITAM-associated receptors
can be assessed to confirm if TREM2 deficiency or the disease-associated variants lead
to a compensatory increase in expression of these receptors. In addition, known ligands
can be used to stimulate TREM2 with variants that affect ligand binding (e.g. p.R47H,
p.R62H, p.D87N). Subsequently, downstream signalling pathways would be assessed to
confirm if the variant leads to recruitment of phosphatases to DAP12 ITAMs and inhibitory
ITAM signalling compared to normal TREM2 without the variant. Furthermore, other
ITAM-associated receptors like FcγR can also be simultaneously stimulated to investigate if
the inhibitory signalling by TREM2 p.R47H can suppress signals from these receptors and
impair innate immune responses such as phagocytosis, chemotaxis and antigen presentation.
Following confirmation of disease-causing mechanism, therapeutic compounds exploiting
this signalling pathway can be identified using the generated in vitro TREM2 model in
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high-throughput drug screening assays.
Moreover, markers of potential disease-causing mechanisms identified in vitro can be
investigated in post-mortem tissue to establish if they also occur in the disease in people.
For example, from the results in Chapter 5, the expression levels of FcγR as well as
phosphorylation of Syk, Pyk2 and Erk1/2 can be compared between AD cases with and
without disease-associated TREM2 variants. This will confirm if the disease-causing
mechanisms identified in vitro is replicated in the disease in people. This will also establish





Figure A1. Comparison of transfection efficiency and cell viability between 2.5 µg and 5 µg of each sgRNA-Cas9 expression plasmid pairs (total 5
µg and 10 µg, respectively) when electroporated together with 100 pmol HDR template into 2×106 BV2 cells. Fluorescence microscopy images were




(c) R47H (Plate 1)
(d) R47H (Plate 2)
Figure A2. Agarose gel screening of CRISPR v3b (a) Q33X, (b) D87N and (c,d) R47H
clones. Clones with single-band amplicons were Sanger sequenced.
TREM2 Exon 2 amplicons from unmodified BV2, labelled “WT”, was used as a size





Figure A3. Agarose gel screening of (a) unstained or (b) Hoechstlo CRISPR v3b clones.
Clones with single-band amplicons were Sanger sequenced. Labelled amplicons indicate
clones that were selected for functional characterisation.
TREM2 Exon 2 amplicons from unmodified BV2, labelled “WT”, was used as a size
reference (646 bp) against indels in clonal lines.
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(a) 0 ng/mL nocodazole
(b) 10 ng/mL nocodazole
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(c) 100 ng/mL nocodazole
(d) 200 ng/mL nocodazole
(e) 500 ng/mL nocodazole
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(f) 1000 ng/mL nocodazole
Figure A4. Agarose gel screening of CRISPR v4 clones treated with (a) 0 ng/mL, (b)
10 ng/mL, (c) 100 ng/mL, (d) 200 ng/mL, (e) 500 ng/mL or (f) 1000 ng/mL nocodazole.
TREM2 Exon 2 amplicons from unmodified BV2, labelled “WT”, was used as a size
reference (646 bp) against indels in clonal lines.
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Stain Region Group Mean (95% CI) SD
Iba-1 CA1 Control/TREM2wt 26.50 (16.31–38.83) 24.14
AD/TREM2wt 38.56 (29.65–47.69) 23.58
AD/TREM2var 29.51 (17.93–40.48) 22.13
CA4 Control/TREM2wt 29.44 (18.32–42.17) 25.15
AD/TREM2wt 34.89 (20.85–49.43) 31.81
AD/TREM2var 21.43 (11.83–31.99) 21.38
CD68 CA1 Control/TREM2wt 2.91 (2.09–3.78) 1.79
AD/TREM2wt 4.20 (3.31–5.41) 2.24
AD/TREM2var 3.28 (2.19–4.69) 2.99
CA4 Control/TREM2wt 4.51 (3.21–6.10) 3.40
AD/TREM2wt 3.75 (2.90–4.65) 2.06
AD/TREM2var 2.12 (1.54–2.77) 1.40
HLA CA1 Control/TREM2wt 21.73 (14.29–30.08) 17.69
AD/TREM2wt 54.82 (38.53–73.71) 40.83
AD/TREM2var 36.61 (19.62–52.72) 32.50
CA4 Control/TREM2wt 42.32 (28.45–57.19) 31.06
AD/TREM2wt 58.53 (35.85–81.94) 51.68
AD/TREM2var 31.07 (14.46–48.68) 34.16
Table A1. Means and standard deviations of Iba-1+ cell counts, CD68 % area
immunostaining and HLA+ cell counts in 0.5×0.5 mm2 areas of the CA1 and
CA4 for Control/TREM2wt, AD/TREM2wt and AD/TREM2var groups.
CI: confidence interval, SD: standard deviation.
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Figure A5. Images separated into individual channels from double staining
immunofluorescence of CD68 and Iba-1 in AD/TREM2wt and AD/TREM2var
cases.
These images correspond to Figure 4.5. Images were captured at 200× magnification. Scale
bars indicate 50 µm.
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Figure A6. Images separated into individual channels from double staining
immunofluorescence of HLA and Iba-1 in AD/TREM2wt and AD/TREM2var
cases.
These images correspond to Figure 4.6. Images were captured at 200× magnification. Scale
bars indicate 50 µm.
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Stain Region Group Mean (95% CI) SD
Iba-1 CA1 Control/TREM2wt 0.097 (0.083–0.113) 0.028
AD/TREM2wt 0.098 (0.086–0.112) 0.028
AD/TREM2var 0.113 (0.098–0.129) 0.030
CA4 Control/TREM2wt 0.099 (0.084–0.114) 0.025
AD/TREM2wt 0.112 (0.091–0.135) 0.052
AD/TREM2var 0.141 (0.109–0.183) 0.079
HLA CA1 Control/TREM2wt 0.073 (0.066–0.081) 0.016
AD/TREM2wt 0.088 (0.080–0.097) 0.020
AD/TREM2var 0.093 (0.082–0.104) 0.023
CA4 Control/TREM2wt 0.066 (0.063–0.070) 0.008
AD/TREM2wt 0.087 (0.077–0.099) 0.025
AD/TREM2var 0.104 (0.085–0.125) 0.042
Table A2. Means and standard deviations of Iba-1+ and HLA+ microglia
circularity in 0.5×0.5 mm2 areas of the CA1 and CA4 for each experimental
group.
CI: confidence interval, SD: standard deviation.
Stain Region Group Mean (95% CI) SD
Aβ (4G8) CA1 AD/TREM2wt 4.82 (2.96–6.89) 5.33
AD/TREM2var 3.72 (2.34–5.81) 3.97
CA4 AD/TREM2wt 0.83 (0.40–1.37) 1.09
AD/TREM2var 1.39 (0.40–2.54) 2.19
Phospho-tau (AT8) CA1 AD/TREM2wt 31.55 (26.24–36.25) 11.50
AD/TREM2var 28.75 (22.57–34.55) 11.76
CA4 AD/TREM2wt 18.33 (12.71–23.56) 14.04
AD/TREM2var 11.05 (7.58–14.68) 7.73
Table A3. Means and standard deviations of Aβ or tau % area staining in
0.5×0.5 mm2 areas of the CA1 and CA4 for AD/TREM2wt and AD/TREM2var
cases.
CI: confidence interval, SD: standard deviation.
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Stain Region Group Mean (95% CI) SD
Iba-1 CA1 Control/TREM2wt 26.50 (15.90–39.18) 24.14
AD/TREM2wt 38.56 (28.78–49.49) 23.58
AD/TREM2R47H 22.11 (9.15–36.22) 20.80
CA4 Control/TREM2wt 29.44 (19.12–41.07) 25.15
AD/TREM2wt 34.89 (21.95–47.99) 31.81
AD/TREM2R47H 15.04 (4.46–28.99) 17.93
CD68 CA1 Control/TREM2wt 2.911 (2.120–3.870) 1.794
AD/TREM2wt 4.204 (3.150–5.320) 2.242
AD/TREM2R47H 2.654 (1.595–3.983) 1.611
CA4 Control/TREM2wt 4.512 (3.195–6.145) 3.398
AD/TREM2wt 3.749 (2.972–4.539) 2.058
AD/TREM2R47H 1.937 (1.218–2.818) 1.218
HLA CA1 Control/TREM2wt 21.73 (14.16–30.33) 17.69
AD/TREM2wt 54.82 (37.80–75.36) 40.83
AD/TREM2R47H 25.96 (9.26–49.34) 29.34
CA4 Control/TREM2wt 42.32 (27.56–57.45) 31.06
AD/TREM2wt 58.53 (37.20–81.04) 51.68
AD/TREM2R47H 14.96 (5.53–26.24) 17.28
Table A4. Means and standard deviations of Iba-1+ microglial abundance,
CD68 staining, and HLA+ microglial abundance in 0.5×0.5 mm2 areas of the
CA1 and CA4 for AD/TREM2wt and AD/TREM2R47H cases.
CI: confidence interval, SD: standard deviation.
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Stain Region Group Mean (95% CI) SD
Iba-1 CA1 Control/TREM2wt 0.097 (0.084–0.111) 0.028
AD/TREM2wt 0.098 (0.086–0.109) 0.028
AD/TREM2var 0.121 (0.102–0.141) 0.028
CA4 Control/TREM2wt 0.099 (0.088–0.110) 0.025
AD/TREM2wt 0.112 (0.092–0.135) 0.052
AD/TREM2var 0.127 (0.109–0.149) 0.029
HLA CA1 Control/TREM2wt 0.073 (0.065–0.082) 0.016
AD/TREM2wt 0.088 (0.079–0.099) 0.020
AD/TREM2var 0.092 (0.079–0.105) 0.022
CA4 Control/TREM2wt 0.066 (0.063–0.070) 0.008
AD/TREM2wt 0.087 (0.078–0.098) 0.025
AD/TREM2var 0.115 (0.090–0.143) 0.047
Table A5. Means and standard deviations of Iba-1+ and HLA+ microglia
circularity in 0.5×0.5 mm2 areas of the CA1 and CA4 for each experimental
group.
CI: confidence interval, SD: standard deviation.
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[123] Coppedè F. The potential of epigenetic therapies in neurodegenerative diseases.
Frontiers in Genetics. 2014;5.
[124] Bennett DA, Yu L, Yang J, Srivastava GP, Aubin C, De Jager PL. Epigenomics of
Alzheimer’s disease. Translational Research. 2015;165(1):200–220.
[125] Marques SC, Oliveira CR, Pereira CM, Outeiro TF. Epigenetics in neurodegeneration:
a new layer of complexity. Progress in Neuro-Psychopharmacology and Biological
Psychiatry. 2011;35(2):348–355.
[126] Wang J, Yu JT, Tan MS, Jiang T, Tan L. Epigenetic mechanisms in Alzheimer’s
disease: implications for pathogenesis and therapy. Ageing Research Reviews.
2013;12(4):1024–1041.
[127] Millan MJ. The epigenetic dimension of Alzheimer’s disease: causal, consequence, or
curiosity? Dialogues in Clinical Neuroscience. 2014;16(3):373.
[128] Jeong S, Liang G, Sharma S, Lin JC, Choi SH, Han H, et al. Selective anchoring
of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA.
Molecular and Cellular Biology. 2009;29(19):5366–5376.
[129] Urdinguio RG, Sanchez-Mut JV, Esteller M. Epigenetic mechanisms in neurological
diseases: genes, syndromes, and therapies. Lancet Neurology. 2009;8(11):1056–1072.
[130] Lee JH, Ryu H. Epigenetic modification is linked to Alzheimer’s disease: is it a
maker or a marker? BMB Reports. 2010;43(10):649–655.
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Inhibition of IL-12/IL-23 signaling reduces Alzheimer’s disease-like pathology and
cognitive decline. Nature Medicine. 2012;18(12):1812–1819.
[224] Fillit H, Ding W, Buee L, Kalman J, Altstiel L, Lawlor B, et al. Elevated cir-
culating tumor necrosis factor levels in Alzheimer’s disease. Neuroscience Letters.
1991;129(2):318–320.
[225] Jekabsone A, Mander PK, Tickler A, Sharpe M, Brown GC. Fibrillar beta-amyloid
peptide Aβ1–40 activates microglial proliferation via stimulating TNF-α release and
H2O2 derived from NADPH oxidase: a cell culture study. Journal of Neuroinflam-
mation. 2006;3(1):24.
[226] Choi SH, Aid S, Kim HW, Jackson SH, Bosetti F. Inhibition of NADPH oxidase
promotes alternative and anti-inflammatory microglial activation during neuroinflam-
mation. Journal of Neurochemistry. 2012;120(2):292–301.
[227] Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent) rather than
activated microglial cells are associated with tau pathology and likely precede neu-
rodegeneration in Alzheimer’s disease. Acta Neuropathologica. 2009;118(4):475–485.
[228] Krabbe G, Halle A, Matyash V, Rinnenthal JL, Eom GD, Bernhardt U, et al.
Functional impairment of microglia coincides with Beta-amyloid deposition in mice
with Alzheimer-like pathology. PloS ONE. 2013;8(4):e60921.
[229] Guillot-Sestier MV, Doty KR, Gate D, Rodriguez J, Leung BP, Rezai-Zadeh K, et al.
Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology.
Neuron. 2015;85(3):534–548.
[230] Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, et al. IL-10
alters immunoproteostasis in APP mice, increasing plaque burden and worsening
cognitive behavior. Neuron. 2015;85(3):519–533.
[231] Lucin KM, O’Brien CE, Bieri G, Czirr E, Mosher KI, Abbey RJ, et al. Microglial
beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer’s
disease. Neuron. 2013;79(5):873–886.
293
[232] Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, et al. Notch3
mutations in CADASIL, a hereditary adult-onset condition causing stroke and
dementia. Nature. 1996;383(6602):707.
[233] Ruchoux MM, Maurage CA. CADASIL: cerebral autosomal dominant arteriopathy
with subcortical infarcts and leukoencephalopathy. Journal of Neuropathology &
Experimental Neurology. 1997;56(9):947–964.
[234] Kinoshita M, Yoshida K, Oyanagi K, Hashimoto T, Ikeda Si. Hereditary diffuse
leukoencephalopathy with axonal spheroids caused by R782H mutation in CSF1R:
case report. Journal of the Neurological Sciences. 2012;318(1):115–118.
[235] Dos Santos MM, Grond-Ginsbach C, Aksay SS, Chen B, Tchatchou S, Wolf NI, et al.
Adult-onset autosomal dominant leukodystrophy due to LMNB1 gene duplication.
Journal of Neurology. 2012;259(3):579–581.
[236] Foulds N, Pengelly RJ, Hammans SR, Nicoll JA, Ellison DW, Ditchfield A, et al.
Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia caused
by a novel R782G mutation in CSF1R. Scientific Reports. 2015;5:10042.
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[543] Suárez-Calvet M, Caballero MÁA, Kleinberger G, Bateman RJ, Fagan AM, Morris
JC, et al. Early changes in CSF sTREM2 in dominantly inherited Alzheimer’s disease
occur after amyloid deposition and neuronal injury. Science Translational Medicine.
2016;8(369):369ra178–369ra178.
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